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Background and Purpose: Individuals who carry certain inherited pathogenic genetic variants 
(PVs) have an increased lifetime risk of developing hereditary breast and ovarian cancer 
(HBOC). Despite the effectiveness of risk reduction modalities, many PV carriers in 
Newfoundland and Labrador (NL) are unidentified. Moreover, for known PV carriers in the 
province, there is no systemic support available to them in their long-term risk management. 
Therefore, these high-risk individuals and families are not receiving the information and support 
needed to live a long, healthy life vis-à-vis their carrier status. The purpose of this practicum is to 
provide a rationale and recommendations for a prospective nurse navigation and follow-up 
program for HBOC PV carriers in NL. 
Methods: A literature review, key informant consultations, and an environmental scan were 
conducted and used to inform a policy proposal for a novel program. 
Results: Significant systemic barriers exist for PV carriers; many HBOC PV carriers and 
families have unmet information and psychosocial needs in the current primary care provider- 
dependent follow-up processes. A need exists for a novel follow-up and navigation and program. 
The literature review, consultations, and environmental scan were used to inform the five sub 
recommendations for the follow-up program including: a 1) carrier registry, 2) a nurse-led 
navigation program for PV carriers, 3) a multidisciplinary approach, 4) a person and family- 
centered approach, and 5) virtual and electronic delivery methods. 
Conclusion: There is an unrivaled, cost-effective opportunity to improve outcomes in NL 
HBOC PV carriers through the proposed follow-up and navigation program. 
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A Policy Proposal for a Dedicated Hereditary Breast and Ovarian Cancer Syndrome 
Follow-Up and Navigation Program 
The burden of breast and ovarian cancer in Canada is significant. Breast cancer accounts 
for 4,992 deaths annually in Canada (12.9% of cancer-related deaths in females) (Canadian 
Cancer Statistics Advisory Committee, 2019). Ovarian cancer, while less prevalent than breast 
cancer (3,000 new cases annually in Canada), is the most lethal gynecologic malignancy and 
accounts for approximately 1,896 deaths annually (Canadian Cancer Statistics Advisory 
Committee, 2019). Various pathogenic variants (PVs), such as genetic variants in BRCA1, 
BRCA2, MLH1, and MLH2 genes, are associated with increased breast and ovarian cancer risk. 
For example, BRCA 1 & 2 PV carriers have a 51-72% lifetime risk of breast cancer and an 11- 
44% lifetime risk of ovarian cancer (Kuchenbaecker et al., 2017; Rebbeck et al, 2015). Several 
recommended strategies are proven to mitigate HBOC risk in known, asymptomatic PV carriers. 
Risk-reducing salpingectomy oophorectomy (RRSO), has been associated with 80% reduction in 
ovarian/fallopian tube cancer risk and a 50% reduction in breast cancer risk in asymptomatic 
women who carry PVs in the BRCA1 &2 genes (Rebbeck et al., 2009). Furthermore, annual 
breast MRI, alternating every six months with annual breast mammography has a combined 
sensitivity of > 90% for detecting early stage breast cancer and is recommended for high risk 
women (Warner, 2018). Risk-reducing mastectomy is also discussed as a potential risk-reduction 
option which has been shown to virtually eliminate the risk of breast cancer in female BRCA 1 
& 2 PV carriers (Li et al., 2016). 
HBOC syndrome is most attributed to PVs in the BRCA 1 & 2 tumour suppressor genes 
but has also been associated with up to 24 various inherited PVs (Nielsen et al., 2016). An 
estimated 20% of cases of ovarian cancer are associated with a hereditary predisposition 
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syndrome (Susyznska et al., 2020). There is no proven method of primary ovarian cancer 
screening effective in reducing ovarian cancer morbidity and mortality in the general, average 
risk population (Buys et al., 2011; Jacobs et al., 2016). Therefore, the identification of an 
inherited ovarian cancer predisposition syndrome, and adherence to risk reduction options, offers 
an unprecedented opportunity to prevent ovarian cancer. 
Despite the survival advantage and cost-effectiveness offered by these HBOC risk 
reduction strategies, in many Canadian jurisdictions, including Newfoundland and Labrador 
(NL), there are no systemic follow-up programs that address the unique needs of HBOC PV 
carriers. Once the initial genetic counselling appointment and disclosure of an individual’s PV 
genetic testing results have occurred, individuals and/or their primary care providers are solely 
responsible for facilitating screening and risk-reduction recommendations. In an unpublished 
manuscript by Roebothan et al. (n.d.) the study authors characterized the population of female 
BRCA1 & 2 carriers in NL and evaluated factors that influence their HBOC screening and 
prevention modality adherence. They noted that only 41.6% of eligible BRCA PV carriers in NL 
had undergone the recommended annual MRI screening in an 18-month period (p < 0.001) 
(Roebothan et al., n.d.). They found that female BRCA PV carriers who were not seen by 
gynecologic and medical oncology specialists were less likely to follow care guidelines, “which 
may be explained by lack of patient knowledge of cancer risks and recommendations, lack of 
primary care physician comfort and/or expertise in BRCA1 & 2 care, or patient-specific factors 
related to anxiety or avoidance” (Roebothan et al., n.d, p.20). In so doing, the authors shone a 
spotlight on the need for a systemic follow-up program, such as a navigation program, for 
individuals with hereditary breast and ovarian cancer syndrome in NL. 
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Background to Practicum Project 
 
In response to this identified need, my MN practicum project was a policy proposal for a 
HBOC PV carrier navigation and follow-up program in NL. My personal interest in the topic 
stemmed from the beginning of my nursing career when I was working on an acute gynecology 
surgery unit. Frequently, I was providing care to women living with ovarian cancer. I quickly 
realized that ovarian cancer outcomes are poor and that by the time many of these women came 
to us for surgery, they were in the advanced stages of the disease. I came to appreciate the urgent 
need for strategies to improve ovarian cancer outcomes. What I did not understand at the time 
was that furthering our understanding of inherited breast and ovarian cancer risk offers an 
opportunity to prevent those diseases. It was not until I attended an ovarian cancer education 
educational symposium, offered through my affiliate university, that this link became fully clear 
to me. Genomic content was virtually absent from my undergraduate nursing education. The 
more I learned, I began to see this omission of genomics for what it is: an enormous, missed 
opportunity. This practicum project was therefore an opportunity to propose recommendations to 
mitigate the current gaps in PV carrier follow-up care and to advocate for an increased role of 
nurses in the provision of hereditary cancer and genomic follow-up care. 
Goal and Objectives 
 
The overall goal of the practicum was to provide a rationale and recommendations for a 
prospective Navigation and Follow-Up Program for HBOC PV carriers in NL. 
The key objectives of the practicum were the following: 
 
1. Describe the current process of follow-up and supportive care for HBOC PV carriers in NL 
in comparison to other regions outside of NL 
2. Identify priority health care needs for the HBOC PV carrier population in NL and how a 
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program would address these needs 
 
3. Develop recommendations for a HBOC PV carrier navigation program based on a literature 
review, consultation from provincial stakeholders, and an overview of programs in regions 
outside of NL 
4. Explore how integration of the nursing profession in genetic care could improve outcomes 
for HBOC carriers and families 
5. Demonstrate advanced nursing practice competencies. 
 
Overview of Methods 
 
To meet these key objectives, an integrated literature review, key stakeholder 
consultations, and an environmental scan were conducted. In the integrative review, barriers and 
facilitators of HBOC PV carrier follow-up care were examined, as were various inherited cancer 
prevention (ICP) follow-up interventions reported in the literature. (N=8) key stakeholder 
consultations were conducted with health care professionals and researchers in NL who had 
perspectives in either genetics, hereditary cancer, or primary care. These stakeholders provided 
further insight into the barriers and facilitators of PV carrier follow-up care in NL and provided 
their priority recommendations for a prospective follow-up program. An environmental scan was 
also conducted by exploring the related hereditary cancer/ genetic follow-up and surveillance 
services offered in other jurisdictions. Informed by the literature search, stakeholder consult, and 
environmental scan, a program policy proposal document for a HBOC PV carrier navigation 
program model in NL was proposed. These project methodologies are summarized in further 
detail in the sections below. 
It should also be noted that the conceptual framework used to guide the development of 
these documents was Hartrick-Doane and Varcoe’s (2015) relational inquiry approach to 
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nursing. Using a relational inquiry approach to HBOC care, health care providers acknowledge 
the interpersonal, intrapersonal, and contextual factors (Hartrick-Doane & Varcoe, 2015), 
influencing PV carriers’ conceptualization of risk, and their adherence to risk-management 
strategies. By using a relational inquiry approach, attention is also given to denounce the harmful 
effects of medical paternalism and to adopt an emancipatory approach to PV carrier follow-up 
care. The influence of this conceptual framework is evident throughout all development stages of 
this project. 
Summary of the Literature Review 
 
To develop an effective policy proposal, it was crucial that the proposal was sufficiently 
supported by evidence in the literature. A literature review was conducted in two parts, reflecting 
my two questions of interest. These questions were: 1) what are the identified barriers/issues in 
the care of individuals who carry PVs for HBOC in the current follow-up processes? and 2) 
What strategies/models have been examined in the literature for the supportive and follow-up 
care of individuals with HBOC PVs? A search was conducted in the Cumulative Index of 
Nursing and Allied Health Literature (CINAHL), Memorial University Library, and Google 
Scholar electronic databases. The full version of the integrated literature review is found in 
Appendix I of this practicum report. In this section of the practicum report, I will overview key 
findings of the literature review that were directly pertinent to recommendations in the policy 
proposal. 
Part One Study Findings 
 
In response to question one, common themes emerged from the studies of the PV 
carriers’ self-reported barriers and experiences in their HBOC navigation journey. These themes 
served to elucidate priority needs for a follow-up and navigation program. These themes 
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included: health care provider-centered barriers, personalized considerations in risk management 
decision-making, unmet information needs, and the need for a coordinated approach to follow-up 
care. 
Health Care Provider-Centered Barriers 
 
Literature review findings were suggestive that PV carriers’ experience significant health 
care provider-centered barriers in the current follow-up processes. Some PV carriers felt like 
they were the ones guiding their primary care provider in their HBOC journey, as they were not 
always provided accurate nor reliable information from their primary care provider (Cherry et 
al., 2013; Leonarcyzk & Mawn, 2015; Watkins et al., 2011). PV carriers reported inconsistencies 
in medical advice and surveillance recommendations from the various members of their health 
care team (Caita-Zufferey et al., 2015; Cherry et al., 2013; Watkins et al., 2011). A focus group 
of health care providers also noted that HBOC PV carriers were being missed in the disintegrated 
lines of communication involving multiple health care providers (Komatsu & Yagasaki, 2014). 
Watkins et al. (2011) noted that breakdowns in lines of communication about Lynch Syndrome 
management occurred most frequently between medical specialists and primary care providers. It 
was also reported that scarcity of health care providers, especially in rural areas posed challenges 
to adherence to recommended screening modalities (Leonarcyzk & Mawn, 2015). Moreover, 
with limited resources, breast care providers noted that they had limited time to focus on 
preventative measures when they were dealing with active of cases breast cancer and hereditary 
breast cancer prevention was placed lower on their list of priorities (Komatsu & Yagasaki, 2014). 
7  
Personalized Considerations in Risk-Management Decision-Making 
 
The literature review findings were indicative that there are considerable nuances in PV 
carriers’ risk management preferences. Yet, PV carriers reported that interactions with health 
care providers left them feeling as though they were “not being seen as a whole person” 
(Leonarcyzk & Mawn, 2015, p.77). Family planning preferences were reported as being 
influential in the uptake and timing of RRSO for many women (Cherry et al., 2013; Etchegary et 
al., 2015). HBOC PV carriers also noted that both their family history of cancer and family 
dynamics had tremendous impacts on their value appraisal and adherence to risk management 
modalities (Caita-Zuffery et al., 2015; Etchegary et al., 2015). For some women who lost family 
members to HBOC, making HBOC risk-management decisions was triggering to those feelings 
of loss (Caita-Zuffery et al., 2015). Others indicated that having experienced a breast/ovarian 
cancer diagnosis of someone close to them was influential in their adherence to recommended 
risk reduction modalities (Etchegary et al, 2015). Some asymptomatic PV carriers reported they 
felt a strong sense of moral obligation to both their ancestors and their dependents to make use of 
the genetic and medical information at their disposal and to stay healthy for their loved ones 
(Caiata-Zufferey et al. 2015). 
HBOC PV carriers verbalized different levels of comfort about discussing PV carriership 
in their families. It was noted there was potential for guilt and/or resentment among families 
when one family member carried a PV and another did not (Hughes & Phelps, 2010). HBOC PV 
carriers also reported varied levels of comfort with openly discussing their carrier status and 
while some voiced that seeking support from other carriers was beneficial, others felt that there 
was a stigma associated with seeking professional and peer support (Hughes & Phelps, 2010). 
For many women, adequate, informed HBOC decision-making involved a combination of both 
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professional and peer support (Cherry et al., 2013; Hughes & Phelps, 2010; Rauscher & Dean, 
2017). 
Many PV carriers reported that they needed time to process information prior to making 
decisions about risk-management (Dean et al., 2017; Etchegary et al., 2015). Yet some women 
reported that they felt “pushed” (Caita-Zufferey, 2015, p.730) by their healthcare provider to 
adhere to risk-management guidelines. It was clear from the literature that there is no one-sized- 
fits-all approach to PV carrier care following the disclosure of genetic testing results. It was also 
evident that HBOC PV carriers seek more than just medical information, they need personalized, 
on-going support as they navigate the peaks and valleys in their PV carrier journey. 
Unmet Information Needs 
 
Many HBOC PV carriers indicated their information needs were not being met by the 
current PV carrier follow-up processes. This was evidenced during data collection in two studies 
when HBOC PV carriers made erroneous statements about risk-management (Cherry et al., 
2013; Hughes & Phelps, 2010). While this finding was not universal among all the studies, it 
highlights that many women are not given the clear information to make a truly informed 
decision about HBOC risk-management. In a study by Etchegary et al. (2015), premenopausal 
women who underwent RRSO reported that prior to surgery, they did not have an adequate 
understanding of the full extent of surgical menopause and thus felt unprepared when these 
distressing symptoms occurred. In a study by Pezario et al. (2012), 73% (n=104) of women 
stated they received no on-going follow up with their Gynecology surgeon following the initial 
post-operative check up. 
9  
There were calls made by PV carriers in the literature for centralized and up-to date 
resources where PV carriers could retrieve reliable medical and research updates about HBOC 
such as an e-mail subscription, or other type of online resource (Hughes & Phelps, 2010). Other 
women indicated that they wanted decisional aid tools and/or prescriptive plans of action for 
their risk-management (Dean et al., 2017; Leonarcyzk & Mawn, 2015). Health care providers 
reported that the information and support needs of HBOC PV carriers could not be met by the 
current routine breast care follow-up and recommended separate outpatient follow-up clinics 
where due attention could be given to the information and supportive care needs of HBOC PV 
carriers (Komatsu & Yagasaki, 2014). 
The Need for a Coordinated Approach 
 
Several study authors concluded that there was a need for an overhaul in many current 
HBOC risk-management and follow-up care policies (Caita-Zufferey et al., 2015; Cherry et al., 
2013; Komatsu & Yagasaki, 2014; Pezario et al., 2012; Watkins et al., 2011). Caita-Zufferey et 
al. (2015) and Komatsu and Yagasaki (2014) both concluded that there was a need to establish 
specialized, multidisciplinary hereditary cancer clinics to meet the current navigational needs of 
HBOC PV carriers. Similarly, there was a call made by Watkins et al. (2011) for an overhaul of 
the current fragmented, physician dependent screening paradigm for Lynch Syndrome PV 
carriers. Other authors highlighted that there was capacity to expand the role of nurses in the 
HBOC follow-up paradigm. Cherry et al. (2013) purported that a nurse ICP navigation model 
could be a promising alternative to the current processes and could provide BRCA PV carriers 
with support, access to other resources, and assistance with referrals and appointment 
scheduling. Komatsu and Yagasaki (2014) also noted that nurses have an opportunity to act as a 
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communication bridge among multidisciplinary HBOC team members and to improve the 
coordination of care. 
Part Two Study Findings 
 
In part two of the integrative review, quantitative study findings were examined wherein 
authors examined HBOC PV follow-up care models and interventions (models/interventions not 
currently in use in NL). These interventions included psychoeducational groups and workshops, 
cognitive behavioral interventions, dedicated HBOC follow-up clinics and technology platforms, 
In this section, there is a focus on interventions in the literature that were directly used as 
prototypes to inform the key policy proposal recommendations. 
An iPhone Application for Screening Adherence 
 
Cohen et al. (2018) provided pilot data on an iPhone application intervention designed to 
assist BRCA PV carriers in their adherence to recommended BRCA screening modalities. Cohen 
et al. (2018) provided preliminary data, suggestive that their iPhone app meets a practical need 
and is highly acceptable for BRCA PV carriers. While 94.3% of study participants reported their 
intention to engage in a BRCA surveillance plan, only 72.6% reported perceived health care 
system support for surveillance (Cohen et al., 2018). By the same vein, 50% of respondents 
reported they have difficulty keeping track of when to schedule their next BRCA screening 
appointment, and 20% reported that they rely on their primary care provider to do so. At 
baseline, the majority of the (n=69) participants who were provided a download code for the 
BRCA iPhone app agreed or strongly agreed that iPhone applications had a positive impact in 
their lives (Technology Acceptance Model Scores ranging from 3.4±1.1 to 4.1±0.7), and the 
majority of respondents also reported comfort with completing iPhone tasks (Comfort with 
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Technology Scores ranging from 3.5±0.92 to 3.8±0.82) (Cohen et al., 2018). Electronic 
smartphone applications are likely to become integrated into routine health care. These apps are 
a potentially valuable tool for PV carriers, as part of a dedicated follow-up program, when 
navigating the recommended ICP screening appointments. 
Psychoeducational Group Sessions 
 
In the studies examining group interventions for HBOC PV carriers, group interventions 
where psychosocial and educational content was offered were met with positive outcomes. ≥ 
96% of participants in an annual Lynch Syndrome educational workshop reported overall 
satisfaction with the workshop (Corines et al., 2017); 91% reported that they found the content 
at the workshop useful and >87% reported that they were satisfied with the technical medical 
information components of the workshop. In other studies of outcomes of psychoeducational 
groups, there has been improvement noted in BRCA PV carriers’ psychometric measures of 
anxiety, worry, and distress following participation in these groups (Esplen et al., 2004; 
Kwiatkowski et al., 2019; Listøl et al., 2017). Therefore, periodic group sessions where family 
members can attend and connect with other carriers may be a valuable component of a dedicated 
PV carrier follow-up program. 
Dedicated HBOC Follow-Up Clinics 
 
During the initial literature search, there were surprisingly few peer-reviewed studies of 
outcomes in multidisciplinary follow-up clinics for HBOC PV carriers (n=1). However, this 
number grew to (n= 5) later in the project development when I expanded my search strategies. 
(Bancroft et al., 2010 ; Engel et al., 2012; Firth et al., 2011; Pichert et al., 2010; Yerushalmi et 
al., 2016). Yerushalmi et al. (2016) reported on a specialized, multidisciplinary BRCA follow-up 
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clinic that PV carriers attended for bi-annual screening and follow-up clinic visits, with 
additional psychosocial support available to clinic attendees if needed. While the overall quality 
of the evidence was somewhat low, the data on patient outcomes in the clinic were promising. 
Only 7.2% of clinic attendees to date developed cancer. Of those 7.2% cases of cancer, 17 were 
breast cancers, one ovarian cancer, and three were additional cancers. Of the 17 cases of breast 
cancer, 94.1% of those cancers were detected at stage I disease when treatment outcomes are 
generally far more encouraging. Of those breast cancer cases, 70.6% were detected by MRI and 
17.6% were detected by mammography (Yerushalmi et al., 2016). It is impossible to conclude 
with certainty that the low incidence of malignancy occurred exclusively as a result of the 
dedicated follow-up clinic, as clinic outcomes were not compared with outcomes from a matched 
control of a family physician based BRCA follow-up model. Still, the rate of RRSO uptake at 
age 40+ at the clinic in Yerushalmi et al. (2016) was high at 87.3% and the median and mean 
ages at time of RRSO were 46.5 and 48 years, ranging from 33-68. This high rate of RRSO 
uptake before natural menopause in clinic attendees was higher than in most other reported 
registries and in the literature (Yerushalmi et al., 2016). The median age at the time of RRSO in 
the multidisciplinary clinic was also lower than the median age at time of RRSO of 49.6±9.7 in 
NL BRCA PV carriers (Roebothan et al., n.d.) Further studies are needed to compare outcomes 
in dedicated follow-up clinics with family physician-based follow-up, still, Yerushalmi et al. 
(2016) provided a glimpse of outcomes in a successful multidisciplinary follow-up clinic. In 
other study findings, PV carriers reported high levels of satisfaction with multidisciplinary 
BRCA follow-up clinics (Firth et al., 2010). Pichert et al. (2010) found that BRCA PV carrier 
participation in a dedicated follow-up clinic was associated with significantly greater 
participation in related clinical trials (p < 0.001). 
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Summary of Consultations 
 
Following the literature review, the next step to inform the policy proposal was to 
conduct a series of interviews with key informants in NL. There were four objectives for 
conducting the consultations. First, was to confirm with stakeholders that a systematic approach 
to HBOC PV carrier follow-up is relevant and acceptable to them. Second, was to identify issues 
in the current process of HBOC PV carrier follow-up care in NL. A third objective was to 
explore how the role of the nursing profession could be optimized in the proposed policy, as well 
as in genetic/genomic care. And the final objective was to provide stakeholders with an 
opportunity to recommend priority features for a HBOC navigation program policy, from their 
vantage point. Individuals who were identified as potential stakeholders were sent a letter 
explaining the nature of the consultations. Participants who agreed to participate in the 
consultations were: (n=2) genetic counsellors, (n=1) oncologist who provides high-risk PV 
carrier follow-up, (n=2) primary care physicians, (n=2) researchers involved in patient-centered 
research pertinent to these high-risk populations in NL, and an (n=1) individual involved in the 
development of a cancer prevention registry in NL. Consultations took place via telephone while 
some participants chose to respond to the questions through email. Different semi-structured 
question guides were developed, customized to the vantage point of the informant. Content 
analysis was used was used to analyze the raw data generated from the interviews. A full 
summary of the consultation methodologies, findings, and the full complement of semi- 
structured question guides is included in Appendix II of this report. Here, I highlight themes 
from the key informant interviews that directly informed the policy document. These themes 
were: the need for a centralized registry and follow-up program, and the potential nursing role. 
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A Centralized Registry and Follow-Up Program 
 
The consensus among key informants was that PV carriers’ needs are not being 
adequately met by the current primary care provider-dependent follow-up processes in NL. Some 
PV carriers in NL have reported frustrated with the uncoordinated, multiple appointments, lack 
of reliable information sources, and lack of psychosocial support. Some PV carriers even stopped 
attending their prevention and screening appointments because it all became too overwhelming. 
Another commonly reported theme in the consultations was the health care provider-centered 
barriers in PV carrier primary care follow-up. An informant who practices as an oncologist and 
works with PV carriers, was quick to shift the blame for this away from primary care physicians. 
She noted that inherited cancer genomics are complex and risk reduction recommendations can 
change rapidly, beyond a reasonable expectation of primary care providers’ level of awareness. 
Primary care providers also have extremely busy family practices. Informants noted that because 
of this, there is a lack of quality assurance in the current primary care system for ensuring these 
tests are ordered and that specialist follow-up is arranged. There is no electronic or systemic 
recall to ensure PV carriers are getting the recommended screening tests at the appropriate 
intervals. One primary care provider found in his experiences, patients tend to be over-reliant on 
their GPs to remember and coordinate all screening appointments. He added that his ‘greatest 
fear was that [he] will miss a screening and early detection will be missed’. 
Informants agreed that a dedicated inherited cancer prevention registry would be ideal 
where data in the registry was connected to a carrier program that would assume responsibility 
for coordinating high risk follow-up, arranging screening, and providing assistance with the 
psychosocial impacts of carriership. An informant noted that there is an ethical responsibility to 
address the emotional needs of carriers and to support them in the genetic results disclosure with 
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their families. Therefore, it was unanimous among key informants that a prospective program 
should not have a sole focus on screening but also on helping PV carriers navigate the 
psychosocial and family implications of carriership. 
Potential Nursing Role 
 
Several informants expressed that there is unmet potential for nurses to become involved, 
and to ultimately improve the delivery of genetic health care. There are nurses who work as 
genetic counsellors in Canada who were ‘grandfathered in’ prior to the advent of the Canadian 
Association of Genetic Counsellors. Since then, the entry level requirement for certification as a 
genetic counsellor is a master’s degree in genetic counselling. One informant agreed that the 
Masters of Genetic Counselling should be the entry level requirement but maintained that there 
are many other ways that nurses may contribute to genomic care. These included, but are not 
limited to collecting adequate family histories, conducting, and assisting in genetic research, 
engaging in genetic follow-up and supportive care. The successful implementation of nurse-led 
navigation programs in other populations, such as patients diagnosed with cancer, was also 
referenced to give credence to the argument that a nurse navigator could provide a similar 
service to PV carriers in this program. One informant also suggested that a nurse practitioner 
associated with a hereditary cancer screening program could be the one to order the 
recommended screening tests. Informants stated that there are clear opportunities to mobilize 
genetic nursing in nursing practice, research, education, and in professional governance. 
Summary of the Environmental Scan 
 
Also included in Appendix II of this practicum report is the full environmental scan 
summary. To complement the key informant interviews, it was also important to determine what 
works well for PV carrier follow-up programs in other health jurisdictions. Therefore, an 
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environmental scan was conducted, and several objectives of the environmental scan were used 
to inform the policy proposal. These objectives were: 1) to gain an idea of what services are 
common features of familial/hereditary cancer follow-up programs in areas of Canada outside of 
NL and globally. 2) To examine features of a high-risk breast screening registry. 
 
 
Familial Cancer Clinics 
 
In other areas of Canada and around the world, familial cancer clinics are available as 
part of routine health care to individuals with inherited cancer predisposition syndromes after 
they receive their genetic testing results. Many of these centers offer multidisciplinary care from 
professionals such as geneticists, genetic counsellors, nurses, dieticians, gynecologists, 
oncologists, social workers, and psychologists. By having a broad multidisciplinary lens in these 
programs, the multiple facets of PV carriership are addressed. Also, a few of these 
clinics/programs offer periodic carrier support groups and sessions where PV carriers can liaise 
with other PV carriers and families and attend support sessions with guest speakers and 
genetic/hereditary cancer experts. Clinic attendees may be given the option to participate in 
research that may be of benefit to them. For example, clinic attendees who are followed long- 
term may be given the option to participate in trials of new prevention modalities, as the field of 
genetic medicine continues to rapidly evolve. PV carriers are scheduled to visit the clinics 
annually or bi-annually for surveillance, follow up and supportive care. In the province of 
Ontario, many of these clinics work with the High-Risk Ontario Breast Screening Program 
(OBSP) to coordinate breast surveillance of eligible high-risk individuals. 
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High-Risk Ontario Breast Screening Program 
 
Definitions of ‘high risk’ of breast cancer across all Canadian provinces, generally 
include: known carriers of breast cancer predisposition PVs, and first-degree relatives of a 
known PV carrier who did not opt for genetic testing, among other risk factors (Canadian 
Partnership Against Cancer, 2018). Most provinces, including NL, have guidelines for 
recommended high-risk screening intervals, consisting of annual mammography, MRI and/or 
ultrasound beginning at age 30, 40 or 50, to stop at age 69-74 (CPAC, 2018). Despite these 
policies, women at high risk of breast cancer in NL are referred back to their primary care 
provider for further management (CPAC, 2018). 
In the province of Ontario, there is a dedicated follow-up program for women at high-risk 
of breast cancer. To be enrolled in the High Risk OBSP, a referring physician must submit a 
requisition form to a designated High Risk OBSP site (Cancer Care Ontario, n.d.) It is implicit in 
the program requisition form that the ordering physician is requesting future MRI testing and in 
some cases, image guided biopsies, which under current Ontario regulations requires a 
physician’s signature (Cancer Care Ontario, n.d.) Women are either directly enrolled in the 
program because they carry a known PV associated with increased breast cancer risk, or are a 
first-degree relative of someone with a known PV and underwent genetic counselling but opted 
not to have genetic testing (Cancer Care Ontario, n.d.) Women who are a first degree relative of 
someone with a known PV must be assessed by a genetic counsellor prior to enrollment in the 
high risk OBSP, even if they do not opt for genetic testing. The high risk OBSP program is 
operated by high risk OBSP navigators responsible for screening and breast assessment 
appointments, following up on abnormal results, arranging annual recalls, and communicating all 




Summary of the Policy Developed 
 
The primary resource output of this practicum project was the 65+ page policy proposal 
document. The influence of the literature review findings, key informant interviews and 
environmental scan are evident in the proposal. The primary recommendation in the policy 
proposal was the establishment of a novel, dedicated HBOC PV carrier navigation and follow-up 
program in NL. There were five key sub recommendations outlined in the policy proposal: 
1) A central HBOC PV carrier registry in NL 
 
2) The establishment of a nurse navigator position to coordinate PV carrier surveillance 
and follow-up. 
3) Coordinated involvement of a multidisciplinary HBOC team 
 
4) A person and family centred approach to care 
 
5) Virtual and electronic infrastructure to support delivery of the program 
 
 
While the full version of the policy proposal document is located in Appendix III of this 
report, a brief overview of the key policy recommendations is summarized in this section. Under 
the prospective program, individuals carrying pathogenic variants, likely pathogenic variants, 
and variants of uncertain significance would be entered into a PV carrier registry, following the 
disclosure of their genetic testing results. It was recommended that information in the carrier 
registry should include demographic information, information on the pathogenic variant, 
information on the testing panel ordered, and information on the recommended clinical actions 
for the variant. Moreover, the registry data should be updated as PV carriers undergo the 
recommended screening and risk-reduction modalities. The registry data should be accessible to 
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all approved multidisciplinary team members in the PV carrier follow-up program. The 
participation of PV carriers in the follow-up program would be voluntary. 
The second recommendation, and central feature of the follow-up and navigation 
program, is the nurse PV carrier navigator role. The nurse navigator would have several 
responsibilities in the delivery of the program. (S)he will be responsible for maintaining ongoing 
follow-up with PV carriers, coordinating and scheduling screening appointments, connecting 
them with other multidisciplinary team members, and assisting with discussing genetic testing 
results with family members. The nurse navigator will rely on the carrier registry data to 
facilitate booking and screening reminders and to develop a personalized plan of care. Moreover, 
under the prospective program, PV carriers will be connected to expert multidisciplinary care 
providers as needed including, but not limited to, gynecologists, oncologists, breast surgeons, 
social workers, psychologists, dieticians, and genetic counsellors as needed, following ongoing 
assessment with the nurse navigator. 
A person-centered approach is recommended for this program when working with PV 
carriers to deliver a follow-up care plan that is psychologically suited to their needs, preferences, 
and individual life circumstances. Given that these individuals are generally asymptomatic and 
lead busy, active lives, this program should have flexible delivery options. This may include 
evening and weekend appointment offerings and different communication options, such as in 
person appointments and/or video and telephone conferencing. The framework recommended to 
guide the delivery of this program is Hartrick Doane and Varcoe’s (2015) relational inquiry. The 
principles of relational inquiry are relevant when delivering person-centered follow-up care that 
acknowledges all the systemic, familial, and individualized factors influencing adherence and 
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appraisal of risk mitigation in PV carriers. The use of this framework is a strategy to ensure a 
person and family centred approach. 
A family centered approach is also a key feature recommended for this proposed 
program. Both affected and unaffected family members of PV carriers may experience 
psychologic distress emanating from the awareness of their own risk and/or the worry of their 
relatives’ increased risk of cancer. In the current approach to PV carrier follow-up, family 
considerations are unaccounted for. This oversight would be addressed in the prospective 
program by encouraging the involvement of family members in a follow-up program. PV carrier 
families would also be supported by the follow-up program in family genetic results disclosure 
sessions. There, HBOC follow-up team members would be present to help explain the 
implications of PV carriership to PV carriers and to their potentially at-risk family members. The 
program would also support at-risk relatives who wish to pursue genetic testing by streamlining 
them with Provincial Medical Genetics. 
The final recommendation in the proposal is that virtual and electronic delivery methods 
should be available for this program. The use of telehealth and virtual appointment delivery will 
ensure that PV carriers provincewide have equitable access to quality follow-up services, 
regardless of their geographic location. PV carriers should also be able to opt for electronic text 
appointment reminders and online information/updates and to connect with other PV carriers 
should they desire. It is recommended that the delivery of the proposed program is compatible 
with the province-wide electronic medical record and electronic health record software so that 
relevant information pertaining to their PV carriership can be clearly communicated and shared 
to all relevant providers in the circle of care, ensuring continuity and consistency of care. 
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Discussion of Advanced Nursing Practice (ANP) Competencies 
 
In addition to the aforementioned documents, a key objective of this practicum project 
was to demonstrate advanced nursing practice (ANP) competencies. In an ANP Framework, the 
Canadian Nurses Association (CNA) (2019) outlined six categories of ANP competencies: direct 
comprehensive care, health system optimization, education, research, leadership, and 
consultation and collaboration. The ANP competencies of research, health system optimization, 




This ANP competency refers to “generating, synthesizing, critiquing and applying 
research evidence” (CNA, 2019, p. 32). This ANP competency was demonstrated through the 
utilization and application of research findings in each stage of policy development. In the 
integrative literature review, findings in peer-reviewed articles were appraised and used as a 
basis to inform the consultations, environmental scan and ultimately, the policy proposal. 
Although this was not a formalized research project, in the key informant consultations and 
environmental scan, I engaged in data collection, data analysis, and undertook the appropriate 
steps to safeguard the data and to ensure ethical conduct in data collection. This data was used as 
evidence to inform the policy proposal. 
Health System Optimization 
 
Advanced practice nurses demonstrate this competency by contributing “to the effective 
functioning of health systems through advocacy, promoting innovative client care and facilitating 
equitable, client-centered health care” (CNA, 2019, p. 30). This program policy is largely an 
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advocacy paper. I presented the argument that PV carriers have an unequivocally increased of 
cancer when compared to the general population and that it therefore unjust to treat them the 
same as people of average risk. In the policy paper, I made recommendations to mitigate the 
systemic barriers that PV carriers experience in their access to follow-up care and to improve 
clinical and satisfaction outcomes in PV carrier populations. I also demonstrated how a 
prospective program could improve clinical efficiency, as I presented in the policy document that 
several of the proposed program features are validated in the literature as being cost-effective. 
Consultation and Collaboration 
 
This ANP competency is hallmarked by “effective collaboration and communication with 
clients, others health-care team members and stakeholders whose services impact the 
determinants of heath” (CNA, 2019, p. 33). This practicum project would never have gotten off 
the ground without the interdisciplinary consultation with my contact persons for the project. 
These two individuals are researchers in the area of hereditary cancer genetics, and they 
endorsed the need for this project and shared resources and input that were invaluable to this 
project. Furthermore, the key informant consultations were conducted with individuals with 
important clinical and research vantage points in the NL health care system. Their perspectives 
provided rich, pragmatic data, which informed the program policy proposal. The 
interdisciplinary collaboration as part of this project was an entry point for potential partnerships 
and future professional collaborations in research and policy development. 
Next Steps 
 
The policy proposal is an in-depth document with detailed recommendations for the 
proposed program. However, the proposal is only an important starting point in what is 
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ultimately required to bring the proposed program to fruition. It is important to continue to 
disseminate findings, seek feedback, amend the proposal as necessary, and to gain the support of 
stakeholders and health system funders. I have several strategies to accomplish this; firstly, is 
through continued collaboration and communication with key stakeholders and contact persons 
for the project. The completed program policy proposal was shared with my identified contact 
person for the project who is actively involved in genetic high-risk care in NL and is a founding 
member of the NL Ovarian Cancer Research and Education Fund. I informed her that she has 
permission to share findings from the program proposal to inform future studies in this area 
and/or to share the proposal with the administrators of her organization(s) for approval and the 
resources needed to implement. The work in this practicum project led me to become involved in 
a research team that she is leading, who are endeavoring to development a framework for a 
Lynch Syndrome hereditary cancer registry. I am hopeful that my work on this practicum project 
was a starting base for future multidisciplinary research collaborations, both in NL and in other 
regions, on the topic of ICP and genomic nursing. Future research may include patient-orientated 
research with carriers who can provide input and feedback on a proposed follow-up program 
model, as well as an in-depth cost-analysis of a prospective program when compared with the 
NL health system costs of non-surveyed HBOC. Ultimately, my desired goal is to inform a pilot 
project of a novel follow-up program for HBOC PV carriers. 
Secondly, it will be important to keep an eye out for professional opportunities to 
promote the visibility of my project and other related work. I recently wrote a related article for 
submission in a Canadian nursing journal. The purpose of submitting an article for publication is 
to generate conversation about the potential nursing role in the delivery of genomic follow-up 
health care.. In the spring of 2021, I will be presenting this practicum project as part of the 
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Tuesday teleconference sessions offered by the College of Registered Nurses of Newfoundland 
and Labrador. 
Finally, I will also keep an eye out for educational opportunities to increase my own 
genomic literacy and competencies. In the long-term, I hope to pursue both further graduate and 
professional development education that is aligned with my interest in hereditary cancer 
prevention and genomics. This will enhance my credibility to disseminate research findings, as 
well as to make recommendations for improved inherited cancer prevention delivery models. In 
short, the buck does not stop here in this report with the work that I have completed to date as 
part of this project. 
Conclusion 
 
The project objectives were met over the course of this practicum project. An overview 
of the current HBOC syndrome follow-up processes in NL were presented with a rationale for 
how this current approach is inadequately meeting the complex medical, informational, and 
psychosocial needs of PV carriers and families. To understand and present possible solutions to 
these gaps, a literature review, key informant consultations, and an environmental scan were 
conducted. These documents were used to inform five key recommendations in a policy proposal 
for prospective registry and follow-up program for HBOC PV carriers in NL. Through 
completion of this project, I was able to demonstrate advanced practice nursing competencies of 
research, health system optimization, and consultation and collaboration. A compelling case was 
made in the proposal document for both the need for, and the feasibility of prospective follow-up 
and navigation program for NL HBOC PV carriers. The policy proposal document is poised to 
help shape healthy public policy for PV carriers and to inform future exploratory and pilot 
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Various pathogenic variants (PV) such as mutations in the BRCA1, BRCA2 genes are 
associated with an inherited breast and ovarian cancer predisposition (HBOC) syndrome. For 
example, individuals who carry PV (deleterious changes) in the BRCA1/2 genes have a 51-72% 
lifetime risk of breast cancer and an 11-44% lifetime risk of ovarian cancer (Kuchenbaecker et 
al., 2017; Rebbeck et al, 2015). Despite the high lifetime risk, breast and ovarian cancer 
associated with germline mutations can be prevented with the uptake of recommended risk- 
reduction modalities proven to be effective in known PV carriers. 
Despite clear evidence that targeted HBOC prevention and screening modalities are 
effective, there is a paucity of follow-up programs in Canada that address the health 
considerations specific to this high-risk population. Once the genetic results disclosure has 
occurred, PV carriers and their primary care providers are often solely responsible for the 
coordination and compliance with screening and prevention recommendations (Roebothan et al., 
n.d.). This is concerning, given that in a study of participants with a personal or family history of 
genetic disease, 64% of study participants reported receiving no genetics education from their 
primary provider (Harvey et al., 2007). In an unpublished manuscript by Roebothan et al. (n.d.) 
the study authors characterized the population of female BRCA1 & 2 PV carriers in 
Newfoundland and Labrador (NL), and evaluated which factors influence their HBOC screening 
and prevention modality adherence. They found that “women who did not access care from 
[cancer and genetic] specialists were less likely to follow care guidelines, which may be 
explained by lack of patient knowledge of cancer risks and recommendations, lack of primary 
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care physician comfort and/or expertise in BRCA1/2 care, or patient-specific factors related to 
anxiety or avoidance” (Roeboethan et al., n.d, p.20). In so doing, the authors highlighted the 
need for a psychosocial and educational follow-up model, such as a navigation program, for 
individuals with HBOC predisposition syndrome. 
To situate this review, I will provide a background of the prevalence and implications of 
HBOC syndrome in Canada, and specifically in the province of NL. From there, I have two 
specific objectives in conducting this integrative review; first is to examine the barriers to quality 
follow-up care for individuals with HBOC predisposition syndrome. The second is to determine 
to what extant HBOC PV carrier follow-up program models/interventions have been 
implemented. The end goal of this literature review is to present the available evidence stemming 
from these two questions so it may be used to inform policy recommendations for a HBOC 
patient navigation program in the province of NL. For this literature review, the bulk of the 
information retrieved will be generalizable to all individuals and families with germline PVs 
known to be predisposing to breast and/or ovarian cancer. 
Background 
 
Hereditary Breast and Ovarian Cancer Syndrome (HBOC) is an adult-onset cancer 
predisposition syndrome associated with significantly increased lifetime risks of developing 
breast and ovarian cancer (Jackson Laboratory, 2020). It should be noted that while HBOC 
syndrome is most often associated with BRCA1 &2 PVs, it has also been associated with up to 
24 various inherited PVs (Nielsen et al., 2016). This includes germline mutations in the 
mismatch repair genes associated with Hereditary Non-Polyposis Colorectal Cancer or Lynch 




Prevalence of HBOC in Canada and NL 
 
The incidence of BRCA PV carriers in the general population is estimated at 
approximately 1 to 300 to 1 in 500 (Nelson et al., 2014). 354,965 Canadians have been or will be 
diagnosed with a hereditary breast or ovarian cancer and therefore as many as 709, 930 (1.9%) of 
Canadians carry a known PV that predisposes them to hereditary breast and/or ovarian cancer 
(Hereditary Breast and Ovarian Cancer Society, 2018). Roebothan et al. (n.d.) conducted a 
retrospective study to characterize the entire dataset of female BRCA1/2 mutation carriers in NL 
and the factors influencing their adherence to recommended risk-reduction modalities. They 
identified a total of 276 BRCA mutation carriers since the introduction of genetic testing in NL. 
While the BRCA carrier prevalence rate of 0.05% in the general NL population was lower than 
expected, they cited the current opportunistic genetic testing paradigm, resulting in the under- 
identification of BRCA carriers in the province, as a possible cause for their findings. Using 
population risk estimates of 1 in 300, Roebothan et al. (n.d.) purported that they estimate the 
prevalence of BRCA 1/2 PV carriers in NL to be upwards of 1,700. The low prevalence of 
BRCA PV carriers in NL could also be attributable to the fact that NL is considered a founder 
population, primarily of Irish and English descent (Zhai et al., 2016). Despite the low prevalence 
of BRCA PV carriers, NL has the highest rate of breast cancer mortality and the fourth highest 
rate of ovarian cancer mortality in the country (Canadian Cancer Statistics Advisory Committee, 
2019). 
Dawson et al. (2020) recently published their case/control study on the molecular 
genetics of HBOC in NL where they performed multigene paneling on five female probands with 
a personal history of breast and/or ovarian cancer who tested negative for known high and 
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moderate risk HBOC variants, but all shared a variant of uncertain significance (VUS) in the 
RAD51C gene. Interestingly, when Dawson et al. (2020) performed control haplotype analysis, 
there was a 52-fold increase of the RAD51C VUS in the NL population versus in general 
Caucasian population control (0.165% vs 0.0032%). From this, they concluded that the 
RAD51C(NM_058216.3: c.571 + 4A > G) variant is pathogenic; this and “other yet 
undiscovered variants may explain the increase incidence and perhaps mortality associated with 
HBOC in NL” (Dawson et al., 2020, p.11). The unique genetic composition of NL is 
characterized by the historical isolated nature of the island, an increased inbreeding coefficient, 
and reduced heterozygosity (Zhai et al., 2016). As new evidence emerges surrounding the 
molecular genetic makeup of HBOC in both NL and global populations, and as additional VUS 
in HBOC are reclassified as pathogenic, this will further the need for programmatic follow-up 
for these high-risk women in NL. 
Recommended HBOC Risk-Reduction Modalities 
 
There is strong evidence of the favorable impact of BRCA risk-reduction modalities on 
morbidity and mortality in asymptomatic BRCA mutation carriers. Risk-reducing salpingectomy 
oophorectomy (RRSO) has been associated with 80% reduction in ovarian/fallopian tube cancer 
risk and a 50% reduction in breast cancer risk in asymptomatic women who carry mutations in 
the BRCA1/2 genes (Rebbeck et al., 2009). Risk-reducing mastectomy (RRM) is also discussed 
as a potential risk-reduction intervention which has been shown to essentially eliminate the risk 
of breast cancer in asymptomatic female BRCA 1/2 carriers (Li et al., 2016). 
Likewise, annual breast magnetic resonance imaging (MRI), alternating every 6 months 
with annual breast mammography has been shown to have a combined sensitivity of > 90% for 
detecting early stage breast cancer and is therefore recommended in this population (Warner, 
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2018). The Breast Disease Site Group (2017) of the Eastern Health (EH) Regional Health 
Authority (and NL tertiary care provider) established a policy recommending alternating annual 
MRI and mammography for women with an increased risk of breast cancer, starting at age 30. 
The Breast Disease Site Group (2012) also established a policy stating that premenopausal 
women ≥ 35 and postmenopausal women with a high risk of hereditary breast cancer should be 
offered oral Tamoxifen (a selective estrogen receptor modulator) once daily for five consecutive 
years. Use of oral contraceptive medication for six or more years has been associated with 
decreased risk of developing ovarian cancer in BRCA 1/2 carriers (OR 0.62, 95% CI 0.35-1.09) 
(Whittemore et al., 2004). 
Complexity of Decisions Surrounding HBOC Syndrome Carriership 
 
While the evidence surrounding risk-reduction modalities is extremely encouraging and 
while increased breast surveillance and prophylactic surgery are widely available in most 
Western countries, decisions surrounding risk-reduction remain complicated for both patients 
and healthcare providers. For example, RRSO and RRM offer the most significant protective 
factors for HBOC but the decision to undergo prophylactic surgery must take into consideration 
other factors in a woman’s life. Women who underwent RRSO reported distressing vasomotor 
and urogenital symptoms associated with surgical menopause, reduced sexual pleasure, and for 
women of childbearing age, an RRSO meant that they were not able to have any further children 
(D’Alonzo et al., 2018). In the same study, women who underwent RRM reported the negative 
effects of the surgery on their body image and sexuality (D’Alonzo, 2018). HBOC PV carriers 
also face complex decisions related to the disclosure of this information to family members, 
and/or the decision to have children given the chance of passing on the mutation (White et al., 
2014). There may be disagreement among family members about whether the knowledge of 
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one’s carrier status is beneficial or if this knowledge may cause iatrogenic psychological harm 
(Speice et al., 2002). 
Problem with the Current Follow-up Processes in NL 
 
Once an individual is referred to the NL provincial genetics program, genetic testing is 
exclusively delivered by medical genetics specialists after in-person counselling (Adams & 
Etchegary, 2015). Following the disclosure of genetic results, navigation of annual recommended 
follow-up modalities, complicated treatment decisions and family considerations are left entirely 
in the hands of the individual and their primary care provider (Roebothan et al., n.d.). Dr. 
Dawson, a gynecologic oncologist and Associate Professor of clinical genetics at Memorial 
University of Newfoundland, described BRCA carriers in the province as being “orphaned by the 
healthcare system” (Mercer, 2018, para 2). Other than the work done through Dr. Dawson’s 
gynecologic oncology inherited cancer prevention clinic at Memorial University, there is no 
programmatic follow-up for these women in the province, resulting in a significant missed 
opportunity. Roebothan et al. (n.d.) noted that only 41.6% of BRCA PV carriers in NL had 
undergone the recommended MRI screening in the past 18 months (p < 0.001). While proven 
effective to prevent disease, the recommended modalities are still largely underutilized by 
HBOC PV carrier populations who stand to benefit from them. 
The current follow-up processes in NL, and in many other jurisdictions, is not only 
ineffective, but this approach is in contradiction with policy statements in fundamental Canadian 
health promotion framework documents such as the Canadian Lalonde (1974) report, A New 
Perspective on the Health of Canadians and Achieving Health for all: A Framework for Health 
Promotion (Epp,1986). Furthermore, with the high costs of cancer treatments and an aging 
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Canadian population, “a cancer care system that focuses on treatment over prevention is not 
sustainable” (Roebothan et al., n.d., p.4). 
It is clear the need exists for improved HBOC previvor support and follow-up care. 
Therefore, there are two questions that must be posed in order develop an effective healthy 
public policy for a HBOC previvor care model. 1) What are identified barriers/issues in the care 
of individuals who carry PVs for HBOC in the current paradigm? and 2) What strategies/models 
have been examined in the literature for the supportive and follow-up care of individuals with 




Two conceptual frameworks were selected to guide this literature review. HBOC is truly 
a family affair and targeted strategies should be approached accordingly. Therefore, I selected 
Street and Soldan’s (1998) conceptual framework of psychosocial issues in families with genetic 
conditions. The authors purported that individuals require routine psychosocial care during the 
pre-illness phase of genetic disease and not just in the incidence of poor coping. They postulated 
that when caring for PV carriers, health care providers should move away from “disease-specific 
framework with its limited acknowledgment of psychosocial issues, to one informed by the 
family systems life cycle and the therapeutic practices that emanate from it” (Street & Soldan, 
1998, p.231). 
The second conceptual framework used to inform the literature review is Relational 
Inquiry which was developed as an approach to nursing practice. Hartrick-Doane and Varcoe 
(2015) enlisted an approach consisting of two main elements, “relational consciousness and 
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inquiry as a form of action” (p.3). To engage in relational consciousness, health care providers 
must be attentive to what is going on interpersonally (among and between people), 
intrapersonally (within people), and contextually (within factors and structures), in all health 
situations (Hartrick-Doane & Varcoe, 2015). They described inquiry as the “how-to” (Hartrick- 
Doane & Varcoe, 2015, p.6) of relational inquiry. In other words, inquiry involves using the 
insight gained through relational consciousness when implementing health interventions. Using a 
relational inquiry approach to the care of HBOC PV carriers acknowledges the complexities of 
the interpersonal, intrapersonal, and contextual factors at play in their journey as HBOC 
previvors. Relational inquiry was influenced by critical theory, a philosophical movement where 
disparities in sociopolitical structures are highlighted and there are calls for action to mitigate the 
lasting effects of disadvantageous socioeconomic, political, and historical ideologies (Polit & 
Beck, 2017). By using a relational inquiry approach, attention is also given to denounce the 
harmful effects of medical paternalism and adopt an emancipatory approach to HBOC care. 
Search Strategy 
 
The literature search was conducted in two parts, reflecting my two separate questions of 
interest. I searched the Cumulative Index of Nursing and Allied Health Literature (CINAHL), 
Memorial University Library, and Google Scholar electronic databases for both literature review 
questions. Additionally, both the ancestry and descendancy approaches as described by Polit and 
Beck (2017) were used as search strategies. Using the ancestry approach, I located relevant 
studies that were listed in the reference pages of retrieved studies and included them in the 
review. Using the descendancy approach, I used the ‘cited by’ option in the MUN Library 
database to find more recent, relevant articles wherein the authors had cited my retrieved studies. 
Adhering to the guidelines of Polit and Beck (2017), studies included in this review were all 
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written in English language within the past 15 years. Retrieved studies were peer-reviewed and 
featured either a qualitative or quantitative design. Inclusion criteria for studies in both question 
one and two were: studies pertinent to individuals and families carrying pathogenic variants 
known to predispose to HBOC. The strength and quality of the evidence presented in the 
quantitative studies were evaluated using guidelines from the Public Health Agency of Canada 
(PHAC) (2014) critical appraisal tool, while the Joanna Briggs Institute (2017) critical appraisal 
checklist for qualitative research was used to appraise the qualitative studies. 
In part one, I sought to answer my question, “What are reported barriers to adequate 
follow-up care of individuals at high risk for HBOC in the current paradigm?” To this end, 
combinations of the descriptors ‘HBOC’, ‘carriers’, ‘Familial Cancer’, ‘Hereditary Cancer’, 
‘Lynch Syndrome’ were used in combination with the search terms ‘AND’ ‘follow-up 
adherence’, ‘barriers’, ‘screening’, “psychosocial”, ‘educational needs’. A total of (n=10) studies 
were retrieved that were deemed applicable to part one of this review. Most of these studies 
(n=9) had a qualitative design. HBOC PV carriers provided rich, first-person testimony of their 
experiences as PV carriers and their perceived barriers with HBOC follow-up and risk 
management. In one study, health care providers provided first person accounts of their 
perceived health care barriers to HBOC management (Komatsu & Yagasaki, 2014). A summary 
of these studies can be found in Appendix A of this integrative review. 
For the second question, I sought to answer, “What strategies/models have been 
examined for the supportive and follow-up care of individuals and families with PVs 
predisposing them to HBOC?” To do so, I used combinations of the search terms ‘HBOC’, 
‘BRCA carriers’, ‘Familial Cancer’, ‘Hereditary Cancer’, ‘Lynch Syndrome’ in combination 
with ‘AND’ ‘patient navigation’, ‘follow-up care’, ‘patient support programs’, ‘supportive care’ 
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and ‘psychoeducational interventions.’ Inclusion criteria specific to question two was that the 
interventions in the studies had to occur in the phase post-genetic counselling. While the 
interventional studies retrieved in question two were of varied time lengths and modes of 
delivery, they were all of sufficient relevance to one of two the key aims of this literature review. 
A total of (n=9) studies were deemed applicable to the focus of question two. Strength of the 
study designs ranged from strong to weak, and the quality of the evidence in the studies ranged 
from high to low as per the PHAC (2014) critical appraisal criteria. A summary of these studies 
can be found in Appendix B. 
Part One Study Findings 
 
In response to question one, five common themes emerged from the studies of the 
participants’ reported barriers and experiences in their HBOC navigation journey. These themes 
were: health care provider-centered barriers, personalized considerations in risk management 
decision-making, unmet information needs, the need for peer support, and the need for a 
coordinated approach to follow-up care. 
Health Care Provider-Centered Barriers 
 
Reiteratively, in many current Canadian HBOC paradigms, once disclosure of the 
individual’s PV carrier status has occurred, the navigation of health considerations specific to 
their carrier status becomes the responsibility of the individual and/or their primary care provider 
(Roebothan et al., n.d.). Taking this into consideration, it is concerning that study participants 
commonly reported receiving insufficient guidance from their primary care provider. Several 
participants voiced that they felt as though they were the ones guiding their primary care 
provider in their HBOC journey, as the information they were provided was not always accurate 
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nor reliable (Cherry et al., 2013; Leonarcyzk & Mawn, 2015; Watkins et al., 2011). Participants 
reported challenges in obtaining relevant HBOC risk-management information from their 
primary care provider, especially about subjects considered taboo such as the potential adverse 
sexual implications of HBOC risk management (Cherry et al., 2013). Some participants reported 
that if PV carriers were younger in age, their primary care provider discredited the importance of 
adherence to recommended screening and essentially ‘kicked the can further down the road’ 
(Watkins et al., 2011). 
There was also considerable confusion reported by PV carriers about inconsistencies in 
medical advice and surveillance recommendations from various members of their health care 
team (Caita-Zufferey et al., 2015; Cherry et al., 2013; Watkins et al., 2011). This caused the 
women to feel overwhelmed and frustrated by the sometimes-conflicting advice they received 
(Caita-Zufferey et al., 2015). A similar concern was echoed in a focus group of health care 
providers who noted that there was a high probability of HBOC PV carriers being missed in the 
disintegrated lines of communication involving multiple health care providers (Komatsu & 
Yagasaki, 2014). Watkins et al. (2011) noted that breakdowns in lines of communication about 
Lynch Syndrome management appeared to be most salient between medical specialists and 
primary care providers. It was also reported that scarcity of health care providers, particularly in 
rural regions posed challenges to adherence to recommended screening modalities (Leonarcyzk 
& Mawn, 2015). Moreover, with limited resources, breast care providers noted that they had 
limited time to focus on preventative measures when they were dealing with active of cases 
breast cancer and thus hereditary breast cancer prevention was placed lower on their list of 
priorities (Komatsu & Yagasaki, 2014). 
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Personalized Considerations in Risk-Management Decision-Making 
 
Another theme that emerged from the data was the imperative of personalized 
considerations when assisting individuals to navigate their HBOC journey. Some participants 
noted that interactions with health care providers left them feeling as though they were “not 
being seen as a whole person” (Leonarcyzk & Mawn, 2015, p.77). In one example, family 
planning vis-a-vis HBOC PV carriership is a highly personalized decision. Individuals and 
families making these decisions require sensitivity and support from health care providers to 
make the most suited, informed choice for their life circumstances. This is perhaps best 
summarized by one HBOC PV carrier that, “[family planning for PV carriers] is not a statistic, 
it’s what they feel in their heart is the right thing to do” (Rauscher & Dean, 2017, p. 491). Some 
participants stated it was important that family planning and counselling involve a two-way 
dialogue about both previvor and their spouse’s feelings about family planning, yet it was 
common for the spouse to be overlooked in these discussions (Rauscher & Dean, 2017). Family 
planning was also influential in the uptake and timing of RRSO for many women (Cherry et al., 
2013; Etchegary et al., 2015). 
HBOC PV carriers also noted that both their family history of cancer and family 
dynamics had tremendous impacts on their value appraisal and adherence to risk management 
modalities. For some women who had lost family members to HBOC, making HBOC risk- 
management decisions was triggering to those feelings of loss (Caita-Zuffery, 2015). Others 
indicated that having experienced a breast/ovarian cancer diagnosis of someone close to them 
was influential in their stringent adherence to recommended risk reduction modalities (Etchegary 
et al, 2015). Other women reported that the risk-management decision experiences of family 
members who were also PV carriers were influential factors in their own risk-reduction decision 
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making (Cherry et al., 2015). Some asymptomatic PV carriers reported they felt a strong sense of 
moral obligation to both their ancestors and their dependents to make use of the genetic and 
medical information at their disposal and to stay healthy for their loved ones (Caiata-Zufferey et 
al. 2015). 
HBOC PV carriers verbalized different levels of comfort about discussing PV carriership 
in their families. It was noted there was potential for guilt and/or resentment among families 
when one family member carried the gene and another did not, and opinions often greatly varied 
between family members about whether or not PV carriership should be disclosed (Hughes & 
Phelps, 2010). HBOC PV carriers also reported varied levels of comfort with openly discussing 
their carrier status and while some voiced that seeking support from other carriers was beneficial, 
others felt that there was a stigma associated with seeking professional and peer support (Hughes 
& Phelps, 2010). Many women reported that they needed time to process information prior to 
making decisions about risk-management (Dean et al., 2017; Etchegary et al., 2015). Yet some 
women also reported that they felt “pushed” (Caita-Zufferey, 2015, p.730) by their healthcare 
provider to adhere to risk-management guidelines. It was clear from the literature that there is no 
one-sized-fits-all approach to HBOC previvor care following the disclosure of genetic testing 
results. It was also evident that mere provision of medical information is insufficient, HBOC PV 
carriers need personalized, on-going support as they navigate the peaks and valleys in their 
journey as a HBOC previvor. 
Unmet Information Needs 
 
There is a need for information that many HBOC PV carriers reported is not being met in 
the current HBOC care paradigm. This was evidenced during data collection in two studies when 
HBOC PV carriers made erroneous statements about risk-management (Cherry et al., 2013; 
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Hughes & Phelps, 2010). One woman stated she believed an RRSO would increase the risk of 
breast cancer when in fact, RRSO decreases the risk of breast cancer (Cherry et al., 2013). 
While this finding was not universal among all the studies, it highlights that many women are not 
given the clear information to make a truly informed decision about HBOC risk-management. In 
the study by Etchegary et al. (2015), premenopausal women who underwent RRSO reported that 
prior to surgery, they did not have an adequate understanding of the full extent of surgical 
menopause and thus felt unprepared when these distressing symptoms occurred. These 
symptoms appear to be more pronounced in women who were premenopausal at the time of 
RRSO; in a study by Pezario et al. (2012), the distribution of women who reported “persistent 
severe” menopausal symptoms showed a linear correlation with younger age at the time of 
RRSO (p=0.002). Moreover, in the same study, 73% (n=104) of women stated they received no 
on-going follow up with their Gynecology surgeon following the initial post-operative check up. 
As these symptoms can be distressing and interfere with a woman’s quality of life, it is important 
that pre-menopausal women who opt for RRSO are informed and adequately supported if these 
symptoms occur. 
There were calls made by study participants for additional resources that could be useful 
to them in their HBOC journey. Some women reported that a directory including a list of 
relevant care providers (i.e. oncologists, gynecologists) would be a beneficial resource for use 
when navigating the health care system (Dean et al., 2017). Women also indicated the need for a 
centralized and up-to date resource where PV carriers could retrieve reliable medical and 
research updates about HBOC such as a newsletter, e-mail subscription, or other type of online 
resource (Hughes & Phelps, 2010). Other women indicated that they wanted decisional aid tools 
and/or prescriptive plans of action for the next steps in their risk-management (Dean et al., 2017; 
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Leonarcyzk & Mawn, 2015). Health care providers reported that the information and support 
needs of high risk HBOC women could not be met by the current routine breast care paradigm 
and recommended the establishment of separate outpatient follow-up clinics so that due attention 
could be given to the information and supportive care needs of HBOC previvors (Komatsu & 
Yagasaki, 2014). 
The Need for Peer Support 
 
A prevailing theme among the studies was the participants’ reported desire and/or 
acclaim for formalized peer support in their HBOC navigation journey. HBOC PV carriers 
reported feeling different from the rest of the population and desired the opportunity to liaise 
with someone who could relate to their experiences as a HBOC previvor (Hughes & Phelps, 
2010). Some HBOC previvors participated in online support groups such as Facing Our Risk of 
Cancer Empowered (FORCE) and Bright Pink (Dean et al., 2017; Leonarcyzk & Mawn, 2015). 
Feedback from participants who engaged in these online platforms was quite positive. For risk- 
reduction decision making, participants emphasized that they wanted to hear both the positive 
and negative risk-management experiences of other PV+ carriers, to make an informed decision 
in their own journey (Cherry et al., 2013; Dean et al., 2017). For many women, adequate 
informed HBOC decision-making involved a combination of both professional and peer support 
(Cherry et al., 2013; Phelps & Hughes, 2010; Rauscher & Dean, 2017). It became clear from 
study findings that when developing follow-up programs for HBOC PV carriers, the need for 
formalized peer support is an important consideration. 
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The Need for a Coordinated Approach 
 
Several study authors concluded that there was a need for an overhaul in many current 
HBOC risk-management and follow-up care paradigms (Caita-Zufferey et al., 2015; Cherry et 
al., 2013; Komatsu & Yagasaki, 2014; Pezario et al., 2012; Watkins et al., 2011). Caita-Zufferey 
et al. (2015) and Komatsu and Yagasaki (2014) both concluded that there was a need to establish 
specialized, multidisciplinary hereditary cancer clinics to meet the current navigational needs of 
HBOC PV carriers. Similarly, there was a call made by Watkins et al. (2011) for an overhaul of 
the current fragmented, physician dependent screening paradigm for Lynch Syndrome PV 
carriers. Other authors highlighted that there was capacity to expand the role of nurses in the 
HBOC paradigm. Cherry et al. (2013) purported that a nurse navigation model for could be a 
useful alternative to the current paradigm and could provide BRCA PV carriers with support, 
access to other resources, and assistance with referrals and appointment scheduling. Komatsu 
and Yagasaki (2014) also noted that nurses have an opportunity to act as a communication bridge 
among multidisciplinary HBOC team members and to improve the coordination of care. To this 
effect, expanding the role of nurses in genetic and hereditary cancer previvor care could be a 
beneficial strategy for improving the follow-up care of this high-risk population. 
Quality of the Evidence 
 
As most of the evidence retrieved for question one came from qualitative studies with 
relatively small sample sizes, there is limited generalizability of the study findings. Though 
generalizability is not an expectation of qualitative research, qualitative research findings can be 
transferrable; this was the case with the qualitative studies in question one. Similarly, there was 
limited sociodemographic diversity among study participants. While this should be taken into 
consideration when weighing the evidence, there is an unassailable value in the rich, first-person 
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accounts of barriers and experiences as a HBOC previvor. As they are the ones who stand to 
benefit from targeted strategies, it is important that their priority needs are seen from their 
vantage point. Moreover, there was considerable overlap among participant and health care 
provider reported themes in the studies, which were conducted in a variety of countries and 
settings. This suggests that these are common issues and experiences shared by many HBOC PV 
carriers. While further studies are needed to quantify the findings discussed here, these study 
findings provide useful direction on priority needs and preferences of HBOC PV carriers when 
designing follow-up care models. It is also of note that all studies in question one were appraised 
using the Joanna Briggs (2017) Qualitative checklist and found to be of sufficiently high quality 
for inclusion in this integrative review. 
Part Two Study Findings 
 
In this section of this review, I will present quantitative study findings (n=9) wherein 
authors examined alternative HBOC PV follow-up care models and interventions. These 
interventions included psychoeducational groups and workshops, peer-support interventions, 
cognitive behavioral interventions, and dedicated HBOC follow-up clinics and technology. The 
effects of these follow-up strategies/interventions on psychosocial functioning, adherence to risk- 
reduction modalities, and unmet information need outcomes in HBOC PV carriers were 
explored. 
Psychoeducational Support Groups 
 
Group settings (facilitated by both peers and/or medical professionals) have been shown 
to be useful for facilitating psychological adjustment in cancer patients (Goodwin et al., 2001). 
Such groups have been linked with establishing feelings of mutual support and a sense of normal 
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through shared experiences, the opportunity to learn through the experiences of others, enhanced 
coping, as well as the acceptance of one’s reality (Landsbergen et al., 2010). The purpose of 
psychoeducational support groups for HBOC PV carriers is to “assist women in making an 
informed choice, respecting and taking into account their private lives and circumstances” 
(Landsbergen et al., 2009, p. 214). This intervention model was examined by Corines et al. 
(2017), Kwiatkowski et al. (2019), Landsbergen et al. (2009), Listøl et al. (2017), and McKinnon 
et al. (2007). Three of the study interventions (Kwaitkowsi et al., 2019; Listøl et al., 2017; 
McKinnon et al., 2007) were one-time psychoeducational intervention group retreats for HBOC 
PV carriers, the psychoeducational support groups in Corines et al. (2017) and Landsbergen et al. 
(2009) occurred over the course of multiple months, or as quarterly and annual sessions. All the 
group interventions featured both psychological and medical content pertinent to HBOC PV 
carriers, such as risk-reducing surgery, considerations about genetic insurance discrimination, 
and family communication about genetic testing. Three major impact outcomes were identified 
of the psychoeducational group interventions including psychosocial impact outcomes, risk 
management adherence outcomes, and unmet information needs outcomes. 
Psychosocial Impact Outcomes 
 
There is evidence that psychoeducational support groups are acceptable to HBOC PV 
carriers; ≥96% of responding participants reported overall satisfaction with an annual Lynch 
Syndrome Educational workshop (Corines et al., 2017). Young female BRCA PV carriers who 
participated in a two-day psychoeducational retreat showed increases in psychometric measures 
of hope, self-esteem, and quality of life, one year following their participation in the intervention 
(p= 0.00032) (Kwiatkowski et al., 2019). Using the Hospital Anxiety and Depression Scale 
(HADS) metric, Listøl et al. (2017) reported that participant HADS-anxiety sub scores decreased 
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significantly from 6.2 to 5.2 (p=0.003), following a one-day psychosocial intervention for BRCA 
PV carriers. There were significant improvements noted in psychosocial functioning in a study of 
a multisite supportive-expressive group intervention for BRCA PV carriers, though this study did 
not meet inclusion criteria for this review as it was written > 15 years ago (Esplen et al., 2004). 
However, it is still worth noting that Esplen et al. (2004) observed significant improvements in 
participants’ psychosocial functioning including cancer worries (p= 0.005), anxiety (p=0.033), 
and depression (p=0.015) following the intervention. While no differences were seen in 
participant Impact of Events (IES) scores following a one day BRCA psychoeducational 
intervention in the study by McKinnon et al. (2007), the authors noted this was potentially 
attributable to the high baseline IES scores in some of the participants. Given that the participant 
feedback on the intervention in McKinnon et al. (2007) was overwhelmingly positive, and the 
overall strength of the study design and quality of the evidence were relatively low, it is likely 
that a different research design would have yielded more favorable results. 
Risk-Management Adherence Outcomes 
 
Participation of HBOC PV carriers in psychoeducational support groups appeared to have 
a positive effect on their adherence to recommended risk-reduction modalities. In Landsbergen et 
al. (2009), individuals who participated in at least six out of eight BRCA psychoeducational 
group sessions were more likely to proceed with their initial preference for RRM within two 
years, when compared to a control group of BRCA PV carriers who did not partake in 
psychoeducational group sessions, 89% vs 63% respectively, (OR 4.8, p = 0.04). In a subsequent 
study by Landsbergen et al. (2010), for BRCA PV carriers who participated in an educational 
support group, their intention to undergo RRM increased from 37% to 44% following the 
intervention (p=0.7), and their intention to undergo RRSO increased from 71% to 81% (p=0.6). 
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It should be noted however that statistical significance was not achieved and thus these findings 
must be interpreted with considerable caution. 
Unmet Information Needs Outcomes 
 
91% of responding participants at a LS educational workshop (LSEW) over years 2-5 of 
the program reported that they found the information presented at the workshop to be useful and 
clear, and ≥87% reported they were satisfied with technical medical information provided to 
them through LSEW (Corines et al., 2017). In Landsbergen et al. (2010), there was a 19% 
increase in percentage of participants’ information needs met following participation in a BRCA 
psychoeducational group, this was close to achieving statistical significance (p=0.06). In Esplen 
et al. (2004), 75% of participants noted improvements in their BRCA decision-making, and 60% 
reported an increase in assertiveness and knowledge regarding medical professional/patient 
communication following participation in a supportive-expressive therapy group. The evidence 
that participation in HBOC psychoeducational groups improves the unmet information needs of 
HBOC previvors must be cautiously interpreted and compared with other modalities of previvor 
information provision. Further robust studies to confirm this assertion are required. 
Targeted Follow-Up Interventions 
 
There were three interventional studies retrieved where the authors implemented an 
intervention to target a specific facet of HBOC PV carriership. This included a mindfulness- 
based stressed reduction training (MBSR) for menopausal symptoms in women who underwent 
RRSO (van Driel et al., 2019), a BRCA peer-support telephone intervention (White et al., 2014), 
and pilot data on an iPhone application to assist BRCA carriers in their adherence to 
recommended screening modalities (Cohen et al., 2018). 
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MBSR Intervention for Women who Underwent RRSO 
 
In an RCT, (n=34) women participated in an 8-week intervention consisting of weekly 
two and a half hour sessions, a four-hour silent retreat evening, and 30-45 minutes of home 
exercises six times a week. (van Driel et al., 2019). When compared with a control group, these 
women had significant improvements in psychometric measures of menopausal related quality of 
life at 12-months post initiation of intervention, with menopause-specific quality of life: 
(MENQOL) scores of 3.6 (95% CI 3.1-4.0) versus 3.9 (95% CI, 3.5-4.4) respectively (p = 0.04). 
van Driel et al. (2019) noted that MBSR may be an acceptable complementary therapy to 
hormone replacement therapy (HRT) for women who report distressing RRSO menopausal 
symptoms, and may be particularly useful for women who have contraindications to HRT such 
as increased risk of breast cancer. There is strong evidence from van Driel et al. (2019) that the 
inclusion of MBSR could be an important component of an effective HBOC follow-up program. 
Peer Telephone-Based Intervention 
 
White et al. (2014) conducted an RCT where an intervention group of BRCA PV carriers 
received phone calls from trained peer volunteers over a 4-month period (an average of 3.7 
calls). There were both short-term and long-term benefits observed from this intervention. The 
intervention was shown to have a positive effect on participants’ psychological stress as reflected 
in their Impact of Events (IES) scale Breast cancer distress scores. Participants in the 
intervention group had a significantly greater reduction in breast cancer related distress when 
compared to a control group both immediately following the intervention -5.96 (95% CI, -9.80- 
2.13; p=.002), and two months later, -5.96(95% CI, -9.80-2.13; p=.002). There was also a greater 
reduction in unmet information needs in the intervention versus control group immediately 
following the intervention, -5.17 (95% CI, -7.96 to -2.37; p= < .00). However, this effect did not 
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reach statistical significance two months later, -.67 (95% CI -4.28 to - 0.93; p =0.21). Still, this 
was a well-designed and adequately powered study and White et al. (2014) gave considerable 
credence to trained, peer-based telephone support as an effective intervention as part of a holistic 
follow-up model for BRCA previvors. 
An iPhone Application for Screening Adherence 
 
Cohen et al. (2018) provided pilot data on an iPhone application intervention that they 
developed for BRCA PV carriers to assist them in their adherence to recommended BRCA 
screening modalities. While the 18-month follow-up data of this pilot project is still yet to be 
published, the baseline and preliminary data from Cohen et al. (2018) is suggestive that this 
iPhone app will be well-received and meet a practical need for BRCA PV carriers. While 94.3% 
of study participants reported their intention to engage in a BRCA surveillance plan, only 72.6% 
reported perceived health care system support for surveillance (Cohen et al., 2018). By the same 
vein, 50% of respondents reported they have difficulty keeping track of when to schedule their 
next BRCA screening appointment, and 20% reported that they rely on their primary care 
provider to do so. At baseline, the majority of the (n=69) participants who were provided a 
download code for the BRCA iPhone app agreed or strongly agreed that iPhone applications had 
a positive impact in their lives (Technology Acceptance Model Scores ranging from 3.4±1.1 to 
4.1±0.7), and the majority of respondents also reported comfort with completing iPhone tasks 
(Comfort with Technology Scores ranging from 3.5±0.92 to 3.8±0.82) (Cohen et al., 2018). 
While it is still too premature to make sound conclusions on the utility of a BRCA iPhone app, 
Cohen et al. (2018) noted that in the first 21-months, 68 out of 69 participant provided codes 
were successfully downloaded and participants accessed the app an average of 6.28 times, 
ranging from 2-57 times. When the follow-up data is available and as health applications become 
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more routinely integrated into routine care, this intervention could be an extremely valuable tool 
for HBOC risk-reduction in a technology-dependent era. 
Dedicated HBOC Follow-Up Clinics 
 
There were surprisingly few peer-reviewed studies of the outcomes in multidisciplinary 
follow-up clinics for HBOC PV carriers (n=1). This was unexpected given in many countries, 
including some urban locations in Canada, familial cancer follow-up clinics are routinely 
integrated into regional genetics programs. Yerushalmi et al. (2016) reported on a specialized, 
multidisciplinary BRCA follow-up clinic that PV carriers attended for bi-annual screening and 
follow-up clinic visits, with additional psychosocial support available to clinic attendees if 
needed. While the overall quality of the evidence was somewhat low, the data on patient 
outcomes in the clinic were promising. Only 7.2% of clinic attendees to date developed cancer. 
Of those 7.2% cases of cancer, 17 were breast cancers, one ovarian cancer, and three were 
additional cancers. Of the 17 cases of breast cancer, 94.1% of those cancers were detected at 
stage I disease when treatment outcomes are generally far more encouraging. Of those breast 
cancer cases, 70.6% were detected by MRI and 17.6% were detected by mammography 
(Yerushalmi et al., 2016). It is impossible to say with certainty if the low incidence of 
malignancy occurred exclusively as a result of the dedicated follow-up clinic, as clinic outcomes 
were not compared with outcomes from a matched control of a family physician based BRCA 
follow-up model. Still, the rate of RRSO uptake at age 40+ at the clinic in Yerushalmi et al. 
(2016) was high at 87.3% and the median and mean ages at time of RRSO were 46.5 and 48 
years, ranging from 33-68. This high rate of RRSO uptake before natural menopause in clinic 
attendees was higher than in most other reported registries and in the literature (Yerushalmi et 
al., 2016). The median age at the time of RRSO in the multidisciplinary clinic was also lower 
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than the median age at time of RRSO of 49.6±9.7 in NL BRCA PV carriers (Roebothan et al., 
n.d.) Further studies are needed to compare outcomes in dedicated follow-up clinics with family 
physician-based paradigms, still, Yerushalmi et al. (2016) provided a glimpse into how a 
successful specialized follow-up clinic can be implemented to meet the needs of the HBOC PV 
carrier population. 
Quality of the Evidence 
 
The quality of the evidence examined in question two was varied. Some studies featured 
a strong RCT design and statistically significance evidence was produced that these interventions 
had a positive effect on participants’ stress and quality of life (White et al., 2014; van Driel et al., 
2019). The inclusion of these studies made a strong case that these types of peer and MBSR 
interventions could be an effective part of follow-up programs for this population. Moderate 
quality evidence of the effect of psychoeducational groups on outcomes in HBOC populations is 
indicative that a similar pilot for an annual HBOC psychoeducational group session may be part 
of an effective follow-up program model. Furthermore, while I found limited evidence about the 
effect of multidisciplinary specialized follow-up clinics on HBOC outcomes, a program model 
similar to the one used by Yerushalmi et al. (2016) could be piloted in another setting to compare 
pre and post effects of the program implementation. It may be useful to complete a 
Controlled/Uncontrolled-Before-After study about the effects of a pilot program dedicated to 
HBOC on screening adherence, disease outcomes, as well as psychosocial adjustment. For the 
latter metric, a psychometric scale was developed by Watkins et al. (2013) that is designed to 
measure psychosocial adjustment challenges in cancer predisposition syndrome populations (the 
PAHDS scale). Further research is warranted to determine if the implementation of a multimodal 
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HBOC previvor follow-up program would have significant positive effects on PAHDS scores, 
other quality of life measures, and unmet information needs in HBOC PV carrier populations. 
Interpretation 
 
It is clear from the literature summarized in Appendix A that there are gaps in the current 
paradigm of care for HBOC PV carriers, leaving this high-risk population at an equally high-risk 
of falling between the cracks of the healthcare system. HBOC PV carriers interviewed in the 
studies reported that the current primary care provider-dependent model of HBOC follow-up did 
not meet their unique needs as high-risk individuals. Participants indicated that they had unmet 
information needs about several ongoing aspects of PV carriership including family planning, 
family communication, symptoms of surgical menopause, and the need for an articulated plan of 
risk-management. Participants verbalized that the current health system often left them feeling 
like a statistic rather than a human being and that they felt as though little consideration was 
given to the highly personal implications that their carriership status had in their lives. Some 
study participants felt a sense of isolation and a sense of feeling different from the rest of the 
population because of their PV carrier status. Many participants desired a formalized channel 
where they could seek peer support from women with HBOC syndrome who previously 
underwent testing and could relate to what they were going through. Both health care providers 
and HBOC PV carriers reported that the current approach is uncoordinated and ineffective. 
These findings are unacceptable for several reasons. Firstly, the current approach is 
contradictory to the positions in several key Canadian Health policies. ‘Health’ is determined by 
the interplay of several complex factors such as income and social status, social support 
networks, education and literacy, physical environments, gender, and biology and genetic 
endowment, among others (Federal Provincial and Territorial Advisory Committee on 
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Population Health, 1999). In an effective population health policy, there is an active effort to 
reduce the health disparities experienced by certain populations due to the interplay of health 
determinants in their life circumstances (Health Canada, 2001). Due to their genetic 
predisposition, female BRCA PV carriers are almost guaranteed to have breast cancer in their 
lifetime, while the rest of the general population has a 1 in 8 lifetime risk of breast cancer 
(Canadian Cancer Statistics Advisory Committee, 2019). Yet, the current opportunistic model of 
genetic testing and lack of coordinated follow-up in many Canadian jurisdictions does little to 
mitigate the health inequities experienced by individuals with inherited cancer predisposition 
syndromes. A systemic, upstream approach to health promotion and disease prevention for 
individuals with hereditary cancer predisposition syndromes, frankly, is long overdue. Health is 
“seen as a resource for everyday life, not the objective of living” (World Health Organization, 
1986, p.1). Yet, there are limited programs in Canada that offer any psychosocial and 
navigational resources to women in their everyday life as HBOC previvors. As stated by 
Thiruchlevam et al.(2018), “genetic testing can be life-changing and indeed life-saving, but it is 
crucial that it comes with all of the facts and appropriate professional support to enable 
individuals to live and plan for a healthy life” (p. 2091). 
Not only is the current paradigm of care for high-risk individuals in Canada unacceptable, 
but it is also “the most expensive and least effective” (Roebothan et al., n.d, p.18). The costs of 
genetic testing have significantly decreased over time and there is irrefutable evidence that 
HBOC risk-reduction modalities are effective. Still, in an 18-month period, only 41.6% of 
eligible BRCA PV carriers in NL were compliant with all the annual breast screening modalities 
recommended for high risk individuals (p <0.001) (Roebothan et al, n.d.). Simply put, the current 
paradigm does not make sense given the plethora of evidence in favor of a coordinated, outcome 
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driven hereditary cancer care policy (Roebothan et al., n.d.). Another area for future research will 
be a cost analysis of the current system and burden of HBOC-associated disease compared with 
the costs of genetic testing and risk-reduction modalities. Recently, Manchanda et al. (2018) 
determined that general population-based testing for PVs in the 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 genes is more cost-effective than the 
current opportunistic model of genetic testing based on clinical criteria and family history. 
The findings in part two and Appendix B of this literature review provide some insight 
into what an effective HBOC policy and systemic follow-up program may look like in NL. In an 
examination of outcomes in a dedicated BRCA follow-up clinic in Israel, only 5.8% of BRCA 
PV carriers who attended the clinic developed breast cancer in the 5-year follow-up after genetic 
testing (Yerushalmi et al., 2016). This is compared to the 10.2% of breast cancer cases detected 
in NL BRCA PV carriers in the period following genetic testing (Roebothan et al., n.d.). 
Moreover, in Yerushalmi et al. (2016), 94.1% of the cases of breast cancer detected post-genetic 
testing were stage I disease versus only 40% of cases of breast cancer detected in NL post- 
genetic testing that were stage I disease (Roebothan et al., n.d.). A pilot study of a systemic 
navigation clinic in NL, modelled similarly to the clinic in Yerushulmi et al. (2016), may be 
useful in determining the appropriateness of this model as part of an effective Canadian public 
health strategy. 
An effective HBOC care program will involve multiple strategies to meet the needs of the 
HBOC previvor population. There is moderate quality evidence that ongoing or annual 
psychoeducational group workshops, retreats, and interventions are an effective way to meet 
information needs of this population and to reduce their feelings of burden experienced as PV 
carriers (Corines et al., 2017; Kwiatkowski et al., 2019; Landsbergen et al., 2009, Listøl et al., 
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2017; McKinnon et al., 2007). Ongoing psychoeducational group interventions may be highly 
acceptable for some HBOC PV carriers as a component of a systemic follow-up program. 
Targeted, effective interventions such as mindfulness-based stress reduction and peer-telephone 
support may also be acceptable interventions to include as part of a follow-up model for HBOC 
PV carriers who are experiencing distressing symptoms associated with RRSO and for those who 
seek formalized support from other HBOC PV carriers (van Driel et al., 2019; White et al., 
2014). Technology will likely play an effective role in disseminating key information and 
screening reminders to participants in a HBOC follow-up program. The pending results of the 
pilot study by Cohen et al. (2018) may have great implications for how iPhone technology is 
used in a variety of hereditary cancer risk-management settings to improve outcomes. 
It should also be noted that in two studies (Cherry et al., 2013; Komatsu & Yagasaki, 
2014), the authors purported that the nursing profession has a potential role to play in improving 
the delivery of services to HBOC PV carriers. Nurses are ideally situated to provide of genetic 
health care, with the discipline’s “focus on health promotion, caring, and the understanding of 
individuals, including their relationships with families, the community, and society” (Calzone et 
al., 2013, p.1). As one of the largest groups of health care providers, nurses frequently engage in 
multidisciplinary collaboration, and are situated to provide a psychosocial and ethical perspective 
to genetic care (Bortoff et al., 2004). The expansion of genetic nursing practice in Canada is 
trailing significantly behind that of other developed countries. Despite several key 
recommendations identified in a 2004 Canadian forum on genetic nursing practice, progress on 
genetic nursing practice in Canada, for the most part, has been at a stand-still for the last 16 
years. This is a significant missed opportunity as it has been demonstrated in the US and the UK 
how “nurses' awareness of genetics enabled them to skilfully address patient and family concerns 
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related to specific hereditary conditions, and lead to the development of specialist nursing roles 
in genetics” (Bortoff et al., 2004, p.25). It is overdue to launch genetic nursing practice in 
Canada and to implement strategies shown to be acceptable and feasible in other countries. There 
are several barriers to mobilizing genetic nursing in Canada; Canadian professional nursing 
organizations have not outlined genetic competencies for nursing practice, there is lack of 
nursing faculty in Canada with adequate experience in genetics, and due to the lack of genetic 
content on RN licensure exams, there is little onus on nursing schools to include genetic content 
in their curriculum (Bortoff et al, 2004). While there are barriers to genetic nursing in Canada, 
they are not insurmountable. The influence of nursing’s “holitstic, humanistic complement to the 
biomedical approach” (Bortoff et al., 2004, p. 24) should be incorporated in the development of a 
tailored, navigation program for HBOC PV carriers. 
Conclusion 
 
With the rapid advancement of genetic technology, the clinical identification and 
management of HBOC is an emanating priority health issue, with several proven treatment 
options available to affected PV carriers to reduce their risk of developing HBOC. In the current 
fragmented paradigm, individuals not only face barriers to obtaining genetic testing but face 
considerable challenges in navigating the implications of PV carriership. As a result, individuals 
with HBOC PVs are under identified, under-screened, and under-supported. Ultimately, they are 
getting ill, and in many cases dying from a disease that we know how to prevent in this 
population. From this literature review, I conclude that the current HBOC paradigm in NL has a 
narrow focus on treating a disease rather than treating a person and enabling them to live a 
healthy life. However, extant models and interventions examined in the literature provide a 
primer of what a basket of primary care services for HBOC PV carriers in NL could look like. 
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This may include but is not limited to a dedicated follow-up clinic, navigational assistance with 
screening and surgical decisions, individual and health care provider education sessions, 
assistance with the family implications of PV carriership, and targeted supportive interventions. 
to manage specific facets of carriership, such as surgical menopause. Coupled with stakeholder 
consultation, and an environmental scan, the findings of this literature review can be used in the 
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N: (n=32) French-Italian 
speaking females, 
unaffected BRCA 1/2 
carriers, age 26-30 yrs, 
diagnosed atleast 3 yrs 









Interviewed 1-2 times, 















1)Sense of moral 
duty to both off- 
spring and 
ancestors to 

























by providers to 
adhere to risk 
management 
guidelines 









continued until data 
saturation 





May be selection bias of 
women who were 
willing to participate 
Recommendations: 
Multidisciplinary 
hereditary cancer clinics 
would be appropriate for 
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related to their 
risk reduction 
options 
N: (n=12) females 
w/ confirmed BRCA 
1/2 PV (n=3 w/ a hx 
of breast cancer) 
who were ≥21 years 
old, no history of 
ovarian cancer, 
atleast 1 intact ovary 
Country/setting: 
USA, participants 
recruited from high- 
risk cancer clinics 
Data collection: 
Standardized set of 
open-ended 
questions (interview 






method of data 
analysis 
Coding in 2 steps, 1st 
step: 2 co-authors 
coded separately 
2nd step: whole team 
coded together 
Key Participant Themes: 
1) Carrier decision 




primary care provider, 
especially about sexual 
adverse events 
considered taboo, info 
from providers was 
variable and not always 
reliable) 
2) Valued the 
opportunity to liaise with 
other women who have 
faced BRCA risk 
decisions (wanted to hear 
both the positives and 
negatives to make an 
informed decision) 
3) Confusions about risk- 
assessment (erroneously 
believed RRSO increases 
breast cancer risk, knew 
very little details about 
procedures) 
4) Timing of surgery 
important vis-à-vis 
family planning 
5) Experiences of family 
who were BRCA+ 
influenced decision 




Rigorous adherence to 
qualitative methodology 
Script developed based 
on counselling with 500+ 
women who received 
BRCA 1/2 test results 
Limitations: 






navigator model so 
nurses can provide 
BRCA previvors with 




support groups led by 
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BRCA 1/2 PV, no 
person history of 

































1) Previvors desired 
information including a 




2) Previvors desired an 
action plan for what the 
next steps were 
3) Previvors reported 
needing time to come to 
terms with decisions 
4) Availability of 
support groups such as 
FORCE and Bright 




1) Previvors placed 
emphasis on the input 
of how other previvors 
made their decisions 
 
2) Some risk 
management decisions 








Rigorous adherence to 
grounded theory 
methodology 
Use of Theory of Motivated 
Information Management as 
theoretical framework 
Krippendorff’s alpha values 
calculated at 2 points in 
coding for intercoder 
reliability T1, α= 0.926; T2, 
α= 0.843) both within limits 
of reliability (α=0.7) 
Limitations: 
Small sample size 
Homogenous, affluent white 
women 
Only small number of young 
age women 
Retrospective, relied on 
participant recall 
Practice Implications 
The mere provision of 
medical information to 
BRCA previvors is inefficient 
Need to explore further 
educational interventions for 
this population 
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To explore the 
experiences of 
women affected 
by LS related to 
their RRSO risk 
management 
decisions 
N: (n=10 females w/ 
confirmed LS 
predisposition PV who 
was considering or 
underwent RRSO) 74% 
contacted agreed to 
participate 
Country/setting: Canada, 
NL provincial medical 
genetics registry 
Data collection: telephone 
interviews (30 min-1hr) 





Naturalistic inquiry (no a 
priori assumption) 
Data presented in 






1) Motivation to 
reduce personal 
risk of cancer, 















were influential to 
decision to undergo 
RRSO 
4) Information 
needs prior to 
surgery, some 








Voices of participants 
accurately represented 
Congruence between 
stated methodology and 
representation and 
interpretation of data 
Limitations: 
Small sample size 




Cannot be generalized 
to women who declined 
RRSO 
Recommendations: 
Continued efforts to 




















the perspective of 
HCPs providing 






N: (n=17) health care 
providers (n=7 breast 
specialists, n=5 staff 
physicians, n=4 nurses, n= 
1 genetic counsellor) 
 
Country/setting: Japan, 2 
institutions providing Rx 
to HBOC patients in Japan 
 
Data collection: semi- 
structured focus groups 
lead by nurse researcher 
(60-70 min), audiotaped & 
transcribed verbatim 
Data Analysis: 
Use of constant 
comparative method, open 
coding 
Interviews deconstructed 




too busy treating 
disease; little 












3) Individuals at 
risk likely to be 






nurses have a 










Good adherence to 
grounded theory 
methodology 




With nature of focus 
group, results possibly 



























N: (n=15) females, age ≥ 
18, self-reported, 






Data collection: purposive 
sampling, interviews 25 
min to 1 hr, telephone or 




Use of appropriate 
phenomenological 


















2) Lack of 
guidelines, lack 
of decisional 





valued a holistic 
approach, 
described “not 




4) Need for 
emotional 
support, online 
























Participants were self- 
reported BRCA, carrier 
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N: (n=150 women)72% 
contacted completed 
questionnaire 
(n=143 women w/ BRCA 
1/2 mutation, no prior 
history of OC, no intact 
ovaries) 
(n=14 still had ovaries 
insitu) 
Country/setting: Australia, 
participants from single site 
familial cancer center 
registry in East Melbourne 
Data collection:. 
Eligible women sent study 
pack which included 
invitation, consent letter and 
questionnaire containing 
data about RRSO, 
menopausal status at time of 
RRSO, risk factors for 
osteoporosis, participation 
in post-operative follow-up 
programs 
Outcomes: 
Prevalence of current 
menopausal symptoms rated 
using menopausal rating 
scale (MRS) (Specific 
menopause symptoms rated 
on a scale of 0-4; score 3-4 
‘severe’ 
Demographic variables 
associated with MRS score 
examined 
Variables associated with 
uptake of RRSO 
Current age > 50: (OR 
28.0; p <0.0001) 
Personal history of breast 
cancer: 
(OR 8.0; p < 0.0001) 
Variables associated with 
persistent severe 
menopausal symptoms 
Pre-menopausal at time 
of RRSO: (OR 1.98; 0.9- 
3.8; p =0.1) 
Women who reported 
“persistent severe” 
menopausal symptoms 
linear correlation with 
age at RRSO (p=0.002) 
73% (n=104) women 
reported no on-going 
follow up with Gyne 
surgeon after immediate 
post-surgical review 






Only 4% of missing 



















genetics team to 
initiate long term 




Need for optimal 
clinical guidelines 
for the care of 
women post RRSO 
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positive for the 
BRCA PV 
N: (n=20) females w/ 
confirmed BRCA 1/2 
PV who were ≥18 years 
old, with a committed 
romantic partner, and 
had at least one 
conversation about FP 
with that partner 
Country/setting: USA, 
participant recruited 













Use of open-coding, 
axial coding 
Research memos taken 
as an audit trail 
Key Participant 
Themes: 
Three themes identified 
1) Importance placed 
on a 2-way dialogue 
about both BRCA 
previvor and their 
spouse’s feelings about 
FP (spouse often 
overlooked) 
2) Importance given to 
information seeking 
from multiple sources, 
supportive resources, 
weighing options 
3) Emphasis placed on 
using emotions in FP 
decision making “It’s 
not a statistic it’s what 
they feel in their heart 
is the right thing to do” 
(p. 491) 




Evidence that measures 
were taken to ensure 
credibility, 
transferability, and 
consistency of findings 
Final sample was based 
on achievement of 
theoretical saturation 





generalizable due to 
nature of data 








Care providers should 
provide individuals at 
increased risk of HBOC 
a list of questions to 
start conversations with 
their partner about FP 




to genetic counselling, 
involve couples and 
families 
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N: (n=17) women 
Inclusion criteria: 18 
years old+, living in the 
Cardiff and 
Vale NHS Trust region 
Country/setting: Wales, 
UK, recruited from 
South Wales genetic 
registry 
Data collection: 







Coding completed by 
2-member team 
Ambiguity in coding 
resolved in discussion 
with team members 
Key Participant Themes 
 
1)Reactions to Learning 
Carrier status 
Feeling different from 
the rest of the 
population 
 
Seeking someone to 
relate to 
  2) Psychological 
support needs 
Feared stigma of 
seeking informative 
support, were more 
likely to attend event 
framed as ‘informative 
support’ 
 
Feelings of guilt in 
families, concern about 
disclosing PV carrier 
status 
 
The need for anonymity 
in groups and 
interventions 
 
3) Information Support 
Needs 
The need for an updated 
trustworthy source of 
medical and research 
updates pertinent to 
BRCA 
The need to confirm 
accuracy of information 









Voices of participants 
accurately represented 
 
Summaries provided to 
participants over course 
of discussion to confirm 




Participants may be 
reluctant to attend 
groups to discuss 
sensitive issues 
 
Lack of representation 
from male BRCA PV 
carriers despite being 
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N: (n=23) individuals w/ 
confirmed MSH2 
mutation (n=14 female, n 
= 9 male) 
 
Country/setting: Canada, 
NL provincial medical 
genetics registry 
 
Data collection: 60-90 
min interview in 
participants homes or 



























young age of PV 






3) Health care 
system barriers 
(lack of continuity 


















by 3-member team 
Independent consultant 
reviewed emergent data 
and theory to enhance 
credibility & accuracy 
Limitations: 
Small sample size 
Inherent bias of 
participant recall 
Recommendations: 
Overhaul of current 
uncoordinated physician 
dependent of screening 
of individuals with LS 
in Canada 
Need for more genetic 
counsellors to improve 
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from a user 
perspective 
N: (n=86) Inclusion criteria: 
women, ≥ 18 yrs old, + for a 
BRCA PV, with at least 1 ovary or 
breast, must own an iPhone 
 
Country/setting: USA, recruitment 
from online support groups and 
genetic counsellors 
 
Methods: Baseline data collected 
from (n=86) participants, at the 
end of the survey, (n=69) 
participants given a code to 
download an iPhone application to 




w/ 50 questions using 
psychometric scales collected at 
baseline prior to intervention (T1) 
(18-month follow-up data pending) 
Analytic data on iPhone app 
download over 21-month period 
 
Outcomes: (calculated using 
descriptive statistics) 
 
ADQ (Adherence Determinants 
Questionnaire) (0-100 % 
percentage possible) 
Comfort with iPhone technology: 
modified Comfort with 
Technology scale (scores ranging 
1-4; 1 being mostly uncomfortable, 
4 being mostly comfortable) 
Perceived usefulness of iPhones: 
The Technology Acceptance 
Model (scores ranging 1-5; 1 being 
strongly disagree, 5 being strongly 
agree) 
ADQ scores 
Intention to engage 
in surveillance plan: 
94.3% ±8.4 







3.4±1.1 to 4.1±0.7 
(majority agreed or 
strongly agreed apps 





3.5±0.92 to 3.8±0.82 
(majority of 
respondents reported 
comfort with iPhone 
tasks) 
 




to schedule next 
screening 
appointment 
20% (n=15) reported 
they rely on their 




# Times app 































active role in 
their care 
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To report on 
participant 
satisfaction 







N: (n=53-75) participants 
annually with confirmed LS 
PV, or family member of 





single site familial cancer 
clinic recruitment 
 
Establishment of annual 
Lynch Syndrome 
Educational Workshop 
(LSEW), which then lead to 
the establishment of 
quarterly Lynch Syndrome 
Patient Advocacy Network 
(LSPAN) quarterly 




Participant survey data from 
both LSEW and LSPAN 
collected and summarized 



























91% found the 
information clear 
 
67% stated the 
presence of a 
genetic counsellor 
at LSPAN was 
helpful 









• Potential bias as 
individuals attending 
LSEW and LSPAN are 
the LS PV carriers with 
greatest support needs 
• No data collected on 
effect of 
LSEW/LSPAN on 
disease knowledge or 
psychosocial well- 
being, or compliance 
with screening/risk- 
reducing surgery 
• No collection of 
demographic data 
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To test the 
cognitive/psychosocial 
impact of a 
psychoeducational 
intervention on young 
women at increased 
risk of HBOC 
N: (n=7) Inclusion criteria: 
women aged 18-30, 
childless, w/ a confirmed 
HBOC PV, no personal 




single-site recruitment, 2- 
day psychoeducational 




collected at baseline (T1), 
end of workshop (T2), after 











Perceived control (IPC) 
Anxiety State (STAI-B) 
Quality of Life: 
(WHOQOL) 
Global HHS 
scores at T4 









over 1 year 
(p= 0.00032)* 
 
Coping by focus 
on problem 
Increased at T2 
(p= 0.011)* then 
returned to 
baseline at T3 
 
Coping by focus 
on emotion 
Decreased steadily 










• This study was 
initially 
pitched as an 
RCT with the 
waitlist acting 




form 2 groups 
• Limited 
sample size 
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N: (n=151) Inclusion 
criteria: women newly 
diagnosed w/ a BRCA PV, 
no personal hx of breast 




Netherlands, recruited from 
single site genetics 
department 
 
IG: (n= 79) women 
participated in at least 6/8 
2.5 hr psychosocial and 
medical information 
sessions q 4-6 weeks 
 
UCG: (n=84) women did 
not participate in the 
psychoeducational groups 
 
Data collection: At 
Baseline, participants’ 
preference for risk reduction 
methodology reported in 
both groups, Medical 
records checked 2 years 
following in two groups to 















at baseline in: 
IG: 34% of 
individuals 
UCG 19% 




RRM after 2 yrs 
Age between 30- 




(OR 42.3, p < 
0.001)* (R2 = 
0.57) 







• Self-selection bias with 
potential baseline 
differing attitudes 
• No evidence if 
participation in group 
allowed previvors to 
better able to cope with 
their daily lives as 
BRCA PV carriers, nor 
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BRCA + PV 
carriers changed 
following a group 
patient education 





BRCA PV + 
individuals 
N: (n=130) women, ≥ 18 yrs old, 
+ for a BRCA PV, with or 
without history of breast/ovarian 
ca, able to read Norwegian 
 
Country/setting: Norway, single 
site 
 
Intervention: a 1-day 




using psychometric scales 
collected at baseline prior to 
intervention (T1), and 2 weeks 
following course (T2) 
 
Outcomes: 
Hospital Anxiety and Depression 
Scale (HADS) 
(2 subscales, scores ranging 0-21 
with ≥8 as cut-off for elevated 
symptoms of anxiety and 
depression) 
 
Coping style measured using 
Threatening Medical Situation 
Invention (TMSI) 
 
Self-efficacy measured by: 
Bergen Genetic Counseling Self- 
efficacy Scale (BGCSES) 
 
Analysis of correlation of 
participant variables with 
anxiety/depressive symptoms 
using mixed-linear model 
analysis 
HADS anxiety sub- 
score (HADS-A) 
T1: 6.2 (± 4.4) 





Greater time since 
disclosure of the gene 
test result:−0.25 (95% 
CI−0.41, −0.09) 
(p=0.002)* 
Higher level of 
situation specific self- 
efficacy: 
−0.96 (95% CI−1.48, 
−0.45) 
(p < 0.001)* 
Women had 
experienced losing a 
first and/or second 
degree relative due to 
breast or ovarian 
cancer: 







experienced losing a 
first and/or second 
degree relative due to 
breast or ovarian 
cancer: 







































up for a 
GPE course 
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To evaluate the 
impact of a 1-day 





N: (n=41) Inclusion 
criteria: men/women with 
personal hx of BRCA PV, 
VUS, or family member 




recruitment from single 
site familial cancer center 
 
Participated in 1-day 
psychoeducational retreat 





at Baseline prior to 
intervention (T1) and 6 




Use of the Impact of 
Events (IES) 15-item scale 
score to assess the stress 
experience related to 
having a PV predisposing 
to HBOC IE scores 
ranging from 0-8 
subclinical; mild, 9–25; 
















T1 :10.5± 8.7 
T2 :10.4±8.7 
(p=0.33) 




• Lack of statistical 
significance reached 
• Lack of control group 
• Lack of difference in 
T1 and T2 IES scores 
possibly attributable 
to the high baseline 
IES scores in some of 
the participants 
• Using different 
research design would 
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N: (n=66 women who had RRSO @ ≤ 
52 yrs of age, 
No prior hx of cancer, chemotherapy 
or radiation) 
 
Country/setting: the Netherlands, 
single site family cancer clinic 
 
Intervention Group (IG): (n=34) 
received 8-week MBSR training, 
consisting of weekly 2.5 hr sessions, a 
4 hr silent retreat evening, committed 
to 30-45 min home exercises 6x a 
week 
 
Care as Usual Group (CUG): (n=32) 
received menopause counselling from 
specialist nurse during the intake visit.. 
(An information booklet summarizing 
this information was provided to 
participants in both groups, 
Both groups offered repeat 




Self-administered questionnaires using 
psychometric scales sent at baseline 
(T0), 3 months (T1), 6 months (T2), 
and 12 months (T3) 
Primary Outcome: 
Menopause-specific quality of life: 
(MENQOL) 29-item scale (scores 
ranging from 1, absence of symptoms, 
to 8, extremely bothersome) 
Secondary Outcomes 
female sexual distress scale (FSDS); 




IG: 3.5 (95% CI 
3.0-3.9) 
CUG: 3.8 (95% 
CI 3.3-4.2) 
(p = 0.04)* 
@ T3 
IG: 3.6 (95% CI 
3.1-4.0) 
CUG: 3.9 (95% 
3.5-4.4) 









(p=0.65), T2 (p 









either T1 (p=0.4), 










• Potential self- 
selection bias 
• Impossible to 
blind 
participants to 














may be especially 
relevant in settings 
where HRT is 
contraindicated 
(i.e breast cancer 
survivors) 
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To assess the 
effectiveness 





with a BRCA 
1/2 PV 
N: (n=207) Inclusion criteria: 
women responded to baseline 
questionnaire, ≥18 years old, 
received genetic results of 
BRCA PV within 5 yrs, and 
verbalized interested in 
receiving peer support 
 
Country/setting: Australia, 
recruitment though 8 familial 
cancer clinics 
 
Random allocation to: 
Usual Care group (UCG): 
(n=102) Received usual 
follow-up care 
 
Intervention Group (IG): 
(n=105) received phone calls 
from trained peer volunteers 




Questionnaires collected at 
baseline (T1), at end of 
intervention (T2), 2 months 
later (T3) 
 
Outcomes: Breast cancer 
related distress (IES scale) 
Unmet information needs 
(UIN 16-item scale) 
Cognitive appraisal about 
genetic testing (CAGT 10- 
item scale) 
Feelings of isolation (single 
item questionnaire) 
Greater decrease in 
IES Breast Cancer 
distress scores in IG 
vs UCG at 
T2: -5.96(95% CI, - 
9.80-2.13; p=.002) 
T3: -3.94 (95% CI, - 
7.70 to -0.17; p =.04)* 
 
Greater decrease in 
Reduction in Unmet 
information needs 
UIN scores for IG vs 
UG at 
T2: -5.17 (95% CI, - 
7.96 to -2.37; p= < 
.00)* 
Not significant at T3: 
-.67 (95% CI -4.28 to 
- 0.93; p =0.21) 
 
Greater decrease in 
Cognitive appraisal 
about genetic testing 
CAGT stress subscale 
for IG vs UCG at 
T2 -.25 (95% CI -2.10 
to -0.40 ; p =.004)* 
Not significant at T3: 
-0.54 (95% CI -1.35 to 
-0.27; p =0.19) 





• Participants could not 
be blinded to IG vs 
UCG 
• Drop out rate higher in 
IG vs UCG 
• 27% of all eligible 
women verbalized 
interest in peer support 
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N: (n=318) women seen 
by the clinic since its 
inception 
(n=292 women opted for 




single-site familial cancer 
follow-up center 
 




support beyond routine 




Clinic attendee risk 
surveillance updated in 
Excel file with each visit 
 
Outcomes: 
Length of follow-up, 
Disease outcomes, risk 
reduction surgery uptake 
 
Descriptive statistics used 
to report clinical outcomes 
Length of Follow-up 
Women followed by 
the clinic 5+ years: 
(n=168) 
Median follow up: 46 
months 
 
Disease outcomes in 
women attending 
clinic during 5 yr+ F/U 
Women who developed 
cancer: 7.2% (n=21, 17 
breast ca, 1 ovarian ca, 
3 additional cancers) 
% of breast cancer 
cases diagnosed w/ 
stage I disease: 94.1% 
% cancer diagnosed by: 




Uptake of Surgeries 
RRSO in women 40+: 
87.3% 
RRSO in women < 40: 
0.84% 
RRM in women 40+: 
16.2% 
RRM in women < 40: 
8.4% 








outcomes from a 
family physician- 
based model of 
referral 
 
• Possibility that the 
low incidence of 
malignancy 
reported to date is 
attributable to the 
relatively short 
median follow-up 




High rate of RRSO 
before natural 
menopause in clinic 
attendees was higher 
than in most other 
reported registries 
and in the literature 
(8-75%) 
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Policy Proposal for a Novel Hereditary Breast and Ovarian Cancer Navigation and Follow-Up 
Program: Consultation Report and Environmental Scan 
Project Introduction and Background 
 
Currently, there is no programmatic and systemic follow-up in Newfoundland and 
Labrador (NL) for individuals with pathogenic variants (PVs) that predispose them to hereditary 
breast and ovarian cancer (HBOC) syndrome (Roebothan et al., n.d.). Following disclosure of 
genetic results, these individuals are essentially “orphaned by the healthcare system” (Mercer, 
2018, para 2). As a result, they are being diagnosed, and in many cases, dying from a disease that 
we know how to prevent in this population. Therefore, the goal of my MN practicum project is to 
develop a policy proposal for a coordinated approach to HBOC PV carrier follow-up in NL. At 
this point in the project, I am referring to this prospective program as a novel HBOC Follow-up 
and Navigation Program for high-risk individuals. I characterize it as ‘novel’ because in my 
current vision, it is most accurately described as a hybrid of patient support, screening and 
follow-up, and patient navigation programs. 
The first patient navigation program was developed in 1990 by Dr. Harold Freeman as a 
model to reduce the inequities experienced by socioeconomically disadvantaged individuals in 
their access to early detection and treatment of cancer (Freeman, 2012). Over the course of the 
past 30 years, the scope of patient navigation programs has expanded “to be applied across the 
entire health care continuum, including prevention, detection, diagnosis, treatment and 
survivorship to the end of life” (Freeman, 2012, p. 1614). Patient navigation programs are 
patient-centered programs with the objective of reducing the fragmentation and barriers that 
individuals face in navigating the healthcare system (Freeman, 2012). Key principles of the 
Freeman patient navigation model are relevant in the development of programs to reduce barriers 
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and improve outcomes in PV carrier high-risk populations. Furthermore, in NL, findings of the 
Cameron Inquiry into Breast Hormone Receptor Testing “highlighted the importance of 
communication and coordination of care throughout the cancer journey, recommending patient 
navigators to assist patients” (Department of Health and Community Services, 2010, p.13). 
This MN practicum project was conceptualized primarily as a result of my attendance at 
two 1-day education symposiums offered at Memorial University of Newfoundland, one on the 
topic of ovarian cancer and the second with a focus on PVs in the BRCA genes. It was evident at 
these symposiums that there is a need to improve the provision of services for individuals and 
families in NL who carry PVs that predispose them to HBOC. I was further compelled to embark 
on this project based on the lack of genetic content in my own nursing education and the paucity 
of available genetic opportunities for nurses in Canada (Bortoff et al., 2004; Dewell et al., 2020). 
I maintain that the lack of nurses in genomics represents a significant missed opportunity to 
improve the quality of care provided to individuals with PVs, as the nursing profession has long 
been considered the “holistic, humanistic complement to the biomedical approach” (Bortoff et 
al., 2004, p. 24). As a Registered Nurse with interest in the topic and an awareness of the urgent 
need to reform the current HBOC follow-up process, this topic was a natural and obvious choice 
for my MN practicum project. 
An important early step in this practicum project was to conduct an integrative literature 
review on the psychoeducational needs of individuals with HBOC syndrome, as well as the 
barriers and facilitators they encounter when seeking support and follow-up care. An additional 
objective of the literature review was to examine extant interventions that were implemented to 
meet the unique needs of PV carriers. The findings of the literature review were revealing; first, 
that in NL and in many Canadian and international health jurisdictions, salient barriers exist for 
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individuals with HBOC syndrome. They are largely under-identified, under-screened, and under- 
supported. The literature review findings were suggestive that a more coordinated approach to 
HBOC follow-up is needed. However, in the second part of the literature review, the findings 
were promising for the future of HBOC follow-up care. An examination of various HBOC 
follow-up care models and interventions provided a fair picture of what a basket of primary care 
services for HBOC PV carriers in NL could look like. This may include but is not limited to a 
dedicated follow-up clinic, navigational assistance with screening and surgical decisions, 
individual and health care provider education sessions, and assistance with the family 
implications of PV carriership. In short, the findings of the literature review were supportive of 
the need and feasibility for this HBOC follow-up program policy proposal. 
The literature review was an important step in the direction towards the development of 
an effective policy proposal for HBOC PV carrier support and follow-up in NL. The next logical 
step in the policy proposal development was to engage in consultation with stakeholders and to 
conduct an environmental scan. Semi-structured interview consultations were conducted with 
relevant stakeholders, such as genetic counsellors and physicians in NL. This allowed the 
stakeholders to provide their input on the most salient needs and recommendations for a tailored 
HBOC PV carrier program in NL. As these stakeholders have important perspectives in 
providing health care to PV carriers in NL, it is important to confirm that the tenets of a HBOC 
PV carrier program would be acceptable to them and compatible with the NL health care system. 
The policy proposal would be futile without their input. To complement this information, an 
environmental scan was also conducted to examine relevant supportive, screening, and follow-up 
services offered in other jurisdictions. Together, this information provides a comprehensive 
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direction for the policy proposal document. This paper provides a report on the stakeholder 
consultations and environmental scan conducted for my MN practicum project. 
Part One: Consultation Report 
 
Objectives of the Consultations 
 
There were four specific objectives for conducting the consultations. First was to confirm 
with stakeholders that a systematic approach to HBOC PV carrier follow-up is relevant and 
acceptable to them. Second, was to identify issues in the current process of follow-up care for 
individuals in NL with HBOC syndrome. A third objective was to explore how the role of the 
nursing profession could be optimized in the proposed policy, as well as in genetic/genomic care. 
And the final objective was to provide stakeholders with an opportunity to recommend priority 
features for a HBOC navigation program policy, from their vantage point. This allowed them to 
propose alternative strategies that I may not have considered. 
Methods 
 
Individuals identified as potential stakeholders for this project were emailed letters 
explaining the nature and purpose of the consultations. This letter is included in Appendix A of 
this consultation report. It was made clear to the participants that their participation was 
voluntary and that they could refuse to participate or omit any question without any coercion or 
repercussions. In the early interviews, some consultees recommended other individuals who 
could also provide valuable input for this project and thus, snowball sampling was used to recruit 
these additional individuals. Participants who were invited to participate in this consultation 
included: (n=2) genetic counsellors, (n=3) oncologist specialists who provide risk-reduction care 
to high-risk individuals, (n=2) primary care physicians, (n=2) individuals who were involved in 
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research pertinent to these high-risk populations in NL, and an (n=1) individual involved in the 
development of a cancer prevention registry in NL. Ultimately, a total of (n=8) key informant 
interviews were conducted. As the participants had different vantage points in the NL healthcare 
system, six different question guides were developed so the questions were most applicable to 
the participant(s). These question guides are included in Appendices C-H of this consultation 
report. 
Each participant was given the semi-structured question guide in advance of the 
interview. Given the current COVID-19 pandemic, participants were given the option to either 
engage in a telephone/online meeting room interview, or to respond directly to the interview 
questions in writing via email. For the phone/online meeting room interviews, hand-written notes 
were taken of participant answers. These answers were then typed in a Word document and 
passworded with access available only to myself and my practicum supervisor.  All raw data 
from the key informant interviews were stored in passworded Word documents on my computer 
and accessible only to me and to my practicum supervisor as needed. Content analysis was used 
to analyze the data generated from the interviews. Content analysis is described as “the process 
of organizing and integrating material from documents, often narrative information from a 
qualitative study, according to key concepts and themes” (Polit & Beck, 2017, p. 723). The 
emergent themes from the raw data are presented in this consultation report. 
Ethical Considerations 
 
As stated, to safeguard the participant information, the raw data were stored in secured 
Word documents. Moreover, the e-mail correspondence between myself and the key informants 
was on a secured university e-mail server. Again, participants were informed that their 
participation was voluntary and that their names and any identifiable information would not be 
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published in the consultation report; findings of these consultations would only be reported as 
general themes of the common barriers and goals for hereditary cancer care in NL. At the end of 
the phone and online interview meetings, the notes were reviewed with participants to confirm 
the accuracy and acceptability of these answers. They were also notified that this data would be 
destroyed upon completion of my degree in December 2020. Prior to engaging in the 
consultations, it was determined that Health Research Ethics Approval (HREA) was not required 
because the nature of the data to be used in the consultations fell under one of items 1, 3, or 5 of 
the HREA authority screening tool. The completed screening tool is included in Appendix B. 
Results 
Every consultee who I spoke with to date agreed that there was value in implementing a 
novel dedicated follow-up and navigation program for PV carriers. While the consultees were 
from a wide variety of health care disciplines and specialty areas, six themes emerged in several 
of the interviews. These themes included 1) the need for a centralized, coordinated registry, 2) 
‘one-stop shopping’, and 3) the need to address the psychosocial dimensions of PV carriership. 
Other common themes were 4) considerations for primary care providers, 5) the role of the 
nursing profession, and 6) funding considerations. 
A Centralized, Coordinated Registry 
 
Some of the consultees expressed concern over the lack of central, trusted authority in 
NL that assumes responsibility for coordinating long-term PV carrier follow-up and risk 
management. We know that this type of approach is theoretically possible because it is currently 
in use in provincial cancer screening registry programs, such as the provincial cervical screening 
initiatives program. In one interview, a participant noted that the use of health registries ensures 
that affected individuals are not ‘falling through the cracks’ in the healthcare system. Some 
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consultees provided examples of these ‘cracks’ in the primary care system in NL, such as 
turnover rates of family physicians, wait times to see a primary care provider, and in some cases, 
lack of primary care provider knowledge and ability to perform the role of managing high-risk 
individuals. One consultee noted that there is ample research evidence from around the world 
that confirms the value of a centralized, coordinated follow-up registry for individuals at high 
risk of inherited cancers. She expressed that a registry of high risk-individuals should ideally 
facilitate appointment/screening bookings and reminders. Another individual involved in a 
screening registry program expressed that having a central authority and database for testing 
follow-up ensures quality control and accountability in the health care system. Of note, a 
dedicated provincial high-risk breast screening program has also been implemented in Ontario 
and will be discussed later in the environmental scan report. 
‘One Stop-Shopping’ 
 
Some of the consultees had been involved in research with individuals living with 
inherited cancer syndromes in NL. A common theme reported in their work with PV carriers was 
that they wanted ‘one-stop shopping’; in other words, carriers wanted a central coordinated clinic 
that addresses and schedules all their risk-reduction follow-up. PV carriers reported very 
practical issues with adherence to recommended screening, such as having to travel long 
distances and take multiple days off work to attend to the various screening and medical 
appointments. One informant noted that in her work with mutation carriers (and their family 
members for that matter), she found that ‘life gets in the way’ of risk management. It was easy 
for asymptomatic PV carriers to forget or disregard the multitude of screening appointments in 
the context of hectic everyday life. For some, all these appointments became so overwhelming 
and mentally taxing that they had to stop for a while. This was particularly common for 
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individuals with Lynch Syndrome where there is an increased risk of inherited cancer in multiple 
organs and thus multiple screening modalities are recommended. To this effect, a follow-up 
navigation program could work with individuals and families to arrange the various screening 
and follow-up appointments in a coordinated, personalized manner. In contrast with the current 
fragmented approach where the coordination of recommended screening and appointments is the 
sole responsibility of the individual and/or their primary care provider. Moreover, some PV 
carriers cited inconsistencies in the risk management information they were provided by their 
primary care providers and by various specialists. By having a centralized provincial authority 
with consistent information, this would reduce the confusion and disillusionment that many PV 
carriers feel with the current system of risk-management. Several of the consultees noted that a 
coordinated program for screening appointments should operate on the assumption that ‘the 
individual is directly informed first’ of any appointments and results, in addition to their primary 
care provider. It was also noted by an informant that any such program should be developed in 
partnership with PV carriers and primary care providers so that the program is informed by the 
people who will use and ultimately stand to benefit from it. 
The Imperative of Psychosocial Considerations 
 
Some informants noted that while a PV carrier registry and the coordination of follow-up 
testing is altogether necessary, a HBOC follow-up navigation program should not have a narrow 
focus on risk-management. One informant stated that ‘there is an ethical responsibility to address 
carriers’ emotional and mental health needs.’ She noted that a novel PV carrier follow-up 
program ideally should offer PV carriers assistance with communicating genetic results with 
their family, as well as offer them with counselling services, and the opportunity to network with 
other carriers and high-risk individuals. Furthermore, it was recommended that a clinic/follow-up 
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program be delivered by a multidisciplinary team, such as social workers, specialists, 
psychologists, and nurses, to adequately address the multiple dimensions and considerations of 
PV carriership. Another informant noted that in her work with PV carriers, higher levels of 
‘family support and cohesion’ were associated with improved psychosocial adjustment to their 
PV carrier status and improved adherence to the recommended screening and risk-reduction 
modalities. An effective PV carrier follow-up program would be one where the family system is 
recognized as a facilitator of psychosocial adjustment and adherence to recommended risk- 
reduction modalities. Therefore, the participation and involvement of family members in a 
follow-up program should be welcomed and encouraged. One consultee noted that unaffected 
family members of PV carriers also experience distress associated with having multiple affected 
relatives with an inherited cancer predisposition syndrome. Yet, in the current system, their 
concerns and perspectives are largely overlooked. This total oversight of family centred care 
should be addressed and rectified in a HBOC follow-up and navigation program. 
A former genetic counsellor expressed that while individuals (and their primary care 
providers) are provided detailed, printed material on the implications of their carrier status at the 
time of genetic result disclosure, it was evident that individuals are not always psychologically 
prepared to ‘readily absorb’ this information at the time of disclosure. Thus, there is value in 
long term follow-up, to determine how individuals and families are coping with carriership and 
to provide them with ongoing information, referrals, and support as their needs may evolve. A 
coordinated program should also be respectful of individuals’ right to an informed choice of 
whether they choose to proceed with genetic testing, surveillance, or preventative surgery. One 
consultee noted that in some instances after multiple unsuccessful attempts to reach out to a PV 
carrier, health care professionals must ‘take the hint’ that an individual is not interested in further 
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follow-up testing and respect this as their right. 
 
Considerations for Primary Care Providers 
 
Literature review findings were suggestive that there are deficiencies in the genetic 
knowledge, skills, and ability of primary care providers to act as coordinator of genetic follow-up 
(Cherry et al., 2013; Leonarcyzk & Mawn, 2015; Watkins et al., 2011); this theme was further 
probed in the consultations. One consultee remarked that she did not think this was a simple 
education problem and noted there are ‘reams of information out there for GPs’ (and primary 
care NPs). When asked, a primary care provider explained that he completes an annual online 
family medical refresher course offered through a Canadian University (in another province) that 
usually features content on genetic screening every 1-2 years. Informants attributed the barriers 
in primary care to the fact that in NL, there is no central, trusted site or authority responsible for 
getting this information into the hands of primary care doctors (and NPs). This lack of central 
authority also means a lack of health care system accountability when these recommended tests 
for PV carriers are not being ordered. Again, some PV carriers may opt not to proceed with 
further surveillance for personal or family reasons, as is their right. However, there are instances 
where individuals are agreeable to the recommended surveillance, but for whatever reason, it is 
not being ordered by their primary care provider. A primary care provider found in his 
experiences, patients tend to be over-reliant on their GPs to remember and coordinate all 
screening appointments. In the context of a busy family practice with no centralized hereditary 
cancer screening reminders, it is easy enough for a GP to overlook a preventative screening 
referral. He added that his ‘greatest fear was that [he] will miss a screening and early detection 
will be missed’. 
In several existing registry systems in the province, primary care providers are provided 
104  
notifications, for example: when their patient is due for recommended screening/follow-up, if the 
recommended imaging is not in the registry after a certain period following the recommended 
screening interval, and of the imaging results. It was expressed that a registry should not have a 
sole focus on assigning responsibility to primary care providers but also on supporting them to 
meet their professional obligations as a primary health care provider. A former genetic 
counsellor reported that their encounters with primary care providers were mostly positive, as 
primary care providers were interested in learning ‘what they had to do’ vis- a-vis their patients’ 
genetic results, recognizing their professional liability to act on the information they were sent 
from Provincial Medical Genetics (PMG). Similarly, a primary care provider reported that he 
‘referred as much as possible to PMG’ and tended to adhere generally strongly to their 
recommendations. 
It was recommended that a follow-up program should involve regular communication 
and support for primary care providers and provided the example of having an identified person 
in a follow-up program with expertise in inherited cancers who could be readily available to 
primary care providers for consultations. This may also improve the appropriateness of formal 
referrals to PMG and the appropriateness of screening, specialist referrals. A primary care 
provider agreed, and also noted that a central registry with patient/primary care provider 
notification of when screening is required would ‘be ideal’ and cited examples of the provincial 
colon and breast screening programs as prime examples of how a prospective registry could 
work. There was some variation in opinions of those interviewed as to whether the primary care 
physician should remain the one to order screening and the role of the registry would be 
‘reminder’ and follow-up. Or, alternatively, if the follow-up registry program would facilitate the 
ordering and booking of the tests and follow the results up with the family primary care provider 
105  
and the individual. This question will need to be examined in greater detail later in the policy 
proposal development. 
The Role of the Nursing Profession 
 
Several informants expressed that there is unmet potential for nurses to become involved, 
and to ultimately improve the delivery of genetic health care. There are nurses who work as 
genetic counsellors in Canada who were ‘grandfathered in’ prior to the advent of the Canadian 
Association of Genetic Counsellors. Since then, the entry level requirement for certification as a 
genetic counsellor is a master’s degree in genetic counselling. One individual expressed that a 
master’s degree in genetic counselling is rightfully so the entry level requirement to practice as a 
genetic counsellor but there is still a plethora of potential nursing roles in genetic care. This 
included, but is not limited to, conducting, and assisting in genetic research, engaging in follow- 
up and supportive care. Other informants hypothesized how the nursing profession could be 
expanded in genetic care; one nurse expert noted that ultimately this directive needs to come 
from ‘the top down’ in the profession i.e. nursing and nursing education regulatory bodies and 
professional organizations. However, they expressed that nurses in practice and in research must 
self-advocate how nurses could improve outcomes in genetic care. The successful 
implementation of nurse navigation programs in other populations, such as patients with a 
confirmed cancer, was also referenced to give credence to the argument that a nurse navigator 
could provide a similar service to PV carriers. The question was also raised if a nurse practitioner 
associated with a hereditary cancer screening program could be the one to order the 
recommended follow-up tests. 
A nurse with experience in genetic counselling spoke of how in the past, they were often 
invited to give guest lectures at nursing schools on the topic of genetics. However, in recent 
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years this seems to have fallen by the wayside. There are unmet opportunities to engage future 
nurses in the topic of genetics and to stimulate their brainstorming on the future of genetic 
nursing. This assertion is supported by anecdotal evidence from my own undergraduate nursing 
education and in informal conversations with nurse practitioners and nurse practitioner students 
who noted that genetic content in their education programs was minimal to nil. There are clear 




When discussing potential barriers to implementing a dedicated follow-up program, 
interview participants consistently cited the challenges in securing ‘dedicated and sustained 
provincial health system funding’. Some informants expressed uncertainty over whether the will 
to create and fund such a service exists ‘in the current climate of very scarce resources’ despite 
the urgent need. Another informant described the current health care system as a ‘sick care 
system’ that is so consumed with expensive disease treatments that there are little resources 
available for disease prevention. Thus, this downstream approach to ‘health’ further perpetuates 
this unsustainable and dysfunctional cycle and inhibits the development of programs, such as this 
proposed program policy. Some informants noted that in this dysfunction, there is a great case to 
be made for these programs in terms of cost-effectiveness. They recommended that I examine 
publications where researchers demonstrated health care value in population-based genetic 
testing and long-term clinical management of hereditary cancer predisposition syndromes 
(Manchanda et al., 2018; Shanahan et al., 2020; Yerushalmi et al., 2016). One informant 
suggested that this program proposal should be framed to policy makers in terms of how it could 
reduce costs associated with expensive cancer treatments and drugs, hospital admissions and ER 
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visits associated with complications of cancer. It is important to convince health system decision 
makers that the question is not ‘how are we going to pay to implement this program?’ rather, 
‘how are we going to pay to NOT implement this program?’ It was recommended that the 
foreseeable price tag of this program should be presented to decision makers and contrasted with 
a cost analysis of the health care system costs of undetected and/or non-surveyed hereditary 
cancer. 
To overcome the challenges in securing program funding, several informants interviewed 
agreed that a pilot project is an effective way to provide ‘proof of concept to health system 
funders and policy makers.’ It was remarked that several successful health care programs and 
interventions once started as health needs assessments, which led to pilot projects, funded largely 
through provincial and federal government grants. It was also suggested that a potential pilot 
program should be evaluated in terms of patient experience and satisfaction, primary care 
provider experience and satisfaction, health system utilization, cost savings, and clinical 
outcomes. There was a wealth of data collected in the consultations that both corroborate the 
literature review findings and provides further direction to proposed program, from the 
perspective of key NL stakeholders. 
Part Two: Environmental Scan 
Objectives of the Environmental Scan 
The key informant interviews provided insight into the local stakeholder’s perceptions of 
the needs, current gaps, and recommendations for a HBOC follow-up program. It is also 
important for this policy proposal to determine what works well for PV carrier follow-up 
programs in other health jurisdictions. To this effect, an environmental scan was conducted. The 
objectives of the environmental scan were: 1) to gain an idea of what services are common 
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features of familial cancer programs in areas of Canada outside of NL and globally. 2) To 
examine breast screening programs in Canada and features of a high-risk breast registry, and 3) 
to examine the gamut of services offered by HBOC non-for-profit organizations. 
Ethical Considerations 
 
The HREA screening tool was completed prior to conducting the environmental scan. It 
was determined that the environmental scan was exempt from requiring HREA ethics approval 
because items 1 and 4 of the checklist were applicable (See Appendix B). The entirety of the 
information collected for the environmental scan was obtained from publicly available websites 
and there was no expectation of privacy from these sources. 
Methods 
 
For the first objective, I scanned the websites of other healthcare facilities in Canada and 
elsewhere in the world where tailored follow-up programs/clinics for HBOC PV carriers are 
offered. I also searched for a variety of available websites of international health care facilities 
that were written in English. To meet the second objective of the environmental scan, I retrieved 
an existing environmental scan of breast screening programs throughout Canada. This document 
provided useful information and led me to the website of the High-Risk Ontario Breast Screening 
Program, a coordinated service that arranges the follow-up imaging for individuals with a 
hereditary breast cancer predisposition syndrome in the province of Ontario. For the third 
objective, when I was completing the literature review, non-for-profit HBOC organizations were 
often referenced by PV carriers as facilitators to follow-up care and psychosocial adjustment. I 
searched websites of these non-for-profit organizations that were commonly referenced in the 




Familial Cancer Clinics 
 
In many larger centers in Canada and around the world, familial cancer clinics are 
available as part of the genetic care process. Comparable to the process offered through PMG, 
genetic counselling and genetic testing referral are offered through many of these centers. This 
also includes immediate genetic testing follow-up and personalized genetic risk assessment. How 
these centers differ from PMG is in their approach to surveillance follow-up and support. Many 
of these centers feature multidisciplinary teams including geneticists, genetic counsellors, nurses, 
dieticians, gynecologists, oncologists, social workers, and psychologists. In these ways, the 
multiple facets of PV carriership are addressed. Also, a few of these clinics/programs offer 
periodic carrier support groups and sessions where PV carriers can liaise with other PV carriers 
and families and attend support sessions with guest speakers and genetic/hereditary cancer 
experts. Many of these programs also differ from the current PMG model in that PV carriers are 
scheduled to visit the clinics annually or bi-annually for surveillance, follow up and supportive 
care. In the province of Ontario, many of these clinics work with the High-Risk Ontario Breast 
Screening Program (OBSP) to coordinate breast surveillance of eligible high-risk individuals. 
Another important impact of these familial cancer clinics/programs is the contribution to 
translational hereditary cancer and genetic research. Clinic attendees may be given the option to 
participate in research that may also be of benefit to them. For example, clinic attendees who are 
followed long-term may be given the option to participate in trials of new prevention modalities, 
as the field of genetic medicine continues to rapidly evolve. Similarly, if clinic attendees undergo 
genetic testing and are found to have variants of uncertain significance (VUS), these variants 
may later be classified as pathogenic. Having a registry and follow-up system would be an ideal 
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way to notify individuals if their identified VUS was reclassified as pathogenic, and of the 
emerging clinical actions recommended for their particular PV. For a full list of familial cancer 
centers examined in this scan, please see Appendices I & J. 
Average and Increased Risk Breast Screening in Canada 
 
The Canadian Partnership Against Cancer (CPAC) (2018) conducted an environmental 
scan of the breast cancer screening programs available in all provinces and territories in Canada. 
With the exception of Nunavut, 12 provinces/territories offer organized breast screening 
programs. All 12 provincial programs offer breast screening services for women at average risk. 
According to Canadian Task Force on Preventive Health Care (2011), women at average risk for 
breast cancer should be screened using mammography from ages 50-74 years old, every two to 
three years. Most provinces recruit women for the provincial breast screening programs via 
physician referral (n=11) and self-referral (n=11) (CPAC, 2018). 
In addition to average risk women, some of these provincial programs manage women at 
‘elevated risk’ and ‘high-risk’ of breast cancer. There is a distinction in ‘elevated risk’ and high- 
risk. CPAC (2018) defined ‘elevated risk’ women as those who have an above average risk of 
breast cancer but less than the highest risk group. Risk factors for ‘elevated risk’ include 
increased breast density, use of hormone replacement therapy in the past, family history of breast 
cancer, and increased risk for benign breast disease (CPAC, 2018). In (n=10) provincial 
programs, women with an elevated risk of breast cancer are screened and managed by the 
program, including in NL, and these women are recommended to undergo annual mammography 
starting at age 40-50 (CPAC, 2018). Generally, provincial definitions of ‘high risk’ of breast 
cancer include known carriers of pathogenic variants, and first-degree relatives of a known PV 
carrier who did not opt for genetic testing, among other risk factors (CPAC, 2018). The CPAC 
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(2018) outlined that a challenge with managing high-risk women is that there are currently no 
national guidelines for screening this population, therefore there are variations in screening 
protocols across various Canadian jurisdictions. Most provinces have guidelines for 
recommended high-risk screening intervals, consisting of annual mammography, MRI and/or 
ultrasound beginning at age 30, 40 or 50, to stop at age 69-74 (CPAC, 2018). In NL, the Breast 
Disease Site Group (2017) of Eastern Health (EH) recommends alternating annual MRI and 
mammography for high-risk women, starting at age 30. What is perplexing is that although most 
provinces and territories have guidelines for high-risk breast management, only five 
provincial/territorial breast screening programs manage high-risk women (CPAC, 2018). Despite 
the Breast Disease Site Group (2017) policy, women at high risk of breast cancer in NL are 
referred back to their primary care provider for further management (CPAC, 2018). 
High-Risk Ontario Breast Screening Program 
 
In the province of Ontario, there is a dedicated follow-up program for women at high-risk 
of breast cancer. To be enrolled in the High Risk OBSP, a referring physician must submit a 
requisition form to a designated High Risk OBSP site (Cancer Care Ontario, n.d.) It is implicit in 
the program requisition form that the ordering physician is requesting future MRI testing and in 
some cases, image guided biopsies, which under current Ontario regulations requires a 
physician’s signature (Cancer Care Ontario, n.d.) Women who are eligible for the program fall 
into one of two categories, category A and B. Women in Category A are directly enrolled in the 
program because they carry a known PV associated with increased breast cancer risk, or are a 
first-degree relative of someone with a known PV and underwent genetic counselling but opted 
not to have genetic testing (Cancer Care Ontario, n.d.) Women in Category B require further 
genetic assessment prior to enrollment in the program; this includes individuals who are a first 
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degree relative of someone with a known PV who have not been assessed by a genetic 
counsellor. Following the genetic assessment, it will be determined whether the woman in 
Category B is enrolled in the High Risk OBSP. Cancer Care Ontario (n.d.) outlined that the high 
risk OBSP program is operated by high risk OBSP navigators with a list of responsibilities. 
These include booking the screening and breast assessment appointments, following up on 
abnormal results, arranging annual recalls, and communicating all imaging results to women and 
the referring physician. From my assessment, it was clear that this program was an effective 
method to address some of the common barriers to screening identified in the consultations. 
Non-For-Profit HBOC Organizations 
 
In a scan of websites, I discovered three non-profit organizations with a focus on HBOC: 
Bright Pink, FORCE: Facing Our Risk of Cancer Empowered, and the HBOC society. Both 
Bright Pink and FORCE are operated out of the United States while the HBOC society is a 
Canadian non-for-profit, with headquarters in Alberta. All three organizations offer some form of 
peer support either through connecting PV carriers with other PV carriers. This is achieved 
through peer navigation and peer mentoring programs as well as through online message boards. 
All three organizations also offer resources and information to PV carriers and families about 
risk management, the genetic testing process, and other concerns related to carriership. 
Bright Pink (2020) distinguishes its mandate as having a focus on health rather than 
cancer. Among its programs is an online digital platform that allows women to assess their risk 
for HBOC and understand how to manage that risk. Bright Pink (2020) identified that over 1.5 
million women have used their online risk platform, resulting in over 600,000 women being 
identified as high-risk. Bright Pink (2020) also offers health provider education initiatives and 
identified that since the advent of this initiatives program, over 18,000 health care providers have 
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participated in their online, continuing education, and in-person education sessions on HBOC. 
FORCE: Facing Our Risk of Cancer Empowered (2018) highlights in its mission statement that 
they also have a focus on advocacy to represent the interests and concerns of HBOC PV carriers 
to the health care providers, research scientists, and legislators. FORCE (2018) also has a focus 
on research advocacy and promotion. Their XRAYS program provides up-to-date research 
findings presented in clear, everyday language. The organization promotes and advocates for 
research specific to HBOC and provides PV carriers with information on the research studies 
they may qualify for. In partnership with the University of South Florida, FORCE (2018) offers a 
patient-powered research registry. This research registry allows PV carriers to offer input on 
ideas and priority areas for future research, to participate in designing research studies, to 
participate in research and become involved in disseminating research results. In this way, 
FORCE ensures that HBOC research is truly patient-informed. It is important to note that these 
three organizations are non-for-profit organizations and therefore their mandate differs from that 
of a provincial health policy. Still, a provincial follow-up program may be effective in 
connecting PV carriers with other PV carriers and promoting their group identity. This may lead 
to the advent of special interest non-for-profit groups that represent the interests of PV carriers in 
the province. From my environmental scan, I could not find any local groups or special-interest 
organizations with local chapters in NL with a focus on HBOC or hereditary cancer. Prospective 
local HBOC organizations and the provincial navigation program could then work in partnership 
with one another to improve the quality of care in this population. 
Conclusion 
 
The consultations and environmental scan are further evidence that the current follow-up 
process for PV carriers in NL is underserving the needs of this population. This current follow- 
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up process is fundamentally wrong; individuals are notified of their carriership but provided with 
no long-term follow-up or support to navigate and cope with the lifelong implications of their 
carriership. Essentially, it is as though PV carriers and their families are being brought up stream, 
then left to navigate for themselves without a paddle. The evidence is indelible, there needs to be 
a service to help PV carriers navigate the uncharted waters. The consultations reinforce the 
literature review findings that a novel follow-up navigation program will need to provide a 
centralized outlet for PV carriers and their primary care providers on information, and 
recommended screening and medical appointments. Likewise, it was also clear from the 
consultations that a novel program must go beyond screening and appointments; it must provide 
ongoing support to carriers, as PV carriership comes with its own unique territory of 
psychosocial and family implications. There is also evidence to suggest that the nursing 
profession has unrivaled potential to contribute to the development and delivery of dedicated 
follow-up programs. Nurses are ideally situated to assume the role of patient navigator for PV 
carriers. 
The environmental scan provided a picture how dedicated follow-up programs are 
commonly implemented in several health jurisdictions, suggesting they are both feasible and 
effective interventions. Furthermore, examining the features of the High Risk OBSP provided a 
model of effective high-risk breast screening follow-up. Roebothan et al. (n.d.) noted that only 
41.6% of eligible BRCA PV carriers in NL had undergone the recommended MRI screening in 
an 18-month period (p < 0.001). A prospective program in NL, similar to the High Risk OBSP, 
would likely improve this low rate of MRI screening uptake in PV carriers. Lastly, it was clear 
that a dedicated follow-up program for PV carriers could be an invaluable starting point for PV 
carriers to connect and form a group identity. This could perhaps result in the advent of local 
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chapters of HBOC non-for-profits organizations and/or support groups. This could allow them as 
group to self-advocate, promote awareness and education, support one another, and disseminate 
relevant information. 
In a policy framework document on cancer control in NL, the Department of Health and 
Community Services (2010) outlined the need to “build upon current activity to develop a 
hereditary cancer screening program ensuring best practice and necessary support, infrastructure 
(e.g. genetic counseling) and resources” (p.13). It is discouraging that over the past 10 years, it 
appears as though the NL government has made little to no progress on actualizing this goal. It is 
clear what needs to be done and how it will improve outcomes and reduce costs associated with 
cancer treatments. This consultation/environmental scan report adds to the mounting evidence 
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Faculty of Nursing  
July 2020 
 
To Whom it May Concern, 
 
My name is Rebecca Puddester and I am a registered nurse. I am also currently a Master of 
Nursing student at the Faculty of Nursing at Memorial University of Newfoundland. My nursing 
career began on a women’s health inpatient unit where I provided care to women with 
gynaecological malignancies. It was there that pointed me in the direction of research related to 
individuals and families with hereditary breast and ovarian cancer (HBOC). It became clear from 
the literature that in many health jurisdictions, there are considerable gaps in the care of 
individuals and families with HBOC predisposition syndrome. This results in missed 
opportunities to improve and indeed, save their lives. My master’s practicum project is to 
develop a policy proposal for a specialized program in Newfoundland and Labrador (NL) that 
would provide on-going health care system navigation, follow-up, risk-reduction, and 
psychosocial support to these high-risk individuals. 
 
Part of this project is to engage with stakeholders and experts involved in the current system of 
identification, follow-up management, and support of HBOC syndrome individuals and families. 
In so doing, this will help to identify gaps in the current system, to determine the acceptability of 
such a program to stakeholders, and to provide direction on useful features of such a program. It 
will also provide stakeholders with an opportunity to propose alternative strategies or 
considerations for the management and support of this high-risk population. 
You have been asked to participate in this consultation because you have been identified as 
having an important vantage point in the NL health care system that should be heard and 
considered prior to the development of any HBOC policy proposal in NL. Your participation in 
this consultation is voluntary. The findings will be anonymous, and your name will not appear in 
any report unless otherwise discussed and confirmed with you. The consultation will involve a 
telephone or online interview with myself, using the semi-structured question guide attached. If 
preferred, you may answer these questions in writing via e-mail. The content of all the 
consultations will be analyzed and reported as themes in the consultation report. The interview 
transcripts will not be included in the final practicum. Moreover, the interview transcripts will be 
secured in a passworded document accessible only to myself and my practicum supervisor. They 
will be destroyed at the completion of my degree in December 2020. 
 
If you have any further questions about this consultation, please do not hesitate to contact either 
myself at rjp823@mun.ca or my practicum supervisor, Dr. Joy Maddigan at n6jm@mun.ca. 
Thank you for your time and consideration, it is greatly appreciated and valued. 
Rebecca Puddester, BN RN 
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Appendix B: Health Research Ethics Authority (HREA) Screening Tool 
Student Name: Rebecca Puddester 




Date Checklist Completed: July 3rd, 2020 
 
This project is exempt from Health Research Ethics Board approval because it matches item 
number  1,3,4,5  from the list below (in bold). 
 
1. Research that relies exclusively on publicly available information when the 
information is legally accessible to the public and appropriately protected by law; or 
the information is publicly accessible and there is no reasonable expectation of 
privacy. 
2. Research involving naturalistic observation in public places (where it does not involve 
any intervention staged by the researcher, or direct interaction with the individual or 
groups; individuals or groups targeted for observation have no reasonable expectation of 
privacy; and any dissemination of research results does not allow identification of 
specific individuals). 
3. Quality assurance and quality improvement studies, program evaluation activities, 
performance reviews, and testing within normal educational requirements if there is 
no research question involved (used exclusively for assessment, management or 
improvement purposes). 
4. Research based on review of published/publicly reported literature. 
5. Research exclusively involving secondary use of anonymous information or 
anonymous human biological materials, so long as the process of data linkage or 
recording or dissemination of results does not generate identifiable information. 
6. Research based solely on the researcher’s personal reflections and self-observation (e.g. 
auto-ethnography). 
7. Case reports. 
8. Creative practice activities (where an artist makes or interprets a work or works of art). 
 
For more information please visit the Health Research Ethics Authority (HREA) at 
https://rpresources.mun.ca/triage/is-your-project-exempt-from-review/ 
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Appendix C: Semi-Structured Interview Guide #1 
A Consultation with Primary Care Providers in NL 
1) Is there a screening tool that you use in your family practice to identify individuals 
who would benefit from a referral to Provincial Medical Genetics (PMG)? 
2) From a primary care provider perspective, what are the most salient barriers to 
ensuring adequate follow-up and risk management for patients with an inherited 
pathogenic variant (PV)? 
3) What resources are available to you when providing genetic follow-up to patients and 
guidelines for recommended screening and risk-reduction? Have you used these 
resources? 
4) Without providing any identifiable patient information, can you describe your 
experiences with managing the recommended screening and risk management for 
your patients with PVs that are considered “actionable”? 
5) How is the topic of genetic risk management incorporated into your continuing 
medical competency education? 
6) If available, would you be interested in participating in a module/workshop about 
management of actionable PVs if it counted towards continuing competency hours? 
7) If there was a coordinated cancer registry with a PV carrier navigation program in 
NL, do you think such a program would be beneficial? If so, what are some key 
features that you think such a program would entail? 
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Appendix D Semi-Structured Interview Guide #2 
An Interview with a Genetic Counsellor in Provincial Medical Genetics 
1) What are some salient barriers to follow-up following genetic testing for 
individuals with pathogenic variants (PV) and variants of uncertain significance 
(VUS) in the current genomic care paradigm? 
2) Can you describe your role from the point of intake of a referred individual to 
PMG, to the disclosure of their genetic results and follow-up? 
3) How long do you follow-up with an individual if they have an identified PV? 
 
4) Do you have continued follow-up with their primary care provider? 
 
5) What is your role in their adherence to recommended screening/risk modalities 
for actionable PVs? 
6) From your perspective, would a PV/VUS registry/follow-up program with a 
coordinated approach to risk-reduction/psychosocial support be a beneficial 
program? If so, what would be some key features of that program in terms of the 
basket of services that it should offer? 
7) What would be some barriers to the development of establishing such a program 
from your perspective? 
8) Some health jurisdictions implement nursing care in genetic programs and follow- 
up. Has this been the case in NL and is there potential for an expanded nursing 
role in genetic care? 
9) To your knowledge, are there any other individuals who are relevant stakeholders 
who you recommend I should consult as part of this practicum project? 
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Appendix E: Semi-Structured Interview Guide #2 
 
An Interview with a Professor of Clinical Epidemiology, specializing in Ethical, Legal, and 
Social Issues Pertinent to Genetics 
1) From your perspective as an expert researcher and professor of clinical 
epidemiology, what are some of the most salient barriers to adequate follow- 
up for individuals in NL who test positive for a known pathogenic variant 
(PV)? 
2) Do you think there is a need for a coordinated approach to follow-up care/risk 
reduction adherence/psychosocial support for individuals in NL with PVs and 
VUS? If so, what do you believe should be key services that such a program 
should offer? 
3) From your perspective, what would be some barriers to implementing such a 
program? 
4) What would be some important ethical and legal considerations to account for 
when developing a program model for follow-up care in NL? 
5) Are there research publications that you recommend I review that are relevant 
to the focus of my policy proposal? 
6) Hypothetically, if in the future, such a program policy proposal was 
implemented, could this program be a feasible basis for a pilot study where 
outcomes were measured and/or qualitative data was collected about 
participant satisfaction with the program? 
7) Are there other relevant stakeholders who you recommend that I should 
include as part of my consultation plan? 
125  
Appendix F: Semi-Structured Interview Guide #4 
 
An Interview with a Nurse Involved in the Development of a Registry for a Cancer 
Screening Program 
1) What lead you to become involved in the development of the provincial screening 
program? 
2) What was/is the role of the program? 
 
3) What were common barriers in adherence to recommended screening? 
 
4) What were barriers/facilitators to developing the program? 
 
5) What was the process for rectifying when primary care providers did not order the 
recommended screening modality based on the algorithm in the provincial screening 
program? 
6) From your perspective, what are key features that should be incorporated in any 
screening registry/navigator program? 
7) How did you secure funding when you proposed the cancer screening registry? 
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Appendix G: Semi-Structured Interview Guide # 5 
 
A Consultation with a Nurse with Experience in Research Pertaining to Individuals with an 
Inherited Cancer Predisposition Syndrome 
1) From your research with individuals carrying pathogenic variants (PV) what were the 
most salient barriers to their adherence to recommended screening barriers? What were 
some facilitators that positively influenced their adherence? 
2) Did you conduct any interviews/consultations with primary care providers or tertiary care 
providers about what barriers they are experiencing providing primary care to individuals 
living with pathogenic variants? 
3) Have you discussed with other individuals in Canada, how NL compares to the follow-up 
and counselling paradigm for individuals with PVs in other areas in Canada? 
4) Given your experience with the topic, if there was a PV carrier navigation program in the 
province, do you think this would be a beneficial intervention? What are some key 
features you think such a program should include? 
5) Your PAHD psychometric scale was validated in a population of Lynch Syndrome PV 
carriers in NL. As the co-developer/primary author of the scale, do you think this scale 
could be used to evaluate the impact of a systematic program for PV carriers in a 
prospective before/after study +/- a control group? Has this scale been validated in other 
populations such as the ARVC PV carriers? 
6) Do you have any recommendations for individuals who I should contact as stakeholders 
both provincially and elsewhere as I go forward in developing the policy proposal? 
7) Canada is trailing behind other developed countries including the US and the UK with 
respect to how nurses are incorporated in the genetic/genomic health care paradigm. This 
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includes a lack of outlined genomic nursing competencies and lack of inclusion of 
genetic content in nursing education. In your opinion, as a profession and a discipline, 
regulatory bodies (CNA, CASN), how do we rectify this? Should this be a priority? 
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Appendix H: Semi-Structured Interview Guide #6 
An Interview with an Oncologist with Experience in Inherited Cancer 
Predisposition Syndromes 
 
1) From the perspective of oncologists/surgeons who perform risk-reduction 
surgeries, what barriers are they experiencing to ensuring adequate identification, and follow- 
up of individuals with PVS predisposing them to HBOC? 
2) In your opinion, how does NL compare to other jurisdictions in Canada in terms 
of follow-up, management, and support to individuals with cancer predisposition syndromes? 
How does Canada compare with other developed countries? 
3) In other jurisdictions outside of NL, what aspects of their PV carrier follow-up 
programs/strategies have been most impressive to you? In other words, what have you seen 
in other provinces that they are doing right in their management of these high-risk 
individuals? 
4) From your perspective, what factors facilitate adequate adherence to risk- 
reduction modalities and screening for HBOC PV carriers? 
5) If there were to be a systematic program for follow-up, management, and support 
of PV carriers, what would be the most important features that such a program should entail? 
6) What do you think would be the greatest barriers/obstacles to implementing such 
a program? 
7) Do you think there is a potential to expand the nursing role in the development 
and implementation of dedicated follow-up and navigation programs for PV carriers? 
8) Is there anything else you would like to add/mention that is relevant to the focus 
of this project that has not been discussed in this interview? 
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Appendix I: Websites of Canadian Genetics Centres Offering Multidisciplinary Care and 
Follow-Up (Outside of NL) 
Atlantic Canada 
 
Maritime Medical Genetics Centre, IWK 
Dr. Richard B. Goldbloom Research and Clinical Care Pavilion 
IWK Health Centre 
5825 South St, Halifax, NS B3H 1V 
Canada 
Services Offered (according to website) 
“Our team of Medical Geneticists, Genetic Counsellors, Nurses, Dietitian & Administrative staff 
provides genetic services to Nova Scotia, New Brunswick and Prince Edward Island” 
“In genetics, we help people learn about diseases in their families and help to determine if there is a 
genetic cause. Our knowledge of genetics has increased tremendously over the past few years, and 
there have been many new developments in testing techniques and availability. A genetic 
assessment can aid families understand the hereditary aspects of diseases in their family.” **No 
discussion of long-term high-risk follow-up of PV carriers on website* 




Cancer Genetics Service, McGill University Health Centre 
Montreal Children’s Hospital 
1001 Boulevard Décarie 
Montréal, QC, H4A 3J1 
Canada *also in partnership with sister hospital, Jewish General Hospital, Montreal QC 
Services Offered (according to website) 
“Our multidisciplinary team of cancer genetics specialists provides personalized cancer risk 
assessments based on medical and family history, and when indicated, help individuals navigate 
through the process of genetic testing” 
“Through supportive counseling and education about hereditary cancers, we help empower 
individuals to use genetic information to make informed decisions about cancer screening and 
primary prevention. We also provide recommendations to other medical specialists working in 
surgery, oncology, gastroenterology, and gynecology, to ensure that individuals at “high-risk” for 
developing cancer have access to the appropriate surveillance and follow-up” 
Website URL https://muhc.ca/med-genetics/clinical-genetics 
High Risk Breast Clinic, Jewish General Hopsital 
High Risk Breast Clinic 
JGH Stroll Cancer Prevention Centre 
E-Pavilion, Room E740 
3755 Ch. de la Cote Ste Catherine 
Montreal, QC, Canada 
Services Offered (according to website) 
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“The objective of the High-Risk Breast Clinic is to provide screening and clinical surveillance to 
women who are at an elevated risk of developing breast cancer. The clinic is also designed to 
provide supportive counselling and prevention strategies that can help lower risk in high-risk 
patients” 
“Depending on your personalized risk assessment and level of risk, you may require further 
appointments and/or regular follow up visits. Most patients have one visit per year or two visits per 
year” 
Website URL: https://www.mcgill.ca/cancerprev/clinical/hrbc 
Hereditary Gynecologic Surveillance Clinic, Jewish General Hospital 
Jewish General Hospital 
3755 Côte-Sainte-Catherine Road 
Room E-740 
Montreal, QC, H3T 1E2 
Canada 
Services Offered (according to website) 
“The objective of the Hereditary Gynaecologic Surveillance Clinic is to promote prevention and 
make best detection services available to women who have been identified as being at a higher risk 
for developing gynaecologic cancers. The focus of the clinic is to offer long-term medical and 
emotional support to these women” 
 
“Depending on your discussion with the staff members of the Hereditary Gynaecologic Surveillance 
Clinic and the medical tests requested, you might need more appointments. The Clinical Care 
Coordinator handles all of the appointment scheduling. Most patients either have one visit per year 
or two visits per year” 




Cancer Genetics and High-Risk Program, Sunnybrook Health Sciences Centre 
Louise Temerty Breast Cancer Centre 
2075 Bayview Avenue, 
M-wing, 6th floor 
Toronto, ON M4N 3M5 
Canada 
Services Offered (according to website) 
“Offers cancer risk assessment, genetic counselling and/or genetic testing to eligible individuals and 
families who may be at risk for hereditary cancer” 
 
“At Sunnybrook, female BRCA carriers may be followed yearly in our Breast High Risk Program. 
This may start at age 25 where visits consist of clinical breast exams until age 30. At age 30, women 
are eligible for mammogram and breast MRI imaging through the High Risk OBSP” 
 
Website URL: https://sunnybrook.ca/content/?page=occ-cancer-genetics 
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Cancer Genetics Clinic, Medical Genetics Program of Southwestern Ontario 
London Health Sciences Centre 
Victoria Hospital 
London Regional Cancer Program 
800 Commissioners Road East 
London, ON, N6A 5W9 
Canada 
Services Offered (according to website) 
“The Cancer Genetics Program (CGP) is a collaborative effort between the London Regional Cancer 
Program (LRCP) and London Health Sciences Centre (LHSC). The program offers genetic 
counselling and testing for families at risk for inherited forms of breast, ovarian or colorectal 
cancer” 
“Following services available to individuals and families: genetic counselling, testing, assessment, 
education, surveillance” 
“A patient support group has been formed to provide emotional support for individuals and families. 
Meetings consist of group discussion as well as occasional guest speakers” 
Website URL: https://www.lhsc.on.ca/medical-genetics-program-of-southwestern-ontario/cancer- 
genetics-clinic 
Clinical Genetics Program, Thunder Bay Regional Health Centre 
980 Oliver Road 
Thunder Bay, ON, P7B 6V4 
Canada 
Services Offered (according to website) 
“The genetic counsellor, genetics nurse and geneticist provide information and counselling to those 
at risk of having a hereditary cancer syndrome. In collaboration with the Regional Cancer Care 
Northwest, a consultation with an oncologist is also available as needed” 
 
“Geneticists, genetic counsellors and genetics nurses are part of a team of health care professionals 
who provide genetic services. Geneticists are medical doctors who have special training in the area 
of genetic conditions. A genetic counsellor has post graduate training in genetic counselling. A 
genetics nurse is a nurse with extra training in genetics. Together, they can provide information 
about genetic conditions and explain how they are passed from one generation to another” 
Website URL: http://tbrhsc.net/programs-services/prevention-and-screening-services/genetics- 
program/ 
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The Charlotte and Lewis Steinberg Familial Breast and Ovarian Cancer Clinic, North York 
General Hospital 
North York General Hospital, General site 
4001 Leslie Street, 3rd floor 
Toronto ON, M2K 1E1 
Canada 
Services Offered (according to website) 
“Provides genetic assessment and counselling for individuals and families at increased risk for 
inherited breast and/or ovarian cancer” 
 
“In our multidisciplinary team setting, we are joined by a family doctor with a special interest in 
breast and ovarian cancer surveillance and prevention, and a gynecologist. Some patients who are at 
high risk for inherited breast and ovarian cancer are seen on a regular basis by this multidisciplinary 
team for surveillance and support. In some cases, genetic testing is available” 
 
The Centenary Genetics Clinic (Rouge Valley Centenary 
2867 Ellesmere Road, Toronto, ON M1E 4B9) is a satellite clinic of the North York General 
Hospital Genetics Program. 
Website URL: https://www.nygh.on.ca/areas-care/genetics/clinical-services 
Familial Cancer Centre, Princess Margaret Cancer Centre 
Princess Margaret Cancer Centre 
M740-610 University Avenue 
Toronto, ON, M5G 2M9 
Canada 
Services Offered (according to website) 
“The Familial Cancer Clinic provides genetic counselling and risk assessment services to people 
with a personal or family history of cancer. We can talk with you about whether the cancer in your 
family may be hereditary and discuss how you can manage your risk of developing cancer. We can 
also let you know if you are eligible for high-risk breast cancer screening (OBSP)” 
 
“Familial Cancer Clinic includes world-class health care professionals working for you and with 
you. Your team can include doctors, genetic counsellors, students, volunteers and many others 




Familial Breast Cancer Clinic, Mount Sinai Hospital 
Marvelle Koffler Breast Centre 
Mount Sinai Hospital 
Joseph & Wolf Lebovic Health Complex 
600 University Avenue, 12th Floor 
Toronto, ON 
Canada 
Services Offered (according to website) 
“Offers a comprehensive counselling and referral service for individuals with a personal and/or 
family history of breast cancer, or other cancers suspicious for a hereditary predisposition.” 
 
“Facilitated by genetic counsellors who provide breast cancer risk assessment to determine 
eligibility for high-risk breast cancer screening through the Ontario Breast Screening Program. Also, 
the genetic counsellor determines eligibility for genetic testing. Following an assessment, referrals 
are made to members of the team in the departments of medicine, nursing, psychiatry, social work, 
and nutrition as required.” 
 
“Individuals who are found to carry a hereditary predisposition may be offered ongoing clinical 
follow-up through our high-risk clinic” 
 
Website URL: https://www.mountsinai.on.ca/care/cancer/cancers-we-treat/marvelle-koffler-breast- 
centre 
Familial Oncology Program, Kingston General Hospital 
25 King St. West 
Kingston, ON K7L 5P9 
Canada 
Services Offered (according to website) 
“The Familial Oncology Program (FOP) offers genetic counselling and testing to you and your 
family if you are at risk of inherited forms of breast, ovarian, colorectal or other cancers” 
 
“Cancer screening and preventative treatment options available to you and your family. To do this, 
we work closely with the High Risk Cancer Clinic and breast cancer screening programs. 
Website URL: https://kingstonhsc.ca/cancer-care/genetics-familial-oncology-program 
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Genetics/Hereditary Breast Cancer Clinic, Women’s College Hospital 
Women's College Hospital 
76 Grenville Street 
Floor 5 
Toronto, ON M5S 1B2 
Canada 
Services Offered (according to website) 
“Provides comprehensive genetic counselling services for individuals with a personal and/or family 
history of cancer” 
 
“Testing services are available to those who are eligible” 
 
“Families may receive other clinic services or long-term follow-up” 
 
“We can also let you know if you are eligible for additional breast cancer screening through either 




Hereditary Cancer Clinic, Children’s Hospital of Eastern Ontario 
Regional Genetics Program, CHEO 
401 Smyth Road 
Ottawa, ON K1H 8L1 
Canada 
Services Offered (according to website) 
“We specialize in the assessment of children, adults, and families with familial or hereditary forms 
of cancer predisposition. We offer genetic counselling and genetic testing services if indicated. 
Through partnership with the Ontario Breast Screening Program (OBSP) we also provide women 
with a personal or family history of breast and/or ovarian cancer with a personalized breast cancer 
risk assessment” 
 
“Our goal is to identify individuals and families who may be at an increased risk of developing 
specific types of cancer and to inform them about the appropriate prevention and screening 
recommendations available” 
 
“Our services are provided by a team consisting of genetic counsellors, geneticists and 
administrative/clerical staff”’ 





Hereditary Breast Cancer Clinic, Health Sciences Centre Winnipeg 
FE-229 Community Services Bldg, 820 Sherbrook Street 
Winnipeg, MB R3A 1R9 
Canada 
Services Offered (according to website) 
“Consisting of geneticists, genetic counselors and laboratory technicians who provide education, 
counseling, risk assessment gene testing, screening recommendations and links to other support 
services” 
 
“We work with colleagues in CancerCare Manitoba and the WRHA Oncology Program to develop a 
multidisciplinary approach to patient information sharing, health and preventative medical care, risk 
assessment and counselling. This service works closely with the DNA Diagnostic Laboratory at the 
Health Sciences Centre” 
 





Allard Hereditary Breast and Ovarian Clinic, Lois Hole Hospital for Women 
Lois Hole Hospital for Women 




Services Offered (according to website) 
“Provides care for women who have a high risk of hereditary breast or ovarian cancer” 
“Offers assessment, surveillance, and follow up for women who have a high risk of hereditary breast 
or ovarian cancer including BRCA1 and BRCA2 mutations” 
 
“Ongoing breast Surveillance and referrals for Gyne-Oncology for Risk Reducing Surgery. 
Support services are offered to clients and their families” 
Comments 
“Clients must be between 25 and 70 and meet the eligibility listed on the referral form. Clients will 
also be considered if they have: 
• a recommendation from a genetics clinic 
• BRCA1 or BRCA2 mutation 
• a first degree relative (a parent, sibling, or child) with BRCA1 or BRCA2 mutation 
• had radiation to their chest before age 30 
• a strong family history of breast or ovarian cancer 
• must meet the referral criteria for acceptance in the clinic 
Website URL: https://www.albertahealthservices.ca/findhealth/service.aspx?Id=1062103 
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Hereditary Cancer Program (BC & Yukon) 
(2 Clinic Locations) 
Hereditary Cancer Program 
600 West 10th Avenue 
Vancouver, BC V5Z 4E6 
Hereditary Cancer Program 
32900 Marshall Road 
Abbotsford, BC V2S 0C2 
Canada 
Services Offered (according to website) 
“Provides genetic counselling and genetic testing for BC/Yukon residents who may have inherited 
an increased risk for specific types of cancer. Similar services are available across Canada and in 
other countries” 
 
“The HCP team includes specialized physicians, genetic counsellors, nurses and support staff. 
Working together, we provide hereditary cancer risk assessment, genetic counselling and genetic 
testing. Our team also provides education (link to other section) about hereditary cancer topics” 
 
Website URL: http://www.bccancer.bc.ca/our-services/services/hereditary-cancer 
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Appendix J : Scan of Websites of Genetics Centres Offering Multidisciplinary Care and/or 
High-Risk Follow-Up (Countries Outside of Canada) 
 
BRCA Multidisciplinary Clinic, Rabin Medical Center’s Davidoff Cancer Center 
Country: Israel 
 
Services Offered (according to website) 
“The BRCA Multidisciplinary Clinic was created to serve patients with a high risk of cancer at 
Rabin Medical Center’s Davidoff Cancer Center. Since its commencement in 2011, the clinic has 
served thou - sands of women. Women who carry the BRCA gene mutation have up to an 80% 
chance of developing breast and/or ovarian cancer. More than 200 mutations have been identi - 
fied, three of which are typical to Ashkenazi Jews.” 
 
“At the Rabin Medical Center BRCA Clinic, patients receive counseling, screening and follow-up 
care” 
 
“BRCA Multidisciplinary Clinic also treats men with prostate cancer. Research data indicates that 
men carry mutations in the BRCA 1 and 2 genes, similar to the syn - drome for breast and ovarian 
cancer in women” 
Website URL: https://afrmc.org/brca.php 
https://afrmc.org/newsarticle/340 
Cancer Genetics Unit, Royal Marsden NHS Foundation Trust 
Country: UK 
 
Services Offered (according to website) 
• Familial cancer risk assessment 
• Diagnostic genetic testing (testing of one or more genes known to associated with cancer 
predisposition) 
• Predictive genetic testing (testing for a specific mutation in a gene, already identified within 
a family) 
• Advice and referral for cancer screening 
• Discussion of cancer risk-reducing management options 
• Assistance with decisions on cancer treatment options 
• Offer of enrolment in genetic research studies 
• Long term open access follow-up for patients with a known gene mutation on the RM 
Carrier Register 
“Our aim is to promote cancer prevention, early detection and to help in some cases with 
management decisions. We assess personal and family history of cancer to decide whether it is 
likely that there is a hereditary cause. We use this assessment to decide whether a genetic test 
might help an individual to clarify their own risk” 
 






Familial Cancer Program, Genetic Services of Western Australia 
Country: Australia 
Services Offered (according to website) 
“We offer a range of services to people with a personal and/or family history of cancer. We can: 
• provide you with information about familial cancer conditions (conditions that may run in 
your family which put you at an increased risk of developing cancer) 
• assess your risk of developing an inherited cancer based on your personal and/or family 
history 
• assess whether genetic testing may be an option for your family 
• recommend risk management options 
• discuss lifestyle strategies to encourage good health and reduce your risk of developing 
cancer 
• address any questions you may have about familial cancer 
• provide support and short-term counselling 
• support and facilitate familial cancer research.” 
• 
“We are a team of health professionals who can provide advice about your familial cancer risk, and 
ways to manage that risk. Our team includes genetic counsellors and geneticists. We provide 
information and support to people and families who have concerns about familial cancer” 
 
Website URL: https://healthywa.wa.gov.au/Articles/F_I/Familial-Cancer-Program 
140  












Navigating Inherited Cancer Risk 
 
A Policy Proposal for a Dedicated Follow-Up and Navigation Program 
Rebecca Puddester 












Policy Proposal for a Novel Follow-up and 
Navigation Program 
 




Background to the Issue: Individuals who carry certain inherited pathogenic 
variants (PVs) have an increased lifetime risk of developing hereditary breast and ovarian 
cancer (HBOC). There is hope in mitigating increased risk in asymptomatic HBOC PV 
carriers through risk-reduction modalities. Risk-reducing salpingo-oophorectomy reduces 
the risk of ovarian cancer by 80% and breast cancer risk by 50% in asymptomatic BRCA 
PV carriers (Rebbeck et al., 2009). Risk-reducing mastectomy in asymptomatic BRCA PV 
carriers almost entirely reduces breast cancer risk (Li et al., 2016), while annual breast 
magnetic resonance imaging and annual mammography alternating every six months, is > 
90% effective in detecting stage I breast cancer in high-risk PV carrier groups (Warner, 
2018). 
Despite the effectiveness of risk reduction modalities, many PV carriers in 
Newfoundland and Labrador (NL) remain unidentified. This also reflects a global trend; 
up to the year 2014, only an estimated 2.6% of BRCA PV carriers in the general population 
had been identified (Manchanda et al., 2018). Moreover, for known PV carriers in the 
province, there is no systemic support available to them in their long-term risk 
management. This fragmented approach is resulting in reduced adherence to risk 
reduction modalities. In an NL study, only 41.6% of BRCA PV carriers in NL had 
undergone the recommended annual MRI screening in an 18-month period (p < 0.001) 
(Roebothan et al., n.d.). PV carriers have reported that their primary care providers were 
insufficiently prepared to coordinate their follow-up care and informational needs 
(Cherry et al., 2013; Leonarcyzk & Mawn, 2015; Watkins et al., 2011). There is no 
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centralized outlet in NL that provides ongoing support, information, or screening 
reminders to PV carriers, or to their primary care providers, as they navigate the lifelong 
implications of carriership. Therefore, these high-risk individuals and families are not 
receiving the information and support needed to live a long, healthy life vis-à-vis their 
carrier status. 
Project Overview: A policy proposal to address the gaps in HBOC PV carrier 
follow-up care in NL was conceptualized as my Master of Nursing practicum project. The 
purpose of the project was to outline recommendations for a HBOC PV carrier navigation 
and follow-up program in NL and to make sub recommendations for features of this 
proposed program. In the first practicum course an integrative literature review, key 
informant consultations, and an environmental scan were conducted. The focus in the 
first practicum course was to determine the main barriers and facilitators in the current 
approach to PV follow-up care, and to identify what interventions and follow-up 
programs for PV carriers have been successfully implemented in other regions; thereby 
confirming what features of extant programs were pertinent to the proposed program. 
Input was also obtained from (n=8) relevant NL health care stakeholders on priority 
issues and recommendations in PV follow-up care. In the second practicum course, all the 
data collected in the first practicum course was analyzed. Informed by this data, a policy 
proposal document was developed for a novel follow-up and navigation program for PV 
carriers in NL. 
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Key Policy Proposal Recommendations: The establishment of a novel, 
dedicated HBOC PV carrier navigation and follow-up program in NL is recommended. 
The five key recommendations for this prospective program are: 
1) A central HBOC PV carrier registry in NL 
 
2) The establishment of a nurse navigator position to coordinate PV carrier 
surveillance and follow-up. 
3) Coordinated involvement of a multidisciplinary HBOC team 
 
4) A Person and family centred approach to care 
 
5) Virtual and electronic infrastructure to support delivery of the program 
 
The following is a brief explanation of the proposed program and the significance 
of the five, recommended program features. Individuals carrying pathogenic variants, 
likely pathogenic variants, and variants of uncertain significance would be entered into a 
PV carrier registry following the disclosure of their genetic testing results. This new 
registry would be a sub-registry of the existing Newfoundland and Labrador Cancer Care 
Registry. The data in the carrier registry should include demographic information, 
information on the pathogenic variant, information on the testing panel ordered, and 
information on the recommended clinical actions for the variant. The registry data should 
also be updated as PV carriers undergo the recommended screening and risk-reduction 
modalities. The registry data would be accessible to all approved multidisciplinary team 
members in the PV carrier follow-up program. PV carrier participation in the follow-up 
program would be voluntary. 
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A central feature of the follow-up and navigation program will be the nurse PV 
carrier navigator role. The nurse navigator would be responsible for maintaining ongoing 
follow-up with PV carriers, coordinating and scheduling screening appointments, 
connecting them with other multidisciplinary team members, and assisting with 
discussing genetic testing results with family members. Therefore, the nurse navigator 
will rely on the carrier registry data to facilitate booking and screening reminders and to 
develop a personalized plan of care. Moreover, under the prospective program, PV 
carriers will be connected to expert multidisciplinary care providers as needed including 
gynecologists, oncologists, breast surgeons, social workers, psychologists, dieticians, and 
genetic counsellors as needed, following ongoing assessment with the nurse navigator. 
A person-centered approach is recommended for this program when working with 
PV carriers to deliver a follow-up care plan that is psychologically suited to their needs, 
preferences, and individual life circumstances. Given these individuals are generally 
asymptomatic and lead active lives, this program should have flexible delivery options. 
Moreover, given that the follow-up will be long-term, it is important to offer flexible 
program delivery modes for PV carriers such as evening and weekend appointments and 
different communication options, such as in person appointments and/or video and 
telephone conferencing. The framework recommended to guide the delivery of this 
program is Hartrick Doane and Varcoe’s (2015) relational inquiry. Relational inquiry is an 
approach to nursing practice where nurses are encouraged to “look beyond superficial 
clinical situations and recognize the impact of various contexts in nursing practice” 
(Younas, 2017, p. 340). The principles of relational inquiry are relevant when delivering 
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person-centered follow-up care that acknowledges all the systemic, familial, and 
individualized factors influencing adherence and appraisal of risk mitigation in PV 
carriers. 
A family centered approach is also a key feature recommended for this proposed 
program. Both affected and unaffected family members of PV carriers may experience 
psychologic distress emanating from the awareness of their own risk and/or the worry of 
their relatives’ increased risk of cancer. In the current PV carrier follow-up processes, the 
perspective of the family is largely overlooked. The prospective program would address 
this oversight by encouraging the participation and involvement of family members in a 
follow-up program. PV carrier families would also be supported by the follow-up program 
in family genetic results disclosure sessions. There, HBOC follow-up team members would 
be present to help explain the implications of PV carriership to PV carriers and to their 
potentially at-risk family members. The program would also support at-risk relatives who 
wish to pursue genetic testing by connecting them with Provincial Medical Genetics. 
The final key recommendation is that virtual and electronic delivery methods 
should be offered for this program. This will include telehealth and virtual appointment 
delivery to ensure PV carriers provincewide have equitable access to quality follow-up 
services, regardless of their geographic location. PV carriers should also be able to opt for 
electronic text appointment reminders and online information. The proposed program 
should also be compatible with the province-wide electronic medical record and 
electronic health record software so that relevant information pertaining to their PV 
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carriership can be clearly communicated and shared to all relevant providers in the circle 
of care, ensuring continuity and consistency of care. 
Interpretation: The genomic era of health care is upon us and with this comes 
the responsibility to translate genomic knowledge into improved health outcomes. As 
clinical genetics and genomics become increasingly integrated in routine health care, PV 
carriers will require support to understand and apply this knowledge in their lives. This 
proposed PV carrier navigation and follow-up program is a viable, promising strategy to 
improve outcomes and save lives in PV carriers. Similar programs have been shown to 
increase PV carrier satisfaction, improve their adherence to risk-reduction 
recommendations, facilitate the cascade genetic testing of other at-risk relatives, and to 
contribute to health care system cost-savings. This policy proposal also highlights an 
opportunity for a key nursing role in genomic care delivery through the proposed PV 
carrier nurse navigator role. There are compelling arguments described in the policy 
proposal to pilot this proposed program in collaboration and consultation with relevant 
stakeholders. Evaluation of a program pilot project will provide proof of its value to the 
NL health care system going forward. 
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Improving Follow-Up Care for Individuals with Hereditary Breast and 
Ovarian Cancer Syndrome: A Policy Proposal for a Dedicated Follow- 
Up and Navigation Program 
Pathogenic variants (PVs), such as PVs in the BRCA 1 &2, MLH, and RAD51C genes, 
are associated with an increased risk of developing hereditary breast and/or ovarian 
cancer (HBOC). Risk-reduction modalities recommended for PV carriers have been 
shown to significantly improve HBOC-associated morbidity and mortality. As a result, 
these and other PVs are considered clinically actionable. Despite this, many PV carriers 
remain unidentified and/or under-surveilled and as a result, many are missing critical 
opportunities to benefit from lifesaving risk-reduction procedures, chemoprevention, and 
surveillance. In the Newfoundland and Labrador (NL) healthcare system, primary care 
providers are responsible for the initiation of genetic referrals and appropriate PV carrier 
follow-up. Many PV carriers do not receive sufficient follow-up, screening, and support to 
adequately manage their risk and cope with the implications of PV carriership. Although 
there are dedicated PV carrier follow-up models and clinical guidelines implemented in 
some areas of Canada and internationally, overall, there is a paucity of follow-up 
programs that address the health considerations of this high-risk population. As the 
identification and long-term follow-up of PV carriers provides an unrivaled opportunity 
for disease prevention, the current follow-up process for PV carriers is unacceptable. In 
this policy paper, issues in the current PV carrier follow-up process in NL will be 
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presented and recommendations for a novel follow-up and navigation program for PV 
carriers will be outlined. 
In partial fulfilment of the requirements of the degree of Master of Nursing, data 
from an integrative literature review and from a consultation plan/environmental scan 
were compiled for this practicum project. Together, the data served as the basis of 
program policy recommendations outlined in this proposal. The establishment of a 
provincial navigation & f/u program is the primary recommendation to improve health 
outcomes for the PV population in NL. Five sub-recommendations identify the essential 
program characteristics needed to remedy the current approach to PV carrier follow-up 
care in NL: 1) the establishment of a centralized, coordinated registry for all known PV 
and VUS carriers in the province who opt for genetic testing. 2) The development of a 
nurse navigator position that would have responsibility for coordinating screening and 
follow-up appointments, providing ongoing individual and family support, and 
connecting individuals with the necessary health care services. 3) The coordinated 
involvement of multidisciplinary healthcare providers in the provision of PV carrier 
follow-up. 4) The adoption of a person-centered, family approach to care and, 5) 
electronic and virtual infrastructure to support the delivery of this service, including 
remote service options for province-wide delivery of this service. Considerations 
surrounding the cost-effectiveness of the program, the suitability of this proposed 
program within the Canadian health care system, and methods for program evaluation 
will also be presented in this policy proposal. 
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Background to HBOC Syndrome 
It has been nearly thirty years since the discovery of BRCA1, a tumor suppressor 
gene associated with hereditary breast and ovarian cancer (HBOC) susceptibility 
(Beamer, 2019). Since that time, there have been significant advances in research and 
clinical genetics. The completion of the mapping of the entire human genome 
(International Human Genome Sequencing Consortium, 2004), allowed for increased 
speed and accuracy of clinical genetic testing, while costs of testing have also significantly 
reduced (Bingham, 2012). As the area of genomics continues to rapidly advance, the 
identification and surveillance of PV carriers is an emanating priority health issue. This is 
particularly relevant in the context of HBOC syndrome, for which there are several 
options available to affected carriers, proven to reduce their risk of developing HBOC. 
With increasing availability of multi-genome sequencing technologies, health care policy 
makers must determine how to utilize genetic HBOC testing effectively and responsibly. 
They must also provide adequate guidance to affected carriers as they navigate the 
management of their risk. Thiruchlevam et al. (2018) accurately noted that “genetic 
testing can be life-changing and indeed life-saving, but it is crucial that it comes with all 
of the facts and appropriate professional support to enable individuals to live and plan for 
a healthy life” (p. 2091). It is an underlying assumption in this policy proposal that PV 
carriers can be identified, surveyed, and supported in a more suitable and cost-effective 
manner than the current process in the NL health care system. 
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‘HBOC syndrome’ refers to a predisposition to developing cancers of the breast 
and/or ovaries, including the peritoneum and fallopian tubes due to an inherited 
pathogenic variant (PV) with an autosomal dominance inheritance pattern (Gabai-Kapara 
et al., 2014). While all cancers occur due to genetic mutations, hereditary cancer occurs 
due to PVs that offspring inherit through one or two parents (National Comprehensive 
Cancer Network, 2019). HBOC syndrome is most often associated with PVs in the BRCA 1 
& 2 tumor suppressor genes but has also been associated with up to 24 various inherited 
PVs (Nielsen et al., 2016). It is estimated that more than 20% of cases of ovarian cancer 
are associated with a hereditary predisposition syndrome (Susyznska et al., 2020). In a 
study of subjects with ovarian cancer, 24% of the ovarian cancer cases were associated 
with germline PVs; 18% were attributable to BRCA1 or BRCA2 and 6% were associated 
with PVs in the BARDI, BRIP1, CHEK2, MRE11A, MSH6, NBN, PALB2, RAD50, RAD51C 
genes (Walsh et al., 2011). Increased lifetime risk for ovarian cancer also occurs in the 
context of PVs associated with Hereditary Non-Polyposis Colorectal Cancer or Lynch 
Syndrome (LS) (Stuckless et al., 2007). 
The estimated lifetime risk of cancer in PV carriers varies depending on the 
specific PV. For example, women who carry PVs in the BRCA1/2 genes have a 51-72% 
lifetime risk of breast cancer and an 11-44% lifetime risk of ovarian cancer 
(Kuchenbaecker et al., 2017; Rebbeck et al, 2015). This is in contrast with a 12% lifetime 
risk of breast cancer and a 1.3% lifetime risk of ovarian cancer before age 70 in the general 
population (National Cancer Institute, n.d). In another example, individuals who are 
carriers of PVs associated with Lynch Syndrome (MLH1 and MSH2) have a 4-20% 
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likelihood of developing ovarian cancer before age 70 when compared to an estimated 1- 




Prevalence of HBOC PVs in Canada and NL 
 
 
It is difficult to fully estimate the total prevalence of all PV carriers as genetic 
aberrations are continually being discovered and reclassified as pathogenic (NCN, 2019). 
The prevalence of BRCA 1 and 2 PVs in the general population is estimated at 
approximately 1 to 300 to 1 in 500 (Nelson et al., 2014). The Hereditary Breast and Ovarian 
Cancer Society (2018) estimated that 354,965 Canadians have been or will be diagnosed 
with a hereditary breast or ovarian cancer and as many as 709, 930 Canadians carry a 
known PV that predisposes them to hereditary breast and/or ovarian cancer. Roebothan 
et al. (n.d.) identified a total of 276 BRCA PV carriers in NL since the introduction of 
genetic testing in NL. While the BRCA PV carrier prevalence rate of 0.05% in the general 
NL population was lower than expected, they cited the current opportunistic genetic 
testing paradigm, resulting in the under-identification of BRCA carriers in the province, 
as a possible cause for their findings. Using population risk estimates of 1 in 300, 
Roebothan et al. (n.d.) estimated the prevalence of BRCA 1 & 2 PV carriers in NL to be 
upwards of 1,700. The low prevalence of BRCA PV carriers in NL could also be attributable 
to the fact that NL is considered a founder population, primarily of Irish and English 
descent (Zhai et al., 2016). Despite the low prevalence of BRCA PV carriers, NL has the 
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highest rate of breast cancer mortality and the fourth highest rate of ovarian cancer 
mortality in the country (Canadian Cancer Statistics Advisory Committee, 2019). 
High rates of breast cancer mortality in NL may be related to findings of a recent 
case control study on molecular genetics of HBOC in NL. Dawson et al. (2020) performed 
multigene paneling on five female probands with a personal history of breast and/or 
ovarian cancer who tested negative for known high and moderate risk HBOC variants. 
However, they all shared a variant of uncertain significance (VUS) in the RAD51C gene. 
The results of a controlled haplotype analysis indicated a 52-fold increase of the RAD51C 
VUS in the NL population versus a general Caucasian population control (0.165% vs 
0.0032%). From this, Dawson et al. (2020) concluded that the RAD51C(NM_058216.3: 
c.571 + 4A > G) variant is pathogenic. They suggested that this and other, yet unknown, 
variants may be responsible for the increased incidence and mortality associated with 
HBOC in NL (Dawson et al., 2020). The unique genetic composition of NL is 
characterized by the historically isolated nature of the island, an increased inbreeding 
coefficient, and reduced heterozygosity (Zhai et al., 2016). This has made the NL 
population more susceptible to the disease expression effects of founder mutations. As 
new evidence emerges surrounding the pathogenicity of HBOC genetic variants in both 
NL and in global populations, this will further the need for programmatic follow-up for 
these high-risk individuals in NL. 
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Incidence and Impact of Breast & Ovarian Cancer 
 
Breast cancer is the most diagnosed cancer in females in Canada, accounting for 
25% (26,900) of new diagnoses annually (Canadian Cancer Statistics Advisory Committee, 
2019). Breast cancer accounts for 4,992 deaths annually in Canada (12.9% of cancer- 
related deaths in females) (Canadian Cancer Statistics Advisory Committee, 2019). While 
ovarian cancer is far less prevalent than breast cancer (3,000 new cases annually in 
Canada), it is the most lethal gynecologic malignancy and accounts for approximately 
1,896 deaths annually (Canadian Cancer Statistics Advisory Committee, 2019). It is often 
described as a “whispering disease” (Martin, 2000, p.8) due to its insidious symptoms, 
with only 25-30% of women with ovarian cancer diagnosed in the early, highly treatable 
stages (Baldwin et al., 2011). Additionally, there has been no proven method of primary 
ovarian cancer screening effective in reducing ovarian cancer morbidity and mortality in 
the general population (Buys et al., 2011; Jacobs et al., 2016). It is because of the lack of 
primary ovarian cancer screening, coupled with the insidious onset of the disease, why it 
crucial to identify women with a high inherited risk for ovarian cancer and allow them to 




HBOC Risk-Reduction Modalities 
 
Much attention has been given to HBOC in the field of cancer genomics as there is 
strong evidence of the favorable impact of risk-reduction modalities on morbidity and 
mortality in asymptomatic BRCA PV carriers. Risk-reducing salpingectomy oophorectomy 
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(RRSO) has been associated with 80% reduction in ovarian/fallopian tube cancer risk and 
a 50% reduction in breast cancer risk in asymptomatic women with BRCA1 & 2 PVs 
(Rebbeck et al., 2009). Risk-reducing mastectomy (RRM) is also discussed with PV 
carriers as a potential risk-reduction intervention which has been shown to essentially 
eliminate the risk of breast cancer in asymptomatic female BRCA 1 &2 PV carriers (Li et 
al., 2016). 
There are also breast screening recommendations for this high-risk population. 
 
Annual breast magnetic resonance imaging (MRI), alternating every 6 months with 
annual breast mammography has been shown to have a combined sensitivity of > 90% for 
detecting early stage breast cancer and is therefore recommended in this population 
(Warner, 2018). The Breast Disease Site Group (2017) of the Eastern Health (EH) Regional 
Health Authority (and NL tertiary care provider) recommended alternating annual MRI 
and mammography for women with an increased risk of breast cancer, starting at age 30. 
The Breast Disease Site Group (2012) also established a policy stating that premenopausal 
women ≥ 35 and postmenopausal women with a high risk of hereditary breast cancer 
should be offered oral Tamoxifen (a selective estrogen receptor modulator) once daily for 
five consecutive years. While this strategy may appear promising, many BRCA-associated 
breast cancers are estrogen-receptor negative, and therefore would not respond to 
Tamoxifen (Stadler & Kauff, 2009). Use of oral contraceptive medication for six or more 
years has been associated with decreased risk of developing ovarian cancer in BRCA1 &2 
carriers (OR 0.62, 95% CI 0.35-1.09) (Whittemore et al., 2004). While oral contraceptives 
reduce the risk of ovarian cancer, there is evidence that the use of oral contraceptives may 
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increase breast cancer risk (Narod et al., 2002). In essence, decisions surrounding HBOC 
risk management are complex and can cause psychological distress to PV carriers and 
their families. Coupled with burdensome treatment decisions, PV carriers may struggle 
with alterations in self-image, the disclosure of this information to family members, and 
with the family-planning implications of having a hereditary condition (White et al., 
2014). With the increased availability of genetic testing, health care providers must 
provide support and guide PV carriers make risk-management choices most suited to 




Issues with the Current HBOC Follow-up Process in NL 
 
Referrals to the NL provincial medical genetics program (PMG) are made by a 
primary care provider such as family doctor or nurse practitioner, or by a specialist 
physician when there is a suspicion of HBOC syndrome. Criteria for referral may include: 
a strong family history of disease, a first-degree relative of a known PV carrier, or other 
clinical features that are suggestive of a hereditary condition, such as early age of onset or 
breast tumors that test negative for estrogen, progesterone, and HER 2 receptors (triple 
negative) (Morrison et al., 2016). Ovarian cancer patients are also offered genetic testing, 
as the confirmation of a hereditary predisposition would confirm the indication for poly- 
ADP ribose polymerase (PARP) inhibitors as a treatment option. PARP inhibitors have 
proven effectiveness in the treatment of BRCA 1 and BRCA 2 associated ovarian cancer 
(Fong et al., 2009). Once an individual is referred to the PMG, genetic testing is 
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exclusively delivered by medical genetics specialists after in-person counselling (Adams & 
Etchegary, 2015). There are significant wait times in NL to be seen by PMG. Hynes et al. 
(2020), conducted a quality improvement project in NL to improve the wait times to be 
seen by PMG for investigation of potential cancer predisposition syndromes. Using a 
novel model of group genetic counselling plus “mini” individualized sessions, they 
successfully reduced wait times from nearly three years down to one year. Still, with a 
backlog of referrals to PMG, any chance of long-term supportive care from genetic 
counsellors in the current provincial financial climate is low. With no care provider 
systemically following up on how PV carriers are understanding and applying the genetic 
information they have been provided by PMG, it is difficult to ascertain to what degree 
this information has been beneficial to them. This is regrettable as the purpose of offering 
genetic testing and counselling is to empower people to lead a healthier, longer life vis-à- 
vis their carrier status. 
Following the immediate disclosure of genetic results, the navigation of annual 
screening, complicated treatment decisions, and family planning considerations are left 
entirely in the hands of the individual and their primary care provider (Roebothan et al., 
n.d.). Dr. Lesa Dawson, a gynecologic oncologist and Associate Professor of Women’s 
Health and Genetics at Memorial University of Newfoundland, described BRCA PV 
carriers in the province as being “orphaned by the healthcare system” (Mercer, 2018, para 
2). Other than the work done through Dr. Dawson’s gynecologic oncology inherited 
cancer prevention clinic at Memorial University and a small group of medical oncologists 
who offer annual follow-up, there is no systematic follow-up for these women in the 
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province, resulting in a significant missed opportunity. In a retrospective study, 
Roebothan et al. (n.d.) noted that only 41.6% of eligible BRCA PV carriers in NL had 
undergone the recommended annual MRI screening in an 18-month period (p < 0.001). 
While proven effective to prevent disease, the recommended modalities are still largely 
underutilized by HBOC PV carrier populations who stand to benefit from them. In the 
literature review and key informant interviews, several themes emerged to suggest that in 
the province, and in other health systems around the world, many of the current PV 
follow-up processes are inadequate. These themes included: carriers’ unmet information 
needs, primary care provider centered barriers, lack of coordination of care, lack of 
quality assurance, carriers’ unmet psychosocial needs, and issues surrounding disclosure 
to families. These issues are translating into adverse and avoidable health outcomes in PV 
carriers. Furthermore, these issues are resulting in complex, advanced cancers that 




Unmet Information Needs 
 
A prevailing finding in the literature review was that many HBOC PV carriers 
around the world are not getting their information needs met by the current HBOC 
follow-up process. In one example, HBOC PV carriers made erroneous statements when 
asked about their perceptions of risk-management (Cherry et al., 2013; Hughes & Phelps, 
2010). PV carriers noted the lack of a central, up-to-date research hub where they could 
retrieve reliable medical and research updates about HBOC, such as a e-newsletter, or 
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other type of online resource (Hughes & Phelps, 2010). While these findings were not 
universal among all the studies, they highlight the reality that many women are not given 
the clear information to make a truly informed decision about HBOC risk-management. 
The decision to undergo RRSO comes with its own gamut of considerations; to 
undergo RRSO with or without hysterectomy, hormonal replacement therapy versus 
nonhormonal treatments for symptoms of premature menopause, as well as interventions 
to optimize bone and cardiovascular health (Walker et al., 2019). The medical and 
psychosocial needs of PV carriers considering RRSO and RRM are complex and these 
women often require personalized support in their risk management. Yet, in a study by 
Etchegary et al. (2015), conducted in an NL population, premenopausal women who 
underwent RRSO reported that they did not have an adequate understanding of the full 
extent of surgical menopause prior to surgery. As a result, they felt overwhelmed and 
unprepared when these menopausal symptoms occurred. It is important to note that 
while RRSO can be lifesaving, health care providers and health care delivery systems must 
take the necessary steps to minimize the potential iatrogenic harms of these procedures. 
In the key informant interviews, another common issue reported with respect to 
unmet information needs is that the current follow-up process does not account for how 
PV carriers’ needs change over time. Genetic counsellors and specialists noted that PV 
carriers do receive detailed information with a printed copy for their records as part of 
the immediate genetic testing results disclosure. Still, individuals are not always 
psychologically prepared to ‘readily absorb’ this information at the time of disclosure. 
 
Their information needs may also change over time; for example, if women have 
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completed their childbearing years since the time of carrier status disclosure, their 
readiness for risk-reducing surgery may have changed (Manchanda et al., 2012). It is also 
difficult to fully ascertain the individual’s level of health literacy and understanding of the 
information provided in a single session with a genetic counsellor. If an individual does 
not fully comprehend the information they are presented with, this will influence their 
value appraisal of and adherence to risk reduction recommendations. 
With no dedicated program following these individuals and no readily available 
resource person available to answer their questions, the information provided at the time 
of genetic results disclosure may be cast aside or poorly understood when it could be in 




Primary Care Provider-Centered Barriers 
 
Reiteratively, in many current Canadian health care systems, the navigation of 
considerations specific to their PV carrier status becomes the responsibility of the 
individual and/or their primary care provider (Roebothan et al., n.d.). Yet in literature 
review findings, several study participants voiced that they felt as though they were the 
ones guiding their primary care provider in their HBOC journey, as the information 
provided by their primary care provider was not always accurate nor reliable (Cherry et 
al., 2013; Leonarcyzk & Mawn, 2015; Watkins et al., 2011). PV carriers reported challenges 
in obtaining relevant HBOC risk-management information from their primary care 
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provider, especially about subjects considered taboo such as the potential adverse sexual 
implications of HBOC risk management (Cherry et al., 2013). 
This theme was further probed in the consultations that were conducted with key 
stakeholders prior to the development of this policy. Informants attributed NL primary 
care barriers to the fact that there is no central, trusted site or authority responsible for 
getting this information into the hands of primary care doctors (and NPs). This lack of 
central authority also means a lack of health care system accountability when these 
recommended screening tests for PV carriers are not being ordered. Some PV carriers 
may opt not to proceed with further surveillance for personal or family reasons, as is their 
right. However, there are instances where individuals are agreeable to the recommended 
surveillance, but for whatever reason, it is not being ordered by their primary care 
provider. A GP reported that in his experiences, patients tend to be over-reliant on their 
primary care providers to remember and coordinate all screening appointments. He 
added that his ‘greatest fear was that [he] will miss a screening and early detection will be 
missed’. In the context of a busy family practice with no centralized hereditary cancer 
screening reminders, it is easy enough for a GP to overlook a preventative screening 
referral. An oncologist agreed that with busy family practices and screening/surveillance 
recommendations for PV carriers that change rapidly, it is unrealistic to expect the onus 
of arranging specialized follow-up care to lie completely with the primary care provider. It 
was also noted that in NL there are high turnover rates of primary care providers and 
many individuals in the province are without a primary care provider. In essence, the 
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systemic overreliance on GPs to coordinate follow-up creates an environment in which 




The Lack of Coordination of Follow-Up Care 
 
In the literature, there was confusion reported by PV carriers about inconsistencies 
in medical advice and surveillance recommendations from various members of their 
health care team (Caita-Zufferey et al., 2015; Cherry et al., 2013; Watkins et al., 2011). This 
caused PV carriers to feel overwhelmed and frustrated by the sometimes-conflicting 
advice they received (Caita-Zufferey et al., 2015). A similar concern was echoed in a focus 
group of breast care providers who noted the high probability of HBOC PV carriers being 
missed in the disintegrated lines of communication involving multiple health care 
providers (Komatsu & Yagasaki, 2014). Watkins et al. (2011) noted that breakdowns in 
lines of communication in Lynch Syndrome management were most obvious between 
medical specialists and primary care providers in NL. It was also reported that scarcity of 
health care providers, particularly in rural regions, posed challenges to adherence to 
recommended screening modalities (Leonarcyzk & Mawn, 2015). Moreover, with limited 
resources, breast care providers noted that they had limited time to focus on preventative 
measures when they were dealing with active of cases breast cancer and thus hereditary 
breast cancer prevention was placed lower on their list of priorities (Komatsu & Yagasaki, 
2014). 
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In the consultations, some informants had been involved in research with 
individuals living with inherited cancer syndromes in NL. A common theme reported in 
their work with PV carriers was that carriers desired a coordinated, ‘one-stop’ clinic that 
addresses and schedules their risk-reduction follow-up. PV carriers reported very 
practical issues with adherence to recommended screening, such as having to travel long 
distances and take multiple days off work to attend to the various screening and medical 
appointments. One informant noted that in her work with PV carriers (and their family 
members for that matter), she found that ‘life gets in the way’ of risk management. It was 
easy for asymptomatic PV carriers to forget or disregard the multitude of screening 
appointments in the context of hectic everyday life. For some, all these appointments 
became so overwhelming and mentally taxing that they had to stop for a while. This was 
particularly common for individuals with Lynch Syndrome where there is an increased 
risk of inherited cancer in multiple organs and thus multiple screening modalities are 




Lack of Quality Assurance 
 
Closely related to issues in care coordination is the absence of quality assurance 
measures in place for known PV and VUS carriers. In the absence of an electronic health 
registry to monitor PV carriers and coordinate surveillance programs through systemic 
tracing, an important opportunity is lost. Marrow et al. (2013) conducted a systematic 
analysis of the impact of registration and screening on colorectal cancer incidence and 
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mortality in familial adenomatous polyposis (FAP) and Lynch syndrome (LS). They 
concluded that there was high quality evidence of the significant benefits of colorectal 
cancer morbidity and mortality rates in individuals who participated in hereditary 
colorectal cancer registries. They also outlined the plethora of organizational, patient- 
focused, and researched focused benefits of hereditary colorectal cancer registries. 
Currently, there is no genetic registry of this kind in NL. 
 
In a policy framework document on cancer control, the NL Department of Health 
and Community Services (2010) proclaimed the need to “develop a hereditary cancer 
screening program ensuring best practice and necessary support, infrastructure (e.g. 
genetic counseling) and resources” (p.13). Patient registries are currently in use in the 
Provincial Cancer Care Program. The Newfoundland and Labrador Cancer Care Registry 
(NLCCR) is an authorized registry under the Provincial Cancer Care program. The NLCCR 
includes five registry subprograms: breast screening, cervical screening, colon screening, 
tumor surveillance, and chemotherapy surveillance (Eastern Health, 2016). Despite the 
existence of the NLCCR and its mandate to improve cancer outcomes, a hereditary cancer 
PV carrier registry has not been included in this provincial cancer registry; this is an 
egregious missed opportunity. 
Another common scenario that is being overlooked in the current system is when 
individuals undergo genetic testing and are found to carry a variant of uncertain 
significance (VUS). In clinical genetics, gene variants are classified on a five-item tier, 
ranging from benign to pathogenic (Richards et al., 2015). VUS fall in the middle of the 
tier and to date, neither the pathogenicity nor the benign status of the variant can be 
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confirmed. It is currently contraindicated to recommend any clinical actions in the 
context of a VUS result from genetic testing (NCCN, 2019). Still, empirical evidence 
surrounding variant pathogenicity is likely to expand as more gene sequencing and 
testing is being carried out. This will likely lead to reclassification of certain variants; 
either as more likely pathogenic or benign (Richards et al., 2015). Informants from PMG 
reported that if a person is found to have a VUS, thy are encouraged to follow-up in two 
to three years’ time to see if the status of their VUS has changed. This opportunistic 
approach leaves no process in place to monitor these individuals or to inform them if the 
status of their VUS has changed. If VUS carriers were included in a carrier registry, this 
could streamline them with up-to-date information and connect them with the 
recommended clinical decision-making tools, should they become available. Relying on 





Unmet Psychosocial Needs of PV Carriers 
 
Beyond issues of medical surveillance is the consideration that PV carriers are 
holistic beings with unique psychosocial needs. In the consultations, it was noted by an 
informant that ‘there is an ethical responsibility to address carriers’ emotional and mental 
health needs.’ Yet, qualitative data in the literature review revealed that in their 
interactions with health care providers, many PV carriers felt they were “not being seen as 
a whole person” (Leonarcyzk & Mawn, 2015, p.77). To narrowly focus on risk management 
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and screening does not address the full complement of implications of being a PV carrier. 
An informant explained that many HBOC families experience severe psychological 
trauma, having witnessed many of their family members die at an early age while facing 
the uncertainty of their own inherited risk. Yet, in the current system, their unique 
concerns and perspectives are largely overlooked. There is no program or healthcare 
professionals available to assist them with communicating genetic results with their 
families, counselling services, or the opportunity to network with other carriers and high- 
risk individuals. 
It is interesting that a consultee noted that in her work with PV carriers, higher 
levels of ‘family support and cohesion’ were associated with improved psychosocial 
adjustment to their PV carrier status and improved adherence to the recommended 
screening and risk-reduction modalities. Yet there is no outlet in the current follow-up 
process to encourage the participation and involvement of family members in risk 




Issues Surrounding Family Disclosure 
 
As it currently stands in NL, individuals with a confirmed PV are responsible for 
notifying their at-risk relatives that they may also be at increased risk. Several informants 
in the stakeholder interviews expressed that this responsibility is an unreasonable burden 
to place on a PV carrier. Moreover, the reliance on PV carriers to recruit other at-risk 
relatives has created significant gaps in the way that at-risk individuals are notified, and 
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many at-risk individuals are likely being missed in this line of family communication. 
Some PV carriers reported feelings of guilt and/or resentment when one family member 
carried the gene and another did not and opinions often greatly varied among family 
members about whether or not PV carriership should be disclosed (Hughes & Phelps, 
2010). It has been reported that the unearthing of this information can cause tensions 
between parents and children. (Dwyer et al., 2020). Probands have described feeling 
conflicted in their sense of duty to inform relatives of their potential risk with their desire 
to protect family members from the worry stemming from the disclosure of that 
information (Croster & Dickerson, 2010). Evidently, there are several social, ethical, and 
legal factors to consider when addressing these gaps. There must be a balance between 
the risk mitigation and the privacy, confidentiality, and right to autonomy of both 
probands and their family members. A master’s student in the clinical epidemiology 
program at the Faculty of Medicine at Memorial University in Newfoundland is currently 
working on a research project to explore optimal means of family outreach in high-risk 
families. This will provide insight on how health care delivery systems should facilitate 
family risk disclosure and/or support PV carriers in the family risk disclosure process. It is 
an assumption in this policy paper that the findings of that research could have 
implications for the novel PV carrier follow-up program. Based on the findings, it could 
provide direction for how the PV carrier navigator and the multidisciplinary team could 
work with families to discuss their risk status and the options available to them, as well as 
provide psychosocial support to the unique needs of at-risk families. 
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A Policy for a Dedicated HBOC Follow-Up and Navigation Program 
 
In examination of the evidence collected for this MN practicum project, it is safe to 
conclude that there are glaring and detrimental gaps in PV carrier surveillance and 
support in NL. It is put forward in this proposal that the best way to address these needs 
is through formulation of a dedicated follow-up and navigation program for PV carriers in 
the province. Informed by the evidence, there are several key features for this novel 
program that are recommended: 
1) A provincial centralized, coordinated PV and VUS carrier registry 
 
2) Establishing the role of a nurse PV carrier navigator 
 
3) A coordinated multidisciplinary team approach to the care of individuals 
and families in the program 
4) A person and family centred approach to follow-up care 
 
5) Electronic and virtual infrastructure to support provincial delivery of the 
program 
It is important to note that several features of the proposed program have been 
influenced by several extant programs that function successfully. These include patient 
navigation programs, patient registries, the Ontario High-Risk Breast Program, and 
dedicated multidisciplinary hereditary cancer follow-up clinics. To understand the 
applicability of these features in the conceptualization of the dedicated follow-up and 
navigation program, this section begins with an overview of these existing programs. 
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Patient Navigation Programs 
 
Patient navigation programs were introduced 30 years ago as a model to reduce 
the health system inequities experienced by socioeconomically disadvantaged individuals 
in their access to early detection and treatment of cancer (Freeman, 2012). Since that 
time, the scope of cancer patient navigation programs has expanded to include 
prevention, detection, diagnosis, treatment, survivorship, and end of life care. (Freeman, 
2012). One of the main implications from the Cameron Inquiry Report into Breast 
Hormone Receptor Testing in NL was the “importance of communication and 
coordination of care throughout the cancer journey, recommending patient navigators to 
assist patients” (Department of Health and Community Services, 2010, p.13). There is 
currently a cancer patient navigation program in the province of NL (Eastern Health, 
2018). In this program, cancer patient navigators are nurses with specialized training in 
oncology, with offices located in seven areas throughout the province (Eastern Health, 
2018). They offer a variety of services to cancer patients such as providing ongoing 
support and information, coordinating appointments, and connecting patients with 
relevant specialists and community resources. Patients can be self-referred to the 
program, or by their family doctor, other care provider, or cancer specialist (Eastern 
Health, 2018). Three other patient navigation programs are also offered in NL for 
palliative care patients, indigenous peoples, and individuals with mental health and 
addictions issues, in order to meet their unique needs and reduce the barriers they 
encounter (Eastern Health, n.d.; Eastern Health, 2019; Eastern Health, 2020). The 
principles of patient navigation, coupled with the ways that these programs are in use for 
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other groups in the province, demonstrate how this model is applicable to a PV carrier 
sub-population. Patient testimonials on the cancer patient navigation program in NL 
have been overwhelmingly positive (Eastern Health, n.d.). Nurse navigators provide 
patients with accurate information that is easily understood, facilitate continuity of care, 
and provide a mentally and emotionally supportive health care experience (Baileys et al., 
2020; Winstead, 2012). For breast cancer patients in particular, the nurse navigator model 
of care has been shown to empower patients, to encourage them to self-advocate, and to 






The Newfoundland and Labrador Cancer Care Registry (NLCCR) received 
authorized registry status in 2017 (“Newfoundland and Labrador Cancer Care Registry 
Launched by Eastern Health”, 2017). The NLCCR includes five registry subprograms: 
breast screening, cervical screening, colon screening, tumor surveillance, and 
chemotherapy surveillance (Eastern Health, 2016). When it was introduced, Eastern 
Health (EH) CEO David Diamond stated that the NLCCR was an important part of EH’s 
ongoing efforts to provide “access to information, education and tools that would lead to 
preventing disease before it starts and detecting it earlier for the benefit of our patients” 
(“Newfoundland and Labrador Cancer Care Registry Launched by Eastern Health, 2017, 
para 5). According to Eastern Health (2016), the aims of the NLCCR include to improve 
clinical decision making and the delivery of care and screening programs. Given these 
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mandates and the wealth of research evidence in favor of PV carrier registries, a 
hereditary cancer PV carrier registry is an unmistakable fit for the NLCCR. Hereditary 
cancer registries are in use around the world and the evidence of their effectiveness is 
strong (Barrow et al., 2013). The benefits of hereditary cancer registries to the health 
system include the easily retrievable storage of genetic and demographic information, an 
efficient way to trace and recruit other at-risk relatives into surveillance programs, the 
coordination of screening, and the monitoring of PV carrier follow up (Barrow et al., 
2013). Barrow et al. (2013) also noted several patient-focused benefits of carrier registries 
such as the continuity of care, psychosocial benefits of involvement, screening reminders, 
and opportunities to participate in clinical trials. On that note, PV carrier registries also 
provide an unrivaled opportunity to promote and conduct research and to improve the 




Ontario High-Risk Breast Screening Program 
 
As part of the environmental scan conducted for this project, the Ontario High- 
Risk Breast Program (High-Risk OBSP) was examined. The High-Risk OBSP is the only 
provincial breast screening program of its kind for high-risk women in Canada. To be 
enrolled in the High-Risk OBSP, a referring physician must submit a requisition form to a 
designated High-Risk OBSP site (Cancer Care Ontario, n.d.) It is implicit in the program 
requisition form that the ordering physician is requesting future MRI imaging and in 
some cases, image guided biopsies, which under current Ontario regulations requires a 
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physician’s signature (Cancer Care Ontario, n.d.) Women eligible for the program fall 
into category A or B. Women in Category A are directly enrolled in the program because 
they either carry a known PV associated with increased breast cancer risk, or are a first- 
degree relative of someone with a known PV and underwent genetic counselling but 
opted not to have genetic testing (Cancer Care Ontario, n.d.) Women in Category B 
require further genetic assessment prior to enrollment in the program; this includes 
individuals who are a first degree relative of someone with a known PV who have not 
been assessed by a genetic counsellor. Following the genetic assessment, it is determined 
whether the woman in Category B is enrolled in the High-Risk OBSP. Cancer Care 
Ontario (n.d.) outlined that the High-Risk OBSP program is delivered by High-Risk OBSP 
navigators with a list of responsibilities. These include booking the screening and breast 
assessment appointments, following up on abnormal results, arranging annual recalls, 
and communicating all imaging results to women and the referring physician. The 
effectiveness of the High-Risk OBSP has been reported and confirmed in the research 




Multidisciplinary Follow-Up Clinics 
 
Outcomes in dedicated HBOC multidisciplinary follow-up clinics have been 
reported in the literature (Bancroft et al., 2010; Firth et al., 2011; Pichert et al., 2010; 
Yerushalmi et al., 2016), and Engel et al. (2012) provided an overview of the program 
structure of a dedicated BRCA follow-up clinic in the US. Yerushalmi et al. (2016) found 
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that of the BRCA PV carriers who attended a dedicated BRCA follow-up clinic for 
biannual screening and follow-up appointments, only 7.2% developed cancer (17 were 
breast cancers, one ovarian cancer, and three were additional cancers.) Of the 17 cases of 
breast cancer, 94.1% of those cancers were detected at stage I disease when treatment 
outcomes are generally far more encouraging; 70.6% of those cancers were detected by 
MRI and 17.6% were detected by mammography (Yerushalmi et al., 2016). Clinic 
outcomes were not compared with outcomes from a matched control of a family 
physician based BRCA follow-up model. Therefore, it is indeterminable if the low 
incidence of malignancy occurred as an exclusive result the dedicated follow-up clinic. 
Still, the rate of RRSO uptake at age 40+ at the clinic in Yerushalmi et al. (2016) was high 
at 87.3%. This high uptake rate of RRSO in clinic attendees was higher than in most other 
reported registries and in the literature (Yerushalmi et al., 2016). The median age at the 
time of RRSO in the multidisciplinary clinic (46.5, 33-68) was also lower than the median 
age at time of RRSO of 49.6±9.7 reported in NL BRCA PV carriers (Roebothan et al., n.d.). 
Yerushalmi et al. (2016) provided a strong case that a “dedicated, multidisciplinary clinic 
for BRCA mutation carriers provides a home for a unique population with unmet needs” 
(p.551). PV carriers have reported high levels of satisfaction with multidisciplinary BRCA 
follow-up clinics (Firth et al., 2010). BRCA PV carrier participation in a dedicated follow- 
up clinic was associated with significantly greater participation in related clinical trials (p 
< 0.001) (Pichert et al., 2010). 
 
As part of the environmental scan, several websites of familial/hereditary cancer 
clinics were examined. These clinics were comparable to the multidisciplinary clinics 
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reported in the literature (Bancroft et al., 2010; Engel et al., 2012 ; Firth et al., 2011; Pichert 
et al., 2010; Yerushalmi et al., 2016). Comparable to PMG, genetic counselling and genetic 
testing referral are offered through many of these centers. Also consistent with the 
services at PMG, immediate genetic testing follow-up and personalized genetic risk 
assessment are also offered. How the multidisciplinary clinics differ from PMG is in their 
approach to surveillance, follow-up, and support. Many of these centers feature 
multidisciplinary teams including geneticists, genetic counsellors, nurses, dieticians, 
gynecologists, oncologists, social workers, and psychologists. With this wide variety of 
medical professionals, the multiple facets of PV carriership are appropriately addressed. A 
few of these clinics/programs also offer periodic carrier support groups and sessions 
where PV carriers can liaise with other PV carriers and families. They also have 
opportunities for PV carriers and families to attend support sessions with guest speakers 
and genetic/hereditary cancer experts. Many of these programs also differ from the 
current PMG model in that PV carriers are scheduled to visit the clinics annually or bi- 
annually for surveillance, follow up, and supportive care. In the province of Ontario, 
many of these clinics work with the High-Risk Ontario Breast Screening Program (OBSP) 
to coordinate breast surveillance of eligible high-risk individuals. 
In short, features of these four existing programs have been borrowed in the 
development of this program policy proposal. This will be evident going forward as the 
five recommended components of the novel follow-up and navigation program in NL are 
delineated below: 
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1. A Centralized PV Carrier Registry in NL 
 
Under the prospective program, the processes following disclosure of genetic 
testing results will be significantly modified. Individuals who undergo genetic testing 
through PMG and are found to carry pathogenic variants, likely pathogenic variants, or 
VUS will be entered into a provincial registry. A PV carrier registry is well-suited to fall 
under the umbrella of the NLCCR, as it fits with the mandate of the NLCCR and under 
the umbrella of cancer prevention. Consent to use information is not collected within the 
current five subgroups of registries in the NLCCR; this ensures the accuracy and 
completeness of the data so it is being used to properly inform clinical decision making 
and health care delivery (Eastern Health, 2018). It should be reviewed with the health 
authority ethics review board if non-identifiable PV carrier data can be collected in this 
registry with presumed consent, as is the case with the other subprograms of the NLCCR. 
Invariably, the exception to this would be, as is the case with the cancer screening 
programs currently under the NLCCR, individuals would have the option not to 
participate and/or receive communication from the PV carrier follow-up program. This 
will be further discussed later in the proposal. Individuals in the PV carrier registry will 
also have the option to be notified if they wish to participate in research studies and 
clinical trials. Participation in these studies and trials would be completely voluntary. 
As is the case with current programs under the NLCCR, custodians of the personal 
health data in the PV carrier registry would be held accountable to the legally binding 
obligations of authorized registries under the Personal Health Information Act (2008) 
(PHIA). Custodians of the PV carrier registry data would be held to stringent expectations 
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as they pertain to the collection, storage, and access to personal health data in the 
registry. However, these expectations would be comparable to the expectations of current 
data custodians of the NLCCR and of other NL Health data IT systems users. Still, prior to 
launching this registry, transparent and clearly described policies are needed regarding 
the collection and use of genetic data. A transparent governance structure and clearly 
described policies are necessary to ensure that the expectations of privacy and 
confidentiality can be forthright regulated. A key informant recommended that all 
policies and patient documents should also be informed by ethics experts, as well as by 
the literature in recent years related to genomic medicine that ‘begins to highlight patient 
data concerns that can be identified and mitigated.’ 
Health care professionals involved in the delivery of the PV carrier follow-up 
program would be included under custodians of the data in the PV carrier registry. A 
registry system would also be a quality assurance measure for PV carriers who are 
otherwise being missed for screening in the current family-physician dependent follow- 
up model. It would be impossible to deliver a HBOC follow-up program without access to 
the registry data and the registry data should be compatible with provincial electronic 
medical records. Part of the role of the PV carrier navigator would be to periodically index 
the registry to ensure that the classifications of the variants are up to date, as are the 
recommended clinical actions associated with the variant. This should be done as part of 
team of genetics and hereditary cancer experts. The registry must be subject to periodic 
reviews and quality/audit controls. For carriers participating in the follow-up program, 
the registry must be updated as PV carriers complete the recommended screening 
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intervals and/or opt for risk-reduction surgery. The information included in the registry 
should include demographic information, information on the pathogenic variant, 
information on the testing panel ordered, and information on the recommended clinical 
actions for the variant. The data in the registry should be compatible/accessible within 
the electronic medical record software that will be used by the nurse navigator when 
providing care to individuals enrolled in the follow-up program. This data should also be 
linkable with electronic pedigree data collected from PMG. Specific recommendations on 
the health IT infrastructure needed to deliver the program will be explored in further 




2. Establishing the Role of a Nurse PV Carrier Navigator 
 
During genetic results disclosure at PMG with a genetic counsellor, PV carriers 
would be given the option to enroll in a follow-up program for PV carriers. PV carriers 
would have the option to withdraw from correspondence with the program at any time 
and/or return without any repercussions or coercion. Central to this policy proposal is the 
need to establish a position for a Registered Nurse or Nurse Practitioner who assumes the 
role of PV Carrier Navigator for individuals in the province. This individual should have 
experience and/or certification in cancer genomics to be ideally suited to take on this 
position. Komatsu and Yagasaki (2014) proposed that specialized cancer nurses are ideally 
suited to utilize genetic health data in electronic health records and to coordinate 
communication among multidisciplinary HBOC team members, including the 
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coordination of multidisciplinary team meetings. Komatsu and Yagasaki’s (2014) postulate 
is consistent with this key policy proposal recommendation. The primary contact 
person/administrator of this program will be the nurse PV carrier navigator. (S)he will 
have access to the data in the registry and will be responsible for establishing annual or 
bi-annual contact with PV carriers. This contact will be arranged either via telephone, 
online video conferencing, online messaging, or in-person depending on the carrier’s 
geographic location and/or personal preference. 
In the annual/bi-annual outreach to carriers, the nurse navigator would discuss 
with them and assess how they are coping with the multiple dimensions of their carrier 
status. This would include assessing their readiness for risk-reduction surgery if 
applicable, providing education and follow-up on their inherited risk, and risk 
management. The nurse navigator would also be responsible for notifying individuals 
when new therapies, recommendations, and clinical trials are available to take part in 
that may be relevant to them. The nurse navigator would also assess the psychosocial 
impact of carriership on individuals and families and provide them with support and 
appropriate referrals as needed. 
As stated, a research project is currently underway in the province to determine 
how to appropriately notify a proband’s relatives of their potential inherited risk. The 
challenge of this process, known as cascade testing, is balancing the privacy and 
confidentiality of the probands with the sense of duty to inform other at-risk relatives. 
Moreover, some individuals may not want to know about their inherited risk. Facilitators 
 
and barriers to cascade testing have been explored in the literature (Dwyer et al., 2020; 
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George et al, 2015; Schwiter et al., 2018). The consensus is that probands seek and value 
the input of health care professionals in the cascade testing process when communicating 
this information with their relatives (Schwiter et al., 2018). Similarly, key informants in 
the consultations expressed that it is unreasonable to place the entire responsibility on 
the probands to notify relatives of their risk. Several informants expressed that a 
dedicated follow-up program, as described in this proposal, would be ideally suited to 
assist with at-risk relative recruitment/notification as part of its gamut of services offered. 
For this program, it is put forward that family risk disclosure sessions should be 
facilitated by the nurse navigator and a social worker or psychologist. In the family 
disclosure process, the role of the nurse navigator is to provide families with information 
on the implications of their relative’s carrier status and what it means to them in a way 
that is easily understood. If desired by at-risk relatives recruited through the program, the 
nurse navigator will notify a genetic counsellor at PMG to coordinate cascade testing and 
genetic counselling. The electronic medical record systems in use should be compatible 
between the nurse navigator, PMG, and other HBOC team members to allow a seamless 
flow of communication. 
Another key role of the nurse navigator will be to coordinate and facilitate breast 
screening appointments in eligible PV carriers. Currently, women at high risk of breast 
cancer in NL are referred back to their primary care provider for further management 
(Canadian Partnership Against Cancer, 2018). Under the proposed policy, this 
responsibility will be re-delegated to the nurse navigator. This service will draw heavily 
on the model used in the province of Ontario for the High-Risk Breast Ontario Breast 
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Screening program. The nurse navigator will determine if an individual is eligible for the 
annual magnetic resonance imaging (MRI) recommended for individuals at high risk of 
breast cancer. As per the Eastern Health Breast Disease Site Group (2017) policy, to be 
effective, breast MRI must be timed within days 5 to 13 of the menstrual cycle in 
premenopausal women and must be alternated every six months with mammography. 
Therefore, this takes coordination, and these women must be streamlined and prioritized 
in the health care system. The nurse navigator will send a requisition form either to a 
breast specialist or to the individual’s primary care provider to sign off on. The completed 
requisition form is then sent back to the nurse navigator with the assumption that the 
ordering care provider has requested future MRI imaging to be facilitated and 
coordinated by the nurse navigator. The nurse navigator would also be responsible for 
booking patients with follow-up breast assessments with medical oncologists following 
abnormal screens, informing PV carriers of the results of the screening, and arranging 
annual recall for women who are due for their next scheduled MRI. Ideally, the nurse 
navigator will be in contact with the PV carrier in the few months leading up to when she 
is due for her MRI. This will allow the nurse navigator to facilitate the annual check in 
with the woman, confirm the timing of her menstrual cycle if applicable, and assess her 
readiness for screening based on her life circumstances. 
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3. A Multidisciplinary Approach to Care 
 
There was overwhelming evidence from the literature review, consultations, and 
the environmental scan that PV follow-up care must be delivered from a multidisciplinary 
standpoint. While the nurse navigator will be the consistent, primary point of contact for 
individuals enrolled in the program, (S)he will also connect carriers with other 
multidisciplinary team members as needed. For example, the navigator will connect 
women with breast specialists in the event of an abnormal screening result. The navigator 
will also connect individuals with surgeons such as gynecologists, breast surgeons, or 
plastic surgeons if they indicate their interest in risk-reduction surgery. For individuals 
with Lynch Syndrome, this may include referrals to gastroenterologists and general 
surgeons. Moreover, if women are experiencing issues with the symptoms of surgical 
menopause following risk-reduction surgery, the navigator will connect them with 
medical professionals who can prescribe therapies to alleviate these distressing 
symptoms. Once an individual is referred to these team members, it is at the discretion of 
the physicians whether they continue to see the patient on a regular basis. Consistent 
communication between all HBOC team members will be essential. The nurse navigator 
may use their discretion to determine when an individual may benefit from a specialist 
referral, provided they consent to do so. Some familial cancer clinics listed in the 
environmental scan also connect PV carriers with dieticians and nutritionists. As it is 
established that maintaining a healthy weight is a protective factor against cancer, 
dietician referrals may be appropriate for some PV carriers as part of a holistic, 
comprehensive cancer prevention strategy. In this model, the nurse navigator may be 
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The nurse navigator will also connect individuals with appropriate 
multidisciplinary team members who focus primarily on their psychosocial needs. If there 
are issues adhering to the recommended screening and risk-reduction modalities due to 
social and economic circumstances, the navigator will connect PV carriers and families 
with social workers and social work assistants. As an example, social work team members 
may arrange transportation/accommodation assistance with travel to specialist and 
screening appointments for PV carriers who may otherwise be unable to attend. They 
may liaise with the PV carriers’ existing social workers in the community where 
applicable. In these ways, these multidisciplinary team members reduce fragmentation 
and barriers that women may encounter in their PV carrier journey. 
Social workers and psychologists may also work with the nurse navigator in the 
family disclosure process. There is a wide body of evidence that PV carriers desire the 
input of health care professionals when disclosing this information with family members. 
Croster and Dickerson (2010) noted that the ‘receivers’ require sensitivity to the impact of 
learning about their inherited risk, time to process the information, and supportive and 
informational resources. Otherwise, this can be an extremely distressing experience for 
them upon realizing they are in a high-risk family. The role of the nurse navigator in the 
family risk disclosure process was outlined in a previous section. The role of the social 
worker/psychologist in the disclosure process will be to moderate and focus on how this 
information is being received, to encourage expression of emotions, and to assess and 
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encourage support systems in place. In a study by McInerney et al. (2005), individuals 
who underwent BRCA PV testing and were randomized to a client-centered counseling 
intervention reported a decrease in conflict among family members (p=0.006). Having a 
social worker/psychologist present with the nurse navigator is an ideal way to 
communicate risk while mitigating the potential iatrogenic distress that the revelation of 
this information may cause. The psychologist/social worker may use their discretion to 
determine if further family counselling and supportive sessions are required. 
As part of providing a multidisciplinary approach to care, periodic group 
psychoeducational sessions for PV carriers and families should be offered as part of this 
program. In psychoeducational sessions, multidisciplinary team members present new 
research findings and updates and there is also opportunity for PV carriers and families to 
seek formalized peer support. Psychoeducational group sessions for PV carriers have been 
widely examined in the literature (Corines et al., 2017; Esplen et al., 2004; Kwiatkowski et 
al., 2019; Landsbergen et al., 2009; Listøl et al., 2017; McKinnon et al., 2007). These group 
interventions featured both psychosocial and medical content pertinent to HBOC PV 
carriers, such as breast reconstruction surgeries, genetic insurance discrimination, and 
family communication about genetic testing. Some of these groups occurred as a one- 
time retreat, as multiple sessions over several months, or annually. Quantitative measures 
of participant satisfaction, percentage of unmet information needs, and psychological 
distress improved following participation in HBOC psychoeducational groups. Several PV 
carriers have reported that both professional and peer support was vital to them when 
making decisions about their HBOC management. (Cherry et al., 2013; Phelps & Hughes, 
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2010; Rauscher & Dean, 2017). Bringing PV carriers together for these psychoeducational 
groups allows them to establish a sense of normal through shared experiences, the 
opportunity to learn through the experiences of others, as well as improved coping 
(Landsbergen et al., 2010). 
In pre-pandemic circumstances, an annual ovarian cancer educational symposium 
takes place at Memorial University of Newfoundland that is largely funded by the Belles 
with Balls charitable organization and by community sponsors. Belles with Balls supports 
the ovarian cancer research and education fund (OCRE) at the Faculty of Medicine at 
Memorial University (Belles with Balls, 2020). The 2019 symposium focused primarily on 
BRCA and hereditary cancer modules. Multidisciplinary team members spoke about 
medical and research findings and a BRCA PV carrier shared her personal experiences as a 
carrier. It is asserted in this proposal that the Belles with Balls are a vital community 
partner for this follow-up program to facilitate multidisciplinary education sessions. If 
content relevant to PV carriers is included in future symposiums, the nurse navigator 
should extend invites to PV carriers in the follow-up program to attend these 
symposiums. In so doing, PV carriers can benefit from the relevant information, medical 




4. A Person and Family Centered Approach to Care 
 
Administrators of the follow-up program must take measures to mitigate the 
 
commonly reported experiences of PV carriers feeling as though they are not being “seen 
 
as a whole person” (Leonarcyzk & Mawn, 2015, p.77). It is important for a follow-up 
program to be person-centered. Team members in the follow-up program must 
acknowledge that there is no one size fits all approach to PV carrier care. The role of the 
nurse navigator and multidisciplinary team members is not to push interventions on PV 
carriers. Rather, to ensure they have all the appropriate facts to make an informed 
decision, and to empower them to select an approach to risk management suited to their 
life circumstances. PV carriers have reported they felt pushed by medical professionals to 
adhere to recommended risk-reduction modalities (Caiata-Zuffery et al., 2015). Despite 
the evidence of the survival advantage offered by risk-reduction surgery, there is nothing 
simple about the decision to undergo these surgeries and it is ill-advised for health care 
providers to treat it as such. This was perhaps most apparent in an interview with a 
woman in the BRCA documentary film, In the family (Rudnick & Kartemquin Films, 
2008). Linda, who put off undergoing risk-reduction surgeries and at the time of the 




















This is 2005, There has to be a better way. The only thing you can do is 
remove body parts? I have no breasts, I have no hair, I have no ovaries, I have no 
uterus, I have no hormones. To say, ‘Oh, it doesn’t matter’ is a lie. It sucks. But in 
spite of how awful it is to feel less than female, being alive is what matters. And in 
retrospect, if I could have turned the clock back, I would have had all those 
[preventative] surgeries. It may not be the ideal life that you want, but it’s life. You 
don’t mess with that (Rudnick & Kartemquin Films, 2008). 
188  
Linda’s honesty and vulnerability captures the complexity of the decisions that 
women face in a hereditary cancer journey. Health care providers must always remain 
cognizant that on the receiving end of the services is a holistic being who is more than a 
survival statistic. A being who deserves a supportive, non-judgmental environment where 
(s)he is able to receive accurate information, free from coercion and medical paternalism. 
A genetic counsellor noted that there comes a point after a certain number of attempts to 
reach out to a PV carrier with no response, care providers must ‘take the hint’ that the 
individual is not interested in further communication about risk (and risk management). 
This should be respected without any undue pressure exerted on the individual. The 
principles of holistic care must remain in the minds of every health care provider working 
with this population. 
From a theoretical nursing perspective, the nurse navigator should be encouraged 
to adopt a relational inquiry approach to providing nursing care (Hartrick-Doane & 
Varcoe, 2015). Using a relational inquiry approach when working with HBOC PV carriers, 
the nurse navigator acknowledges the complexities of the interpersonal, intrapersonal, 
and contextual factors that influence their risk management decisions. The relational 
inquiry approach was influenced by critical theory, a philosophical movement where 
disparities in sociopolitical structures are highlighted and there are calls for action to 
mitigate the lasting effects of disadvantageous socioeconomic, political, and historical 
ideologies (Polit & Beck, 2017). Using relational inquiry is a way to provide an 
emancipatory approach to HBOC care. It is recommended that the nurse navigator be 
familiarized with Hartrick-Doane and Varcoe’s (2015) How to Nurse: Relational Inquiry 
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with Individuals and Families in Changing Health and Health Care Contexts as it is an 
appropriate framework and tool for the nurse navigator when designing and delivering 
the program. 
Another way that this program should be person-centered is that team members 
must acknowledge that asymptomatic PV carriers are not ‘sick’. In fact, in this proposal, 
there is refrainment from referring to PV carriers as ‘patients’ as this already labels them 
as sick, which does not instill much hope for their futures. However, it is important to 
appreciate that the fact PV carriers are considered ‘well’ may be a barrier to their risk- 
reduction adherence. Many of these women lead active, busy lives and cancer prevention 
may be appraised as lower on their list of priorities when they do not ‘feel sick’. This 
barrier can be overcome by designing a flexible, user-friendly follow-up program that 
strives to meet PV carriers where they are in their lives. For example, many PV carriers 
may be younger and middle-aged women who are still working and have various family 
commitments. It may be unreasonable for them to take time off work or other 
commitments during the middle of the day to have their appointment with the nurse 
navigator. The nurse navigator should be able to offer flexible hours, such as a weekly or 
bi-weekly availability for evening and/or weekend appointments. This way, PV carriers 
would not have to use sick time or family leave, that they may not even have at their 
disposal, to attend a routine appointment. As the nurse navigator will also be the one to 
facilitate screening appointments and specialist appointments, efforts should be taken to 
find an appointment date and time that is acceptable for the PV carrier. Though this may 
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not always be possible, the nurse navigator should consult the individual with what 
times/dates are preferrable when booking them with their appointments. 
A follow-up program can also be person-centered by giving PV carriers options in 
their preferred method of communication with the program. Some may prefer to come 
see the nurse navigator in person while others, especially in rural regions, may prefer to 
communicate via telephone, online teleconferencing, or email/online chat platforms. 
Providing PV carriers options in their preferred method of communication is likely to 
have a positive effect on their comfort levels and sense of satisfaction, which in turn will 
likely have a positive effect on their participation in the program. The nurse navigator 
should also be readily available to PV carriers when they may have further questions or 
concerns either via telephone or email. 
Intertwined with the concept of person-centered care is family-centered care. It is 
established that “approaches to care that acknowledge all relevant people and effects will 
result in more efficient allocation of resources than do piecemeal approaches” 
(Wittenberg & Prosser, 2016, p. 1806). While this statement is true in all health spheres, it 
is especially accurate for PV carrier populations. On an obvious level, being in a high 
genetic risk family confers psychological distress about one’s own increased risk for 
cancer. A personal family history of ovarian cancer in PV carriers has been shown to be a 
significant factor in the decision to undergo RRSO (Bradburry et al., 2008; Etchegary et 
al., 2015; Metcalfe et al., 2008; Schwartz et al., 2003). PV carriers who lost close family 
members to HBOC have reported that the process of their own HBOC risk management 
decision-making was triggering to their feelings of loss (Caita-Zuffery, 2015). Some 
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asymptomatic PV carriers have reported their strong sense of moral obligation to both 
their ancestors and their dependents to make use of the genetic and medical information 
at their disposal and to stay healthy for their loved ones (Caiata-Zufferey et al. 2015). A 
key informant noted that PV carriers who reported higher levels of ‘family support and 
cohesion’ experienced improved psychosocial adjustment to their PV carrier status, as 
well as improved adherence to the recommended screening and risk-reduction 
modalities. In an effective PV carrier follow-up program, the family system is recognized 
as a facilitator of psychosocial adjustment and adherence to recommended risk-reduction 
modalities. 
One consultee noted that unaffected family members of PV carriers also 
experience distress associated with having multiple relatives affected by an inherited 
cancer predisposition syndrome. Yet, often, these unaffected family members are not 
included in the care circle despite the unique psychological trauma they may experience. 
A fitting example of this was in a scene in the documentary, In the family (Rudnick & 
Kartemquin Films, 2008) when three young sisters were given their BRCA-1 genetic 
testing results. While two of the sisters tested positive, it was the sister who tested 
negative for the BRCA 1 PV who broke down in tears and said that this was the exact 
opposite outcome she had been hoping for. It is in these heartbreaking moments we are 
reminded that the concepts of ‘family’ and ‘health’ in hereditary cancer care cannot be 
separated. Therefore, the participation and involvement of family members in a follow-up 
program should be welcomed and encouraged. Within the boundaries of privacy and 
confidentiality, PV carriers should be offered follow-up sessions where family 
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members/support persons can attend, even if they themselves do not carry a PV. Provided 
that PV carriers consent in advance to discussing their information with family, family 
members should also be able to ask questions and seek supportive care as this inherited 




5. Electronic and Virtual Infrastructure to Support Delivery of the Program 
 
It is unrealistic to expect clinicians to manage the complexities of genomic 
information without the assistance of health information technology (IT) (Welch et al., 
2014). In NL at PMG, pedigrees are currently completed by hand during the genetic 
counselling process. It was discussed with key informants that PMG is exploring options 
with IT management to enlist electronic pedigree drawing software. As part of this 
practicum project, a brief internet search was conducted of the available pedigree 
drawing and genetic risk assessment software products. One product of note was the 
Progeny pedigree and risk assessment software. According to the Progeny Genetics (2020) 
website, their software offers many benefits: individuals can answer questions about 
family history online prior to their appointment, the system is able to run automated risk 
assessment models, order and track genetic testing, and integrate structured pedigrees 
into electronic medical records. It is a premise of this proposed policy that a pedigree 
drawing system should have the capacity to allow a seamless flow of pedigree and risk 
data to both the provincial electronic health record (EHR) and to the provincial medical 
record system (EMR). Further discussion between health care stakeholders and the 
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different pedigree software and EMR vendors is warranted to determine the compatibility 
of these systems with the health IT systems already in place in NL. 
It is important to distinguish the difference between electronic medical records 
(EMR) and electronic health records (EHR). EMRs are digital versions of patient medical 
charts contained in physicians’ offices, while the EHR is a province wide health record 
that contain information from various health services and health authorities (NLMA, 
2018). In NL, the current provincial EMR is the eDOCSNL EMR. As of 2019, 291 family 
physicians, 76 specialists, 25 nurse practitioners, 114 fee-for-service clinics, and 33 RHA 
primary health clinics in NL were using eDOCSNL (eDOCSNL, 2019). The software 
product used to deliver eDOCSNL is the MedAccess EMR manufactured and distributed 
by TELUS health (NLMA, 2018). There are many benefits to the eDOCSNL EMR that are 
beyond the scope of this paper. However, it is important to note here that a significant 
benefit of the eDOCSNL system is its compatibility and transferability with the province 
wide EHR (HEALTHe NL) (NLMA, 2018). Preferably, all HBOC team members involved in 
the delivery of the program would use the eDOCSNL provincial EMR system. The 
MedAccess EMR product allows patients to schedule their own appointments and 
complete forms online, use online messaging, and benefit from automated appointment 
reminders (Telus, 2020). These product features could be used to facilitate coordinated, 
person-centered PV carrier follow-up care. There are also features of the MedAccess EMR 
that allow communication between health care providers on the platform (Telus, 2020). 
This would allow seamless communication between the nurse navigator and 
multidisciplinary team members. As the data in eDOCSNL is compatible with HEALTHe 
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NL, it can be accessed not only by team members with a focus on inherited cancer 
 
prevention, but also by other providers in a individuals’ care circle. This includes PV 
carriers’ primary care providers, and other providers with access to HEALTHe NL. In the 
future, HBOC program administrators should also work with the EMR vendor to 
customize clinical decision support (CDS) tools for the PV carrier program where 
applicable. The use of CDSS allows the patient data to be matched to clinical practice 
guidelines and software algorithms (Berner, 2016). This can be used to alert the navigator 
who delivers the PV follow-up program when a PV carrier is due for a recommended 
screening test/and or annually scheduled follow-up. 
Technology must also be integral in how the follow-up program reaches PV 
carriers provincewide. Being a provincial service, the PV navigator program will span four 
regional health authorities over a wide geographic area with a dispersed population. It is 
unpractical to expect individuals to travel large distances to tertiary care centers for 
routine follow-up appointments. This is not a new issue; NL was one of the first provinces 
to offer facility-based, face-to-face telehealth appointments for individuals living in rural 
regions in the province (Newfoundland and Labrador Centre for Health Information 
(NLCHI), 2017). Through this service, individuals living in rural and remote regions have 
equitable access to health care in over 100 health care facilities throughout the province 
(NLCHI, 2017). Under this prospective program, the nurse navigator and HBOC 
multidisciplinary team members who had yet to do so, would complete the application 
form to use provincial telehealth services. With this facility-based service, hypothetically, 
a high risk BRCA PV carrier on Fogo Island could have a face-to-face appointment with 
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the nurse navigator in St. John’s without having to leave her community. The use of 
Telehealth services will allow PV carriers all over the province to connect with HBOC 
follow-up care team members when it would not otherwise be possible. 
Another virtual delivery option for the HBOC follow-up program is through the 
virtual care or home-based telehealth offered to Newfoundlanders and Labradorians 
through the NL Centre for Health Information. Social distancing precautions during the 
COVID-19 pandemic necessitated the delivery of health care appointments from remote 
locations. As a result, many health care providers began offering virtual care 
appointments where patients could connect with their healthcare provider without 
leaving their home. To do so, patients require only an MCP card, a personal e-mail 
address, an internet or wi-fi connection, and a tablet, computer or smart phone with a 
camera and speaker (NLCHI, 2020). In the province of NL, health care providers use 
either Cisco Jabber, Telus EMR Virtual Visit, or Telus EMR Health Myself Solution as 
videoconferencing tools in the delivery of virtual care (Newfoundland and Labrador 
Medical Association, 2020). These virtual platforms could be invaluable tools in the 
delivery of the follow-up navigation program. For eDOCSNL MedAccess EMR users, 
virtual care options are integrated into the EMR and they can sign-up for virtual patient 
visits through the core application as well as through the TELUS Health Myself Virtual 
Visits application (NLCHI, 2020). If the HBOC follow-up and navigation program were to 
utilize the MedAccess EMR software, virtual visits could be embedded in the PV carrier’s 
eDOCSNL EMR profile. 
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To understand how a HBOC follow-up program is well aligned with Canadian 
healthy public policy frameworks, a revisit of historic Canadian health promotion 
documents is warranted. The first government publication in the global sphere to 
challenge traditional notions of ‘health’ was the Canadian Lalonde (1974) report, A New 
Perspective on the Health of Canadians. Lalonde (1974) challenged the notion of ‘health’ as 
the sheer biomedical capacity to treat the sick, but rather it is determined by four 
interdependent health fields: human biology, environment, lifestyle, and health care 
organizations. Since Lalonde’s (1974) first conceptualization of health field determinants, 
the number determinants of health have been updated and expanded several times. There 
are currently 12 determinants of health outlined by the Public Health Agency of Canada 
(PHAC) (n.d.), including ‘biology and genetic endowment’ (PHAC, n.d.). Lalonde (1974) 
laid the groundwork for other fundamental Canadian documents on health policy and 
health promotion that followed. In Achieving Health for all: A Framework for Health 
Promotion, Epp (1986) went a step further and purported that a) health inequities exist 
among individuals and groups due to nuances in their health determinants, and that b), a 
paradigm shift from disease treatment towards prevention is needed. He recommended 
three population health strategies to achieve this: fostering public participation, 
strengthening community health services, and coordinating healthy public policy (Epp, 
1986). In the same year, the World Health Organization (WHO) (1986) released the 
Ottawa Charter for Health Promotion. In the charter, ‘health promotion’ was defined as 
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means of achieving health equity and reducing the differences experienced by groups and 
individuals. The WHO (1986) acknowledged that people require “a secure foundation in a 
supportive environment, access to information, life skills and opportunities for making 
healthy choices. People cannot achieve their fullest health potential unless they are able 
to take control of those things which determine their health (p. 1). 
All three of these frameworks have pertinency to this proposed policy. ‘Biology and 
genetic endowment’ is included in PHAC’s (n.d.) list of 12 determinants of health. There is 
sound evidence that because of their genetic endowment, HBOC PV carriers are at an 
exponentially greater risk of breast and ovarian cancer when compared to the general 
population. Determinants of health occur simultaneously and are often interrelated; an 
individual may be affected by multiple determinants of health that are associated with 
poorer health outcomes (PHAC, n.d.). For example, if PV carriers have a lower level of 
health literacy, are on a fixed-income, and have limited social support networks, these 
factors will also increase their likelihood of developing HBOC (and other chronic 
conditions for that matter). The PV carrier navigation/ follow-up program is a strategy to 
ensure that PV carriers with lower levels of health literacy, education, as well as those 
living in rural areas are given an equitable opportunity to benefit from hereditary cancer 
prevention guidelines. The proposed program reduces barriers to accessing follow-up 
care, provides PV carriers with information, and promotes positive individual and family 
coping. This is approach consistent with the conceptualizations of health promotion 
strategies by both Epp (1986) and WHO (1986). Without such supportive programs in 
place, this will result in widening health disparities among the privileged and 
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underprivileged subgroups in PV carrier populations (Sayani, 2019). As PV carriers have 
an unequivocally increased risk of cancer, it is unjust to treat them the same as people of 
average cancer risk. In an equitable health system, PV carriers deserve to be identified, 
prioritized for screening and intervention, and supported as they navigate life as a PV 




Cost-Effectiveness of the Follow-Up Program 
 
It was aptly noted that “the current ideological climate of neoliberalism reflects 
and reinforces short-term policy interventions that favour continued and increased 
funding to address perceived urgent problems of today, rather than investments to create 
better health outcomes in the future.” (Collins & Hayes, 2007, p. 341). It is this pervasive 
view of health funding that has roadblocked the development of preventative health 
programs, such as the one proposed in this policy. For health system funders to invest in 
these long-term projects comes at the potential sacrifice of campaign donations and voter 
support (Collins & Hayes, 2007). It is unfortunate that this ideological climate has created 
a culture of disunion between evidence and health policy. In this proposal, policy makers 
are invited to challenge these ideological misgivings, and to invest in a healthy public 
policy for HBOC PV carrier follow-up that is not only lifesaving, but also cost saving. In 
this section, evidence is presented how this program can be cost saving to the health care 
system in the long-term. 
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As cancer genetics is a relatively new area of medicine, there is a paucity of data on 
long-term follow-up outcomes for PV carriers. At this current juncture, outcome and 
cost-analyses of real-world clinical simulation models offer the best evidence on which to 
base the clinical management decisions for PV carriers. In a recent microsimulation 
model study out of Australia, the authors validated the cost-effectiveness of long-term 
BRCA PV carrier follow-up. Petelin et al. (2020) used input data from a real-world clinical 
database of 983 BRCA PV carriers. They compared the estimated long-term health system 
costs for both BRCA PV carriers who attended a multidisciplinary high-risk BRCA clinic 
and those who did not. Petelin et al. (2020) found that in asymptomatic BRCA PV carriers 
aged ≥ 20 who attended the high-risk clinic, there was a cost-effectiveness ratio (ICER) of 
$32,359 to $48,263 per quality adjusted life years (QALY). As their findings are based on 
Australian data, this study has implications for the Canadian health care system as both 
countries have publicly funded health care systems. This study is especially relevant 
because Petelin et al. (2020) reported on the projected cost savings of a follow-up clinic 
with features comparable to the program proposed in this policy paper. 
There are limited publications on the cost-effectiveness of long-term management 
strategies in PV carriers. There is, however, substantial evidence that the risk-reduction 
options available to PV carriers are cost-effective. Petelin et al. (2018) conducted a 
systemic review of cost-effectiveness of HBOC cancer risk management strategies. In the 
studies examining the cost-effectiveness of RRSO in BRCA PV carriers, Petelin et al. 
(2018) noted ICERs ranging from AU $1,876 to AU $5,789 per QALY gained. In the same 
study, Petelin et al. (2018) pooled cost analyses of breast screening in PV carriers. Breast 
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screening consisted of the recommended annual MRI alternating with mammography as 
per the high-risk screening guidelines for PV carriers. Adherence to this high-risk 
screening recommendation was shown to have a QALY cost-savings ranging from AU $28, 
273 to AU $236, 644, when compared to either MRI or mammography alone (Petelin et al., 
2018). These findings have implications for this proposed program. In eligible BRCA PV 
carriers in NL, Roebothan et al. (n.d.) found that carriers who had been assessed by a 
gynecologic oncologist were more likely to be compliant with high-risk MRI screening 
recommendations compared to those who had not (68.9% versus 31.1%; p = 0.006). 
Eligible PV carriers who had been assessed by a medical oncologist were also likely to be 
more adherent with MRI recommendations versus PV carriers who did not (71.4% versus 
28.6%; p = 0.041) (Roebothan et al., n.d.). There were also statistically significant 
associations between uptake of RRSO in PV carriers who had been assessed by: a 
gynecologic oncologist (83.5% versus 16.5% p = 0.012), assessed by a medical oncologist 
(86.4% versus 13.3%; p = 0.003), or the by University-based Inherited Cancer Prevention 
Clinic (83.9% versus 16.1%; p = 0.038) (Roebothan et al., n.d.) As stated, a key role of this 
proposed follow-up navigation program will be to streamline PV carriers to these 
multidisciplinary specialists. Taking into consideration that specialist assessment has 
been shown to increase uptake of cost-effective risk-management options in PV carriers, 
it is a logical inference that this follow-up program may contribute to cost savings. 
Another aspect of cost-effectiveness that must be considered is the cost savings 
incurred from identifying more PV carriers in the population. Up to the year 2014, only an 
estimated 2.6% of BRCA PV carriers in the general population had been identified 
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(Manchanda et al., 2018). As costs of testing depreciate further, it is highly likely that 
HBOC population-based genetic screening will become a routine component of universal 
health care in the future (Beitsch et al., 2019). Manchanda et al. (2018) determined that 
population-based genetic testing for HBOC variants, BRCA1, BRCA2, RAD51C, RAD51D, 
BRIP1, and PALB2 in unselected, general population women is more cost-effective than 
any clinical criteria/family history-based testing. It is also more effective than testing for 
BRCA1/BRCA2 variants alone. The prospect of population-based genetic testing offers an 
unrivaled opportunity to transform the current cancer care paradigm to a “predictive, 
preventive, personalized, and participatory (P4) medicine strategy for cancer prevention” 
(Manchanda et al., 2018 p. 715). Despite this, uncertainty remains about the indication for 
population-based genetic testing HBOC variants due to the low prevalence of PVs in the 
general population. This is due to the relatively lower risk of developing HBOC in women 
without a familial history, the direct and indirect costs of testing, as well as the potential 
psychological and clinical consequences of testing positive (Lippi et al., 2017). In a long- 
term follow-up of population-based AJ BRCA testing, Manchanda et al. (2020) found that 
testing did not adversely affect long-term psychological wellbeing or quality-of-life in PV 
carriers. Rather, Manchanda et al. (2020) noted that population-based testing decreased 
their anxiety and could identify an additional 150% of BRCA PV carriers. 
While a consensus has not been reached to date on the indication and 
sustainability of population-based testing, it is safe to conclude that a) an insufficient 
number of PV carriers are being identified and b), if population-based HBOC PV testing 
becomes integrated into routine care, there will be an increased demand for professional 
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support for the influx of PV carriers who require assistance to interpret and apply their 
newfound knowledge. Until a consensus is reached on the indication for population- 
based testing, cost-savings must be incurred by identifying a greater number of PV 
carriers in the population. Currently, the best way to do this is through cascade testing. In 
other words, through the process of informing at-risk relatives of known PV carriers of 
their risk who then also undergo genetic testing (Griffin et al., 2020). Cascade testing has 
not reached its full potential in identifying PV carriers. In the literature, percentages of 
family members who pursued cascade genetic testing ranged from 50% to 9% (Finlay et 
al., 2008; Trottier et al., 2015; Suthers et al., 2006). There is economic value in optimizing 
cascade testing in at-risk relatives. In a Canadian patient-level simulation study, Hurry et 
al. (2020) compared costs in two groups: 1)individuals who did not undergo genetic 
testing and underwent treatment if cancer developed, and 2) BRCA PV index patients 
who were tested and cascade testing occurred in their first-/second-degree relatives and 
all opted for risk-reducing surgery. For group two, Hurry et al. (2020) noted a cost savings 
ICER of CAD $14,942 per QALY when compared to the costs incurred in group one. 
Moreover, their model predicted 127 fewer ovarian and 104 fewer cases of breast cancer 
with twenty-one fewer all-cause deaths. This Canadian data is extremely encouraging. It 
is also demonstrative that from an economic and sustainability perspective, the process of 
cascade testing must be improved. Professional support has been identified as a facilitator 
of cascade testing (Griffin et al., 2020). This follow-up program will support families in 
the genetic results disclosure process and support at-risk relatives who wish to pursue 
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cascade testing. This is another means by which the proposed program will contribute to 




Evaluation: Program Pilot Project 
 
As this is a novel3 program, the best way to provide proof of concept to health 
system funders and decision makers is through a program pilot project. There is a strong 
case to be made for a pilot project of this program to receive health research agency 
funding. A compelling argument for this is made by revisiting two critical documents on 
the future of health care in Canada, the Kirby report (Kirby & Senate Standing Committee 
on Social Affairs, Science and Technology (SSCSAST), 2002), and the Romanow report 
(Commission on the Future of Health Care in Canada(CFHCC) & Romanow, 2003). In 
both reports, the committees determined that health research is essential to the quality 
and sustainability of the Canadian health care system. Kirby and SSCSAST (2002) noted 
that priority health research areas were health determinants, individual and population 
level disease prevent strategies, and primary care delivery. Likewise, Romanow and 
CFHCC (2002) cited the areas of health promotion, genomics & proteomics, and 
interprofessional collaboration as health research priorities in Canada. This proposed 
program policy fits well with these recommendations in both the Kirby report (Kirby & 
SSCSAST, 2002) and the Romanow report (CFHCC & Romanow, 2002). Furthermore, on 
the website of the federal health research funding agency, the Canadian Institute of 
Health Research (CIHR) (2020), personalized health and personalized medicine are listed 
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as current, priority research areas. This proposed program is also well-aligned with this 
CIHR research priority mandate as it takes a creative, novel approach to managing an 
individual’s risk of cancer based on their personal genetic information. For the above 
reasons, it is asserted that there are credible grounds for awarding health research 
funding to pilot the delivery of this program. The outcomes of this proposed pilot project 
in NL will likely have implications for how comparable programs can be implemented in 
Canada and around the world. Several outcomes of the pilot project should be measured: 
qualitative and psychometric measures of carrier and family experiences and satisfaction, 
health system utilization, cost savings, and clinical outcomes. 
There are several quantitative and qualitative tools that are well suited to measure 
outcomes of the follow-up program. To measure PV carrier and family satisfaction, 
program evaluators should seek qualitative feedback from PV carriers and families who 
use the program through semi-structured questions. The psychosocial impact of the 
follow-up program should also be measured using quantitative instruments. Before-and- 
after psychometric measures such as the Impact of Events (IES) scale, and the Hospital 
Anxiety and Depression Scale (HADS) have been used to assess the impact of PV carrier 
interventions (Esplen et al., 2004; Kwiatkowski et al., 2019; Listøl et al., 2017; McKinnon et 
al., 2007). There is also a unique opportunity to use a psychometric instrument developed 
in an NL Lynch Syndrome carrier population. The Psychosocial Adjustment to Hereditary 
Diseases scale (PAHD) (Watkins et al., 2013) is a validated psychometric scale designed to 
identify psychosocial adjustment challenges in PV carriers (Watkins et al., 2013). PV 
carrier PAHD scores should be collected prior to and after one to two years of 
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participation in the program. The PAHD scale can be used to determine if there was an 
improvement in psychosocial adjustment following participation in a dedicated follow-up 
program. 
A comparison should be made between the retrospective data collected by 
Roebothan et al. (n.d.) on risk-reduction modality adherence in BRCA PV carriers and in 
comparable data of PV carriers who participated in the novel follow-up program. In the 
long-term, clinical outcomes should be reported including the number of cancers 
detected and the cancer stage at time of detection. A comparison should also be made of 
the number of family referrals for cascade testing at PMG before and after the advent of 
the follow-up program. There is a unique opportunity in NL to determine if the proposed 
program could facilitate the identification of more individuals with the newly identified 
RAD51C NL founder mutation. Therefore, the number of RAD51C PV carriers detected 
through participation in the program should also be reported in a program evaluation. 
As stated, to convince policy makers of the long-term value of the program, its 
cost-effectiveness must be clearly demonstrated. The Canadian study by Hurry et al. 
(2020) can be used as a reference model to design a cost-savings analysis specific to the 
NL health care system. The costs of delivering follow-up program should be contrasted 
with the costs of a non-surveyed hereditary cancer and ICERs per QALY should be 
calculated. Cost-savings to the health care system as well as improved outcomes must be 
clearly demonstrated to garner the continued provincial government funding required to 
deliver the follow-up program over the long term. Without proof of concept, policy 
makers and health system funders will likely be unwilling to support the continuation of 
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the program. It is therefore critical to present a detailed, high quality evaluation and 






The postulates of this program proposal are the result of several months of 
researching the literature, consulting with relevant stakeholders, and scanning existing 
services available both in NL and other regions. To the best of my knowledge, this is the 
first document developed in a NL setting that proposed detailed policy direction for a 
much-needed reform of PV carrier follow-up care. It is acknowledged and accepted that 
there may be variance in opinion of how this follow-up program should be optimally 
delivered. It would be misguided to assume that this proposal is a stand-alone basis on 
which to develop this novel program. Ideally, a group of knowledgeable multidisciplinary 
experts in genetics, health ethics, cancer, and health system delivery should review this 
document and deliberate on the efficacy and feasibility of its proposed features. PV 
carriers should also be given an opportunity to provide their input on the features of a 
proposed program. This is the best way to ensure the comprehensiveness and the 
acceptability of the proposed follow-up program to all relevant stakeholders. While this 
document provides detailed policy direction, it is not uncompromising, and it also serves 
as an invite to further the conversation around improving PV carrier follow-up care in NL. 
It is hoped that this paper will generate a robust, much-needed discussion towards the 
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goals outlined in this policy proposal. It is only through collaboration with all relevant 
stakeholders that these goals can be achieved. 
Instating this program will inevitably come with its challenges. The program 
would be the first of its kind in the province and as is the case with any novel program, 
there is no existing ‘instruction manual’ to guide its delivery. It should begin as a pilot 
project and be subject to evaluation and revisions, as necessary. With the ever-evolving 
world of science and technology, the delivery of the program will change over time as PV 
carrier needs evolve. As personalized medicine continues to expand, more than likely, 
there will be less invasive ways to manage HBOC risk. Until then, the current risk- 
management options offer PV carriers the best chance of long-term survival and PV 
carriers have a right to be aware and make use of these options. Hopefully, in the future, 
the program will be involved in providing PV carriers with options for cutting-edge and 
minimally invasive risk- management. 
There will more than likely be obstacles to securing sustained provincial 
government funding. However, these obstacles are not insurmountable, nor are they 
reason enough to halt attempts to develop innovative health care delivery strategies. 
Indeed, any meaningful progress in health care innovation began with people who 
challenged the conventionality of the time. We cannot ignore that the world is on the 
cusp of a scientific revolution in the genomic era. There is mounting evidence in favor of 
population-based genetic testing for hereditary conditions (Manchanda et al., 2020). 
Canada has a responsibility to stay abreast of trends in genomic medicine, and to develop 
 
pragmatic, innovative ways to ensure that its citizens can avail of the best available 
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medical and technological discoveries. We also cannot overlook that these genetic and 
technological advances are meaningless without the necessary support systems in place to 
help PV carriers apply this information to their life circumstances. 
It is warranted to acknowledge that in this proposal, many other individuals with 
high-risk of inherited disease have been overlooked. This includes individuals with high 
risk for colorectal cancers such as familial adenomatous polyposis, and for other 
autosomal dominant inherited conditions such as polycystic kidney disease (PKD). This is 
not to suggest that these individuals do not require supportive care and improvements in 
PV carrier follow-up. Rather, given that this is a novel program concept, it was decided to 
focus exclusively on HBOC risk-management in the early stages of program development. 
Optimally, as the follow-up program expands, individuals affected by a wider variety of 
PVs would be surveyed by the program. Alternatively, this program can be used as a 
prototype to develop other specific, dedicated programs for PV carriers, such as a 
dedicated PKD or cardiogenetic follow-up program. 
Finally, it is acknowledged that the integration of precision health care (such as 
this proposed program) will only be enacted and sustained through a paradigm shift in 
public priorities and perception around genetic care (Dewell et al., 2020). Precision health 
care addresses the unique complement of biological, environmental, behavioral, and 
other information relevant to the health an individual (Chambers et al., 2016; Feero, 2017). 
Health care providers must communicate the value of precision/genetic health care in a 
way that is aligned with public perceptions of health care priorities (Dewell et al., 2020). 
Cancer is the second leading cause of death globally (WHO, 2018) and most people will 
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be affected by cancer in their lifetime, either themselves or through the diagnosis of a 
loved one. Thus, few would argue against improved cancer care as a health care priority. 
Cancer, in its very basic definition, is a disease of atypical genes and gene expression 
(Kiernan & Vallerand, 2016). Health care providers and researchers have an important 
role to play in communicating the link between genetic care and cancer outcomes to the 
public and stakeholders (Dewell et al., 2020). Public awareness shapes the narrative of 
priority research funding and health system utilization. This was evidenced in 2013 when 
Hollywood actress Angelina Jolie disclosed her BRCA PV carrier status and there was an 
exponential increase in referrals for genetic testing for HBOC around that time (Evans et 
al., 2014). The narrative must continue in the public sphere that gene sequencing will 
offer an unrivaled opportunity to improve cancer outcomes now and in future 






18 years ago, it was projected that with rising health care costs and equally rising 
public expectations, the Canadian health care system was facing a grave situation if its 
focus remained on disease treatment in lieu of prevention (Kirby & SSCSAT, 2002). It is 
discouraging that this prediction has held true of in the case of the current Canadian 
cancer care system. An aging population, aggressive and costly cancer therapies have 
further contributed to the unsustainability of cancer care in Canada (Roebothan et al., 
n.d.). This situation must be urgently addressed. In this proposal, a robust cancer 
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prevention strategy is presented. Establishing this proposed PV carrier follow-up and 
navigation program is an invaluable opportunity to save both lives and money. Women 
with HBOC PVs should not be getting breast and ovarian cancer; we decisively know how 
to prevent it. There is an ethical responsibility of the health care system to allow PV 
carriers to make an informed choice about their risk-reduction and to support them and 
their families as they navigate the lifelong realities of PV carriership. The current 
approach to PV follow-up care can be likened to an analogy of leading PV carriers 
upstream in a river, then leaving them to navigate for themselves without a paddle. As a 
health care system, we have a duty to provide them with an oar and compass, to empower 
them to go where they need to go in their lives. Undoubtedly, it will be called into 
question whether we can afford ‘oars and compasses’ for every PV carrier. Yet the 
mounting costs of repeated search and rescue missions in the river for ‘lost’ PV carriers is 
never questioned; many missions ending in unfortunate outcomes. It is time to change 
the narrative, from ‘how can we afford this? to ‘how can we afford NOT to do this?’ This 
follow-up and navigation program will serve as the oar and compass that PV carriers need 
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